AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2018 Pre-ASCOCHICAGO, Report ILLINOIS • MAY 31 – JUNE 4, 2019

Cover page, paste image over entire page

2019 ASCO Planner

May 2018 / 1

Information Classification: General NOT A PRODUCT SPONSORED BY ASCO 2019 ASCO Annual Meeting Planner Friday, May 31 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Clinical Science Symposium EGFR and ROS1: Targeting Resistance Location: Hall D1 1:00 PM 2:30 PM Chair - EGFR and ROS1: Targeting Resistance Gregory J. Riely 1:00 PM 2:30 PM Chair - EGFR and ROS1: Targeting Resistance Jose Maria Pacheco 1:00 PM 1:12 PM How Can We Overcome TKI Resistance in EGFR-Mutant NSCLC? Katerina A. Politi 1:12 PM 1:24 PM JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell JNJ-61186372 Johnson & Johnson Eric B. Haura 9009 lung cancer (NSCLC). 1:24 PM 1:36 PM Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in U3-1402 Daiichi Sankyo Pasi A. Janne 9010 EGFR TKI-resistant, EGFRm NSCLC. 1:36 PM 1:48 PM Using Antibodies in a TKI World Jessica Ruth Bauman 1:48 PM 2:00 PM Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion- repotrectinib Turning Point Byoung Chul Cho 9011 positive non-small cell lung cancer (TRIDENT-1 study). Therapeutics 2:00 PM 2:12 PM cROS1ng Barriers in Resistance Benjamin Besse 2:12 PM 2:30 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Genitourinary (Prostate) Cancer Location: Arie Crown Theater 2:45 PM 5:45 PM Chair - Genitourinary (Prostate) Cancer Joshi J. Alumkal 2:45 PM 5:45 PM Chair - Genitourinary (Prostate) Cancer Alan Haruo Bryce 2:45 PM 2:57 PM Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic darolutamide Bayer Karim Fizazi 5000 castrate-resistant prostate cancer (nmCRPC). 2:57 PM 3:09 PM Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for Christian Carrie 5001 metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475). 3:09 PM 3:21 PM PSMA heterogeneity and DNA repair defects in prostate cancer. Alec Paschalis 5002 3:21 PM 3:33 PM Therapeutic Advances, Balancing Quality of Life Daniel Eidelberg Spratt

3:33 PM 3:45 PM Panel Question and Answer Panel Discussion 3:45 PM 3:57 PM Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or Jevtana; Xtandi; Sanofi; Astellas; Kim N. Chi 5003 enzalutamide (ENZ) in poor prognosis metastatic CRPC. Zytiga Johnson & Johnson

3:57 PM 4:09 PM TAXOMET: A French prospective multicenter randomized controlled phase II study comparing MARC Pujalte Martin 5004 docetaxel plus metformin versus docetaxel plus placebo in mCRPC. 4:09 PM 4:21 PM TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib Lynparza AstraZeneca Joaquin Mateo 5005 for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. 4:21 PM 4:33 PM Aggressive Therapy for Aggressive Disease Mary-Ellen Taplin 4:33 PM 4:45 PM Panel Question and Answer Panel Discussion 4:45 PM 4:57 PM First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus Erleada Johnson & Johnson Kim N. Chi 5006 placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). 4:57 PM 5:09 PM Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial Xtandi; Xofigo Astellas; Bayer Bertrand F. Tombal 5007 comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.

5:09 PM 5:21 PM Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and Xtandi; Zytiga Astellas; Johnson & Michael J. Morris 5008 prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Johnson

5:21 PM 5:33 PM Androgen Targeted Therapy: Is More Better? Michael Anthony 5:33 PM 5:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Head and Neck Cancer Location: E450 2:45 PM 5:45 PM Chair - Head and Neck Cancer Assuntina Gesualda Sacco 2:45 PM 5:45 PM Chair - Head and Neck Cancer Xiuning Le 2:45 PM 2:57 PM Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of (pembro) as first- Keytruda Merck & Co. Danny Rischin 6000 line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

2:57 PM 3:09 PM Ado- emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results Kadcyla Roche Bob T. Li 6001 from a phase II basket trial. 3:09 PM 3:21 PM TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and Joel Guigay 6002 neck squamous cell carcinoma (R/M HNSCC). 3:21 PM 3:33 PM The Three Pillars of Systemic Therapy Vanita Noronha 3:33 PM 3:45 PM Panel Question and Answer Panel Discussion 3:45 PM 3:57 PM Gemcitabine and cisplatin (GP) induction (IC) plus concurrent chemoradiotherapy Jun Ma 6003 (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. 3:57 PM 4:09 PM Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent Ming-Yuan Chen 6004 chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial. 4:09 PM 4:21 PM Believe it or Not! Intensification of Therapy for Nasopharynx Cancer A. Dimitrios Colevas 4:21 PM 4:33 PM Panel Question and Answer Panel Discussion 4:33 PM 4:45 PM A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy Anthony Charles Nichols 6006 versus trans-oral robotic surgery (ORATOR). 4:45 PM 4:57 PM Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early Yasuhisa Hasegawa 6007 oral cancers: A randomized, multicenter, non-inferiority trial. 2019 ASCO Annual Meeting Planner Friday, May 31 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:57 PM 5:09 PM Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. Imfinzi; AstraZeneca Renata Ferrarotto 6008 tremelimumab 5:09 PM 5:21 PM Three Ways That Less May Be More: Deintensifying Surgery St. John Maie 5:21 PM 5:33 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Health Services Research, Clinical Informatics, and Quality of Care Location: S102 2:45 PM 5:45 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Jimmy Ruiz 2:45 PM 5:45 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Erica T. Warner 2:45 PM 2:57 PM Effect of montelukast and rupatadine on infusion time, rate, severity of reactions, and cost Singulair; Rupafin; Merck & Co.; Uriach; Rouslan Kotchetkov 6500 of administration. Rituxan Roche 2:57 PM 3:09 PM Comparison of normal saline versus heparin flush solutions for maintaining patency of central Amy Pai 6501 venous catheter in cancer patients. 3:09 PM 3:21 PM Preventing excess narcotic prescriptions in MIS urologic oncology discharges (PENN): A prospective Ruchika Talwar 6502 cohort quality improvement initiative. 3:21 PM 3:33 PM Significance of examined lymph node number in accurate staging and long-term survival in resected Lei Huang 6503 stage I-II pancreatic cancer: More is better? A large international population-based cohort study.

3:45 PM 3:57 PM Panel Question and Answer Panel Discussion 3:57 PM 4:09 PM Economic analysis of alternative pembrolizumab and dosing strategies at an academic Keytruda; Opdivo Merck & Co.; Bristol- Evan Thomas Hall 6504 cancer center. Myers Squibb

4:09 PM 4:21 PM A process to reduce hospital admissions in the OCM population through focused intervention of Manuel Perry 6505 super-utilizers. 4:21 PM 4:33 PM The financial impact of physician practice patterns: An analysis of as-needed versus Christine Barrett 6506 prophylactic in patients with prostate cancer receiving docetaxel. 4:33 PM 4:45 PM Costs Matter: Strategies for Success Kerin B. Adelson 4:45 PM 4:57 PM Panel Question and Answer Panel Discussion 4:57 PM 5:09 PM Quality of end-of-life cancer care at minority-serving US cancer centers: A retrospective study of Garrett Wasp 6507 Medicare claims data. 5:09 PM 5:21 PM Impact of a same-day breast biopsy program on disparities in time to biopsy. Matthew Seidler 6508 5:21 PM 5:33 PM Disparities: Measurement to Action Erica T. Warner 5:33 PM 5:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Pediatric Oncology I Location: S504 2:45 PM 5:45 PM Chair - Pediatric Oncology I Margaret E Macy 2:45 PM 5:45 PM Chair - Pediatric Oncology I Melinda Gordon Pauly

2:45 PM 2:57 PM Randomized phase 2 trial of the combination of vincristine and irinotecan with or without Anne Sophie 10000 temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). Defachelles

2:57 PM 3:09 PM Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk Lucas Moreno 10001 neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

3:09 PM 3:21 PM Chemotherapy Combinations for Solid Tumors: The Whole Is Not Greater Than the Sum of the Parts Lars M. Wagner

3:21 PM 3:33 PM Panel Question and Answer Panel Discussion 3:33 PM 3:45 PM Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on Richard Aplenc 10002 outcome for children with high risk acute myeloid leukemia: A report from the Children's Oncology Group. 3:45 PM 3:57 PM AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for Vyxeos Jazz Todd Michael Cooper 10003 children with relapsed acute myeloid leukemia (AML): A Report from the Children's Oncology Group. Pharmaceuticals

3:57 PM 4:09 PM Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed Venclexta AbbVie Seth E Karol 10004 or refractory acute myeloid leukemia. 4:09 PM 4:21 PM Pediatric AML: Can We Move Beyond Cytarabine? Michel Zwaan 4:21 PM 4:33 PM Panel Question and Answer Panel Discussion 4:33 PM 4:45 PM Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children's Sumit Gupta 10005 Oncology Group (COG). 4:45 PM 4:57 PM Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic Oncaspar; Asparlas Les Laboratoires Lynda M. Vrooman 10006 leukemia/lymphoma: Results of DFCI 11-001. Servier 4:57 PM 5:09 PM A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with Smita Bhatia 10007 acute lymphoblastic leukemia (ALL): A COG ACCL1033 study. 5:09 PM 5:21 PM Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Susan R. Rheingold 10008 Oncology Group (COG) study. 5:21 PM 5:33 PM Preventing Relapse in ALL by Optimizing Chemotherapy Exposure Maria Luisa Sulis 5:33 PM 5:45 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Clinical Science Symposium Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance Location: Hall D1 8:00 AM 9:30 AM Chair - Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance Melissa Lynne Johnson

8:00 AM 8:12 AM Serum IL-6 and CRP as prognostic factors in patients receiving single agent and Jeffrey S. Weber 100 combination checkpoint inhibition. 8:12 AM 8:24 AM Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in Bavencio; Inlyta; Merck KGaA; Pfizer Toni K. Choueiri 101 advanced renal cell carcinoma (aRCC). Sutent 8:24 AM 8:36 AM Identifying Biomarkers That Predict Benefit: Hope for the Future Charles G. Drake 8:36 AM 8:48 AM Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of Keytruda Merck & Co. Ferdinandos Skoulidis 102 pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

8:48 AM 9:00 AM Association of polybromo-associated baf (PBAF) complex mutations with overall survival (OS) in Sarah Abou Alaiwi 103 cancer patients (pts) treated with checkpoint inhibitors (ICIs). 9:00 AM 9:12 AM Learning From Patients Treated With Immunotherapy: Molecular Markers of Benefit and Resistance Antoni Ribas

9:12 AM 9:30 AM Panel Question and Answer Panel Discussion

Clinical Science Symposium Harnessing Technology in Symptoms and Survivorship Location: S102 8:00 AM 9:30 AM Chair - Harnessing Technology in Symptoms and Survivorship Sunil Verma 8:00 AM 9:30 AM Chair - Harnessing Technology in Symptoms and Survivorship Cardinale B. Smith Poster Discussion Session Developmental Immunotherapy and Tumor Immunobiology Location: Hall D1 1:15 PM 2:45 PM Chair - Developmental Immunotherapy and Tumor Immunobiology Aparna Kalyan 1:15 PM 2:45 PM Chair - Developmental Immunotherapy and Tumor Immunobiology Russell Kent Pachynski

1:15 PM 1:27 PM versus placebo after complete resection of stage III melanoma: Long-term follow-up Yervoy Bristol-Myers Squibb Alexander M. M. 2512 results the EORTC 18071 double-blind phase 3 randomized trial. Eggermont 1:15 PM 1:27 PM CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: CX-072 CytomX Aung Naing 2513 Preliminary results of PROCLAIM-CX-072. Therapeutics 1:15 PM 1:27 PM A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in ALX148 ALX Oncology Laura Quan Man Chow 2514 patients with advanced malignancy. 1:15 PM 1:27 PM Advances in Immune Checkpoint Inhibition David B. Page 1:27 PM 1:37 PM Panel Question and Answer Panel Discussion 1:15 PM 2:45 PM Distinct immunogenomic properties of with stable disease as best response to immune Natalie Vokes 2515 checkpoint blockade (ICB). 1:15 PM 2:45 PM Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A Flora Mulkey 2516 systematic analysis by the United States Food and Drug Administration (FDA).

1:15 PM 2:45 PM Prognostic and predictive value of an immune-related adverse event among stage III melanoma Keytruda Merck & Co. Alexander M. M. 2517 patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial. Eggermont

1:37 PM 1:49 PM The Evolving Role of Biomarkers in Immune Checkpoint Inhibition Kurt A. Schalper 1:49 PM 1:59 PM Panel Question and Answer Panel Discussion 1:59 PM 2:11 PM Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, Contego Iovance Amod Sarnaik 2518 lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies Biotherapeutics including anti-PD-1. 1:59 PM 2:11 PM Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. Karlo Perica 2520

1:59 PM 2:11 PM New Directions for Cellular Therapy Ignacio Melero 2:11 PM 2:21 PM Panel Question and Answer Panel Discussion 2:21 PM 2:33 PM First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II murlentamab GamaMabs Pharma Alexandra Leary 2521 (AMHRII) acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).

2:21 PM 2:33 PM Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An Stivarga; Opdivo Bayer; Bristol-Myers Shota Fukuoka 2522 open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Squibb

2:21 PM 2:33 PM A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 mRNA-4157 Moderna Howard A. Burris 2523 alone in patients with resected solid tumors and in combination with pembrolizumab in patients Therapeutics with unresectable solid tumors. 2:21 PM 2:33 PM Novel Combinations With Distinct Mechanisms of Action Geraldine Helen O'Sullivan Coyne 2:33 PM 2:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: Hall D2 1:15 PM 4:15 PM Chair - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Alexander Chi 1:15 PM 4:15 PM Chair - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Jay M. Lee 1:15 PM 1:27 PM Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for Yasuhiro Tsutani 8500 recurrence: A multicenter study. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 1:27 PM 1:39 PM Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) Alimta Eli Lilly Hirotsugu Kenmotsu 8501 for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. 1:39 PM 1:51 PM Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent Theodoros Tsakiridis 8502 chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

1:51 PM 2:03 PM Patients, Agents, and Combinations Jamie E. Chaft 2:03 PM 2:15 PM Panel Question and Answer Panel Discussion 2:15 PM 2:27 PM Neoadjuvant in resectable non-small cell lung cancer (NSCLC): Interim analysis and Tecentriq Roche David J. Kwiatkowski 8503 biomarker data from a multicenter study (LCMC3). 2:27 PM 2:39 PM Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung Opdivo; Yervoy Bristol-Myers Squibb Tina Cascone 8504 cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

2:39 PM 2:51 PM Neoadjuvant Immunotherapy: Why, How, When? Maximilian Diehn 2:51 PM 3:03 PM Panel Question and Answer Panel Discussion 3:03 PM 3:15 PM Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated trilaciclib G1 Therapeutics Lowell L. Hart 8505 extensive-stage small cell lung cancer receiving topotecan. 3:15 PM 3:27 PM Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single- Zepsyre PharmaMar Luis G. Paz-Ares 8506 agent trial. 3:27 PM 3:39 PM Relapsed SCLC: New Cytotoxic Strategies Anna F. Farago 3:39 PM 3:51 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Pediatric Oncology Location: S504 1:15 PM 2:45 PM Chair - Pediatric Oncology Emily Kanaya Slotkin 1:15 PM 2:45 PM Chair - Pediatric Oncology Steven G. DuBois 1:15 PM 1:27 PM Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine Pablo Berlanga 10018 program? The European MAPPYACTS experience. 1:15 PM 1:27 PM Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud. Scott Newman 10019

1:15 PM 1:27 PM Participant hopes and expectations regarding outcomes of genomic sequencing research in pediatric Jonathan M Marron 10020 oncology. 1:15 PM 1:27 PM Population-based cancer predisposition testing as a component of newborn screening: A cost- Jennifer Yeh 10021 effectiveness analysis. 1:15 PM 1:27 PM Precision Medicine in the Era of Patient-Centered Care 1:27 PM 1:45 PM Panel Question and Answer Panel Discussion 1:45 PM 1:57 PM Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children Furqan Shaikh 10022 and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. 1:45 PM 1:57 PM Outcome of children with malignant germ cell tumors by response status at the end of induction Adriana Fonseca 10023 chemotherapy. 1:45 PM 1:57 PM High-dose plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): naxitamab Y-mAbs Brian H. Kushner 10024 Efficacy against histologically-evident primary refractory metastases in bone marrow (BM). Therapeutics

1:45 PM 1:57 PM Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results naxitamab Y-mAbs Jaume Mora 10025 of HITS pilot/phase II study. Therapeutics 1:45 PM 1:57 PM Investigating Pediatric Solid Tumors: From Single Institution to International Collaboration Alberto S. Pappo

1:57 PM 2:15 PM Panel Question and Answer Panel Discussion 2:15 PM 2:27 PM Frailty among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS). Samah Hayek 10026

2:15 PM 2:27 PM Impact of protein supplementation on lean muscle mass in adult survivors of childhood cancer Matthew R Krull 10027 engaged in resistance training. 2:15 PM 2:27 PM Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation Lindsay M. Morton 10028 sensitivity syndrome genes: A report from the Childhood Cancer Survivor Study.

2:15 PM 2:27 PM The promoting resilience in stress management (PRISM) intervention for parents of children with Mallory R. Taylor 10029 cancer: A randomized controlled trial. 2:15 PM 2:27 PM Early Interventions to Support Patients, Parents, and Survivors Debra L. Friedman 2:27 PM 2:45 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Developmental Therapeutics and Tumor Biology (Nonimmuno) Location: E450 3:00 PM 4:30 PM Chair - Developmental Therapeutics and Tumor Biology (Nonimmuno) Kwok-Kin Wong 3:00 PM 4:30 PM Chair - Developmental Therapeutics and Tumor Biology (Nonimmuno) Eddy Shih-Hsin Yang 3:00 PM 3:12 PM A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with mirvetuximab ImmunoGen Mihaela C. Cristea 3009 FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast soravtansine cancer (TNBC). 3:00 PM 3:12 PM Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate XMT-1536 Mersana Anthony W. Tolcher 3010 (ADC), in patients (pts) with solid tumors likely to express NaPi2b. Therapeutics 3:00 PM 3:12 PM Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with telisotuzumab AbbVie; Roche D. Ross Camidge 3011 erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. vedotin; Tarceva

3:00 PM 3:12 PM Next-Generation ADC Platforms and Combinations 3:12 PM 3:22 PM Panel Question and Answer Panel Discussion 3:22 PM 3:34 PM A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) NU-0129 Northwestern Priya Kumthekar 3012 nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients. University 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 3:22 PM 3:34 PM Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. ABBV-621 AbbVie Mark J. Ratain 3013 3:22 PM 3:34 PM Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial IACS-010759 University of Texas Timothy A Yap 3014 electron transport chain, in patients (pts) with advanced solid tumors. MD Anderson Cancer Center

3:22 PM 3:34 PM Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non- CC-90010 Celgene Victor Moreno 3015 Hodgkin lymphoma (R/R NHL). 3:22 PM 3:34 PM Targeting Cell Death and Epigenetic Pathways Udai Banerji 3:34 PM 3:44 PM Panel Question and Answer Panel Discussion 3:44 PM 3:56 PM Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated James V. Tricoli 3016 Laboratory Network. 3:44 PM 3:56 PM Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) entrectinib Roche Salvatore Siena 3017 metastases: Integrated analysis from three clinical trials. 3:44 PM 3:56 PM Precision Testing and Precision Medicine Joshua K. Sabari 3:56 PM 4:06 PM Panel Question and Answer Panel Discussion 4:06 PM 4:18 PM Genome-wide cell-free DNA fragmentation profiling for early cancer detection. Alessandro Leal 3018 4:06 PM 4:18 PM Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2- Jean-Yves Pierga 3019 negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study. 4:06 PM 4:18 PM Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients Ugo De Giorgi 3020 (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.

4:06 PM 4:18 PM Circulating Biomarkers: It's in the Blood Geoffrey R. Oxnard 4:18 PM 4:30 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Gastrointestinal (Colorectal) Cancer Location: Hall B1 3:00 PM 6:00 PM Chair - Gastrointestinal (Colorectal) Cancer Mark Kozloff 3:00 PM 6:00 PM Chair - Gastrointestinal (Colorectal) Cancer Wen Wee Ma 3:00 PM 3:12 PM Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer Ioannis Sougklakos 3500 patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

3:12 PM 3:24 PM Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) Timothy Iveson 3501 oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). 3:24 PM 3:36 PM Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant Qian Shi 3502 colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. 3:36 PM 3:48 PM Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction- Katherine L. Pogue- 3503 benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Geile Treatment of Colon Cancer). 3:48 PM 4:00 PM Adjuvant Therapy: Maximizing Benefit, Minimizing Toxicity, Getting Answers Sooner David P. Ryan 4:00 PM 4:12 PM Panel Question and Answer Panel Discussion 4:12 PM 4:24 PM FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant Matthew T. Seymour 3504 chemotherapy (NAC) for colon cancer. 4:24 PM 4:36 PM NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally Thomas J. George 3505 advanced rectal cancer (LARC)—First experimental arm (EA) initial results. 4:36 PM 4:48 PM Neoadjuvant Therapy: Should Medical Oncologists Go First? Jordan Berlin 4:48 PM 5:00 PM Panel Question and Answer Panel Discussion 5:12 PM 5:24 PM Randomized phase III study comparing FOLFOX + versus folfoxiri + bevacizumab (BEV) Avastin Roche Javier Sastre 3507 as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). 5:24 PM 5:36 PM Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second- Chiara Cremolini 3508 line treatment of unresectable mCRC. 5:36 PM 5:48 PM Metastatic Disease: Can We Do Better With the Worst? Hanna Kelly Sanoff 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Location: E451 3:00 PM 6:00 PM Chair - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Gail J. Roboz

3:00 PM 6:00 PM Chair - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Susan Mary O'Brien

3:00 PM 3:12 PM Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) Xospata Astellas Mark J. Levis 7000 AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

3:12 PM 3:24 PM A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid CX-01 Cantex Tibor Kovacsovics 7001 leukemia (AML). Pharmaceuticals 3:24 PM 3:36 PM Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival Mansour Alfayez 7002 outcomes in acute myeloid leukemia. 3:36 PM 3:48 PM AML: Disease risk factors, biology, and treatment. Leslie R. Ellis 3:48 PM 4:00 PM Panel Question and Answer Panel Discussion 4:00 PM 4:12 PM Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with Mavenclad; Rituxan Merck KGaA; Roche Dai Chihara 7003 untreated hairy cell leukemia. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:12 PM 4:24 PM Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: flumatinib; Gleevec Jiangsu Hengrui Li Zhang 7004 Results from the China randomized phase III study. Medicine Co.; Novartis 4:24 PM 4:36 PM ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid Tasigna Novartis Timothy P. Hughes 7005 leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

4:36 PM 4:48 PM Chronic leukemias: From start to finish. Jacqueline Suen Garcia

4:48 PM 5:00 PM Panel Question and Answer Panel Discussion 5:00 PM 5:12 PM End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor Yescarta Gilead Sciences Bijal D. Shah 7006 (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). 5:12 PM 5:24 PM Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving Uday R. Popat 7007 myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study.

5:24 PM 5:36 PM Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. Hind Rafei 7008

5:36 PM 5:48 PM Adoptive immunity: Something old, something new. Caitlin Costello 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Clinical Science Symposium Next-Generation Therapeutics and Biomarkers in Melanoma Location: S100bc 3:00 PM 4:30 PM Chair - Next-Generation Therapeutics and Biomarkers in Melanoma Suzanne Louise Topalian

3:00 PM 4:30 PM Chair - Next-Generation Therapeutics and Biomarkers in Melanoma Jessica Cecile Hassel 3:00 PM 3:12 PM Phase 1 study of MK-4166, an anti-human glucocorticoid-induced receptor MK-4166; Keytruda Merck & Co. Kyriakos P. 9509 (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced Papadopoulos solid tumors. 3:12 PM 3:24 PM GITR as an Emerging Novel Checkpoint in Immunotherapy Janice M. Mehnert 3:24 PM 3:36 PM Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or Tafinlar; Mekinist Novartis Mahrukh M Syeda 9510 metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).

3:36 PM 3:48 PM Toward the Future of Noninvasive Monitoring of Response to Targeted Therapy 3:48 PM 4:00 PM Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy Ines Esteves Domingues 9511 and combination immunotherapy. Pires Da Silva

4:00 PM 4:12 PM Analysis of the Tumor Microenvironment to Guide Immunotherapy Thomas Gajewski 4:12 PM 4:30 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Sarcoma Location: S404 3:00 PM 4:30 PM Chair - Sarcoma Michael Wagner 3:00 PM 4:30 PM Chair - Sarcoma Priscilla Merriam 3:00 PM 3:12 PM Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A anlotinib Advenchen Jie Xu 11012 multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). Laboratories

3:00 PM 3:12 PM Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) apatinib; LSK Biopartners; Lu Xie 11013 progressing after chemotherapy: A prospective, open label, phase II trial. camrelizumab Incyte 3:00 PM 3:12 PM A three-gene signature to predict survival in pediatric osteosarcoma (OS) to follow patients toward Natacha Entz-Werle 11014 liquid biopsy: A collaborative work in OS2006 protocol. 3:00 PM 3:12 PM Breaking New Ground in Bone Sarcoma Katherine A. Janeway

3:12 PM 3:22 PM Panel Question and Answer Panel Discussion 3:22 PM 3:34 PM Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and Keytruda Merck & Co. Melissa Amber Burgess 11015 dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

3:22 PM 3:34 PM SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, Yervoy; Opdivo; Bristol-Myers Erlinda Maria Gordon 11016 and trabectedin as first-line treatment of advanced soft tissue sarcoma. Yondelis Squibb; Johnson & Johnson 3:22 PM 3:34 PM A randomized phase II study of nivolumab monotherapy versus nivolumab combined with Yervoy; Opdivo Bristol-Myers Squibb Arun S. Singh 11017 ipilimumab in advanced gastrointestinal stromal tumor(GIST). 3:22 PM 3:34 PM Building the Evidence for Immunotherapy in Sarcoma Thierry Alcindor 3:34 PM 3:44 PM Panel Question and Answer Panel Discussion 3:44 PM 3:56 PM Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical Shiraj Sen 11018 benefit, and survival in sarcoma patients on phase 1 trials. 3:44 PM 3:56 PM Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective Yondelis Johnson & Johnson Shibu Thomas 11019 genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D). 3:44 PM 3:56 PM Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center Mark A. Eckardt 11020 pathologic diagnosis. 3:44 PM 3:56 PM Genomic and Pathologic Considerations in Sarcoma Elizabeth Demicco 3:56 PM 4:06 PM Panel Question and Answer Panel Discussion 4:06 PM 4:18 PM A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of Stivarga; Votrient Bayer; Novartis Nicolas Penel 11021 regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ). 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:06 PM 4:18 PM Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal avapritinib Blueprint Medicines Michael C. Heinrich 11022 tumors (GIST). Corporation

4:06 PM 4:18 PM ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for Gleevec; Stivarga Novartis; Bayer Desmond Yip 11023 the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

4:06 PM 4:18 PM Tyrosine Kinase Inhibition: Are We Making Progress? Anthony Paul Conley 4:18 PM 4:30 PM Panel Question and Answer Panel Discussion

Clinical Science Symposium Targeting Breast Cancer: Breaking the Code Location: Hall D1 3:00 PM 4:30 PM Chair - Targeting Breast Cancer: Breaking the Code Julia R. White 3:00 PM 4:30 PM Chair - Targeting Breast Cancer: Breaking the Code Carlos L. Arteaga 3:00 PM 3:12 PM Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations Pedram Razavi 1009 with acquired resistance to CDK4/6 inhibitors. 3:12 PM 3:24 PM Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced Ben O'Leary 1010 breast cancer in the PALOMA-3 trial. 3:24 PM 3:36 PM Beyond ER: Unraveling CDK4/6 Resistance Philippe L. Bedard 3:48 PM 4:00 PM Genomic correlates of response to adjuvant trastuzumab (H) and (P) in HER2+ breast Herceptin; Perjeta Roche Ian E. Krop 1012 cancer (BC): Biomarker analysis of the APHINITY trial. 4:00 PM 4:12 PM Adjuvant Targeted Therapy: When Is More Better? Matthew P. Goetz 4:12 PM 4:30 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Genitourinary (Prostate) Cancer Location: Arie Crown Theater 4:30 PM 6:00 PM Chair - Genitourinary (Prostate) Cancer Pedro C. Barata 4:30 PM 6:00 PM Chair - Genitourinary (Prostate) Cancer Dana E. Rathkopf 4:30 PM 4:42 PM Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with Xtandi; LY3023414 Astellas; Eli Lilly Christopher Sweeney 5009 metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

4:30 PM 4:42 PM Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) Keytruda; Xtandi Merck & Co.; Peter C.C. Fong 5010 with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE- Astellas 365 study. 4:30 PM 4:42 PM Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) Xtandi Astellas Xiangnan Guan 5011 resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.

4:30 PM 4:42 PM ENZA-mining: Resistance and Combination Therapy William K. Oh 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter Michael J. Morris 5012 study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). 4:52 PM 5:04 PM Association of noninvasive, radiographic measurement of prostate-specific membrane antigen Panagiotis J. 5013 (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). Vlachostergios

4:52 PM 5:04 PM Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 Jeremie Calais 5014 PET/CT in patients with early biochemical recurrence of prostate cancer.

4:52 PM 5:04 PM PSMA: Is Seeing Believing? Scott Williams 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among David Margel 5015 patients with advanced prostate cancer. 5:14 PM 5:26 PM Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until Catherine Handy 5016 metastasis. Marshall 5:14 PM 5:26 PM Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and Giulia Baciarello 5017 docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

5:14 PM 5:26 PM Taking Patient Preferences to Heart Julie Nicole Graff 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in Anis Hamid 5018 metastatic castration resistant prostate cancer (mCRPC). 5:36 PM 5:48 PM Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 Clare Gilson 5019 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.

5:36 PM 5:48 PM HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) Jason W.D. Hearn 5020 treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial. 5:36 PM 5:48 PM Predictive Biomarkers in Prostate Cancer Isla Garraway 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Gynecologic Cancer Location: S406 4:30 PM 6:00 PM Chair - Gynecologic Cancer Karen McLean 4:30 PM 6:00 PM Chair - Gynecologic Cancer Dmitriy Zamarin 4:30 PM 4:42 PM Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian Ofev Boehringer Gwenael Ferron 5512 cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study. Ingelheim 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:30 PM 4:42 PM Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer adavosertib AstraZeneca Kathleen N. Moore 5513 (PPROC): An open label, four-arm, phase II study. 4:30 PM 4:42 PM Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, Rongyu Zang 5514 phase II trial. 4:30 PM 4:42 PM How Much Is Too Much? Achieving a Balance in Treatment Intensity Joan L. Walker 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a Eiji Kondo 5515 randomized phase III study (JGOG3017/GCIG). 4:52 PM 5:04 PM Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study Alice Bergamini 5516 (multicenter Italian trials in ovarian cancer). 4:52 PM 5:04 PM A comparison of adjuvant therapy approaches for patients with early-stage uterine serous Katherine Kurnit 5517 carcinoma. 4:52 PM 5:04 PM Studying the Zebras: Rare but Not Forgotten BJ Rimel 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to adavosertib AstraZeneca Stephanie Lheureux 5518 gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.

5:14 PM 5:26 PM Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, Keytruda Merck & Co. John B. Liao 5519 and primary peritoneal cancer-interim results. 5:14 PM 5:26 PM Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), mirvetuximab ImmunoGen; Roche David M. O'Malley 5520 in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final soravtansine; findings from the FORWARD II study. Avastin 5:14 PM 5:26 PM The Recurrent Search for the Holy Grail in Ovarian Cancer Elise C. Kohn 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian Recentin; Lynparza AstraZeneca Stephanie Lheureux 5521 cancer—A Princess Margaret Consortium – GCIG Phase II Trial. 5:36 PM 5:48 PM Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients Rubraca Clovis Oncology Robert L. Coleman 5522 (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. 5:36 PM 5:48 PM A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab veliparib; Avastin AbbVie; Roche Deborah Kay Armstrong 5523 in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

5:36 PM 5:48 PM Playing the PARP Iain A. McNeish 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Head and Neck Cancer Location: S100a 4:30 PM 6:00 PM Chair - Head and Neck Cancer 4:30 PM 6:00 PM Chair - Head and Neck Cancer Miren Taberna 4:30 PM 4:42 PM EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab Imfinzi; AstraZeneca Lisa F. Licitra 6012 (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M tremelimumab HNSCC). 4:30 PM 4:42 PM Palbociclib plus versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, Ibrance; Erbitux Pfizer; Eli Lilly Douglas Adkins 6013 HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).

4:30 PM 4:42 PM Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in RM-1929 Rakuten Medical David M. Cognetti 6014 patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

4:30 PM 4:42 PM Therapy for Recurrent/Metastatic HNSCC: One Step Forward, Two Steps Back Benjamin J. Solomon 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) Libtayo Regeron Michael Robert Migden 6015 with locally advanced cutaneous squamous cell carcinoma (laCSCC). Pharmaceuticals 4:52 PM 5:04 PM Discordant treatment response in primary tumors and lymph node metastases after four weeks of Adam Luginbuhl 6016 preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC).

4:52 PM 5:04 PM Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with JS001 Shanghai Junshi Fenghua Wang 6017 refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical Biosciences Co. study. 4:52 PM 5:04 PM Immunotherapy: Can't Get Enough of IT! Katharine Andress Rowe Price 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with BLU-667 Blueprint Medicines Matthew H. Taylor 6018 advanced RET-altered thyroid cancers. Corporation

5:14 PM 5:26 PM Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, anlotinib Advenchen Dapeng Li 6019 randomized, double-blind, placebo-controlled phase IIB trial. Laboratories 5:14 PM 5:26 PM Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen Xtandi Astellas Alan Loh Ho 6020 receptor-positive salivary cancers. 5:14 PM 5:26 PM The Best of the Rest: Thyroid and Salivary Jochen H. Lorch 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Longitudinal circulating Epstein–Barr virus DNA response to induction chemotherapy and chemo- Jia-Wei Lv 6021 radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer. 5:36 PM 5:48 PM Mature results of the LCCC1413 phase II trial of de-intensified chemoradiotherapy for HPV- Bhishamjit S. Chera 6022 associated oropharyngeal squamous cell carcinoma. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 5:36 PM 5:48 PM NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation Keytruda Merck & Co. Julie E. Bauman 6023 therapy (IMRT), and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma (HNSCC). 5:36 PM 5:48 PM Optimizing Radiotherapy for Head and Neck Cancers Sue Sun Yom 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Health Services Research, Clinical Informatics, and Quality of Care Location: S102 4:30 PM 6:00 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Katherine S. Virgo 4:30 PM 6:00 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Gabriel A. Brooks 4:30 PM 4:42 PM The financial impact of fractionation scheme and treatment planning method for rectal cancer in the Assaf Moore 6518 United States. 4:30 PM 4:42 PM Quantification of the financial burden of antineoplastic agent price increases. Michail Alevizakos 6519 4:30 PM 4:42 PM Trends in financial relationships between industry and individual medical oncologists in the United Deborah Catherine 6520 States from 2014 to 2017: A cohort study. Marshall 4:30 PM 4:42 PM Recognizing Value When You See It Aaron Philip Mitchell 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Comparative effectiveness of proton therapy versus photon therapy as part of concurrent Brian Christopher 6521 chemoradiotherapy for locally advanced cancer. Baumann 4:52 PM 5:04 PM Enhancing community capacity to improve cancer care delivery and the effect on patient-reported Manali I. Patel 6522 outcomes, healthcare utilization and total costs of care. 4:52 PM 5:04 PM Early case ascertainment and prospective multidisciplinary review for management of new Thach-Giao Truong 6523 melanoma diagnoses within an integrated healthcare system: The Kaiser Permanente Northern California experience. 4:52 PM 5:04 PM Care Delivery in Anytown, USA: What Is Feasible? John Vernon Cox 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Effect of exercise during adjuvant chemotherapy for breast cancer. Barbara K Haas 6524 5:14 PM 5:26 PM Clinical outcomes and cost-effectiveness of breast cancer screening for childhood cancer survivors Jennifer Yeh 6525 treated with chest radiation: A comparative modeling study. 5:14 PM 5:26 PM Previsit breast cancer educational microlearning videos: Impact on patient satisfaction and Rachel M Hurley 6526 engagement. 5:14 PM 5:26 PM Optimizing Breast Cancer Care Across the Continuum Neelima Denduluri 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Growth factor use and rate of neutropenic complications in breast cancer patients treated with dose- Racha Halawi 6527 dense paclitaxel: A 5-year experience from a safety net hospital.

5:36 PM 5:48 PM Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple Nathaniel Rosko 6528 myeloma. 5:36 PM 5:48 PM Reinforcing Bones and Bone Marrow Anne C. Chiang 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Highlights of the Day Session Highlights of the Day Session I Location: Hall D1 7:30 AM 9:15 AM Chair - Highlights of the Day Session I Melissa Lynne Johnson

7:30 AM 7:45 AM Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers David Harpole 7:45 AM 8:00 AM Gastrointestinal (Colorectal) Cancer Andrea Cercek 8:00 AM 8:15 AM Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Jorge E. Cortes

8:15 AM 8:30 AM Head and Neck Cancer Francis P. Worden 8:30 AM 8:45 AM Genitourinary (Prostate) Cancer Celestia S. Higano

Clinical Science Symposium Are We Hitting the Bull's-eye With Targeted Therapy? Location: S406 8:00 AM 9:30 AM Chair - Are We Hitting the Bull's-eye With Targeted Therapy? Daniela Matei 8:00 AM 9:30 AM Chair - Are We Hitting the Bull's-eye With Targeted Therapy? Kunle Odunsi 8:00 AM 8:12 AM Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial Gloria S. Huang 5509 cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.

8:12 AM 8:24 AM Sugar and Sex: Identifying Biomarkers in Endometrial Cancer Victoria Lin Bae-Jump

8:24 AM 8:36 AM Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor Kisqali; Femara Novartis Gerardo Colon-Otero 5510 (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.

8:36 AM 8:48 AM Endocrine Therapy: The Old Frontier Revisited? Helen Mackay 8:48 AM 9:00 AM A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients entinostat; Bavencio Syndax; Merck KGaA Karen Anne Cadoo 5511 (pts) with advanced epithelial ovarian cancer (EOC ). 9:00 AM 9:12 AM Dissecting a Negative Trial: Finding a Niche for Immunotherapy in Ovarian Cancer John L. Hays 9:12 AM 9:30 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Developmental Immunotherapy and Tumor Immunobiology Location: Hall D2 8:00 AM 11:00 AM Chair - Developmental Immunotherapy and Tumor Immunobiology Naoko Takebe 8:00 AM 11:00 AM Chair - Developmental Immunotherapy and Tumor Immunobiology Heather L. McArthur 8:00 AM 8:12 AM Phase I study of pembrolizumab in people with HIV and cancer. Keytruda Merck & Co. Thomas S. Uldrick 2500 8:12 AM 8:24 AM Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected. Imfinzi AstraZeneca Maria Gonzalez-Cao 2501 8:24 AM 8:36 AM A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, Keytruda Merck & Co. Sara I. Pai 2502 and/or pulmonary involvement. 8:36 AM 8:48 AM Expanding Patient Populations for Immunotherapy Claire Frances Friedman

8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson Can-Fite Salomon M. Stemmer 2503 namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

9:12 AM 9:24 AM Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully nidanilimab Cantargia Ahmad Awada 2504 humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. 9:24 AM 9:36 AM Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune CPI-006 Corvus Jason J. Luke 2505 modulating activity, in a phase 1 trial in advanced cancers. 9:36 AM 9:48 AM Expanding Targets for Immunotherapy Benjamin Garrett Vincent 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: birinapant; Keytruda Medivir; Merck & Russell J. Schilder 2506 Results from the dose-escalation phase of BPT-201. Co. 10:12 AM 10:24 AM Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) ADU-S100; Aduro; Novartis Funda Meric-Bernstam 2507 with advanced/metastatic solid tumors or lymphomas. spartalizumab 10:24 AM 10:36 AM First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± REGN-3767; Libtayo Regeneron Kyriakos P. 2508 cemiplimab in patients (pts) with advanced malignancies. Papadopoulos 10:36 AM 10:48 AM Expanding the Horizon of Rational Immunotherapy Combinations Sanjay Goel 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Clinical Science Symposium Dissecting Genomic Biomarkers in Head and Neck Cancer Location: E450 8:00 AM 9:30 AM Chair - Dissecting Genomic Biomarkers in Head and Neck Cancer Trisha Michel Wise- Draper 8:00 AM 9:30 AM Chair - Dissecting Genomic Biomarkers in Head and Neck Cancer Glenn J. Hanna 8:00 AM 8:12 AM Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). William Nassib William 6009

8:12 AM 8:24 AM Oral Precancer Biomarkers for Progression Mark W. Lingen 8:24 AM 8:36 AM Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck Chieko Michikawa 6010 cancer from a phase II clinical trial: NRG Oncology RTOG 0234. 8:36 AM 8:48 AM The Guardian of the Genome Luc Morris 8:48 AM 9:00 AM PIK3CA mutation as a prognostic factor in HPV-associated oropharynx cancer. Brian T. Beaty 6011 9:00 AM 9:12 AM Picking Out the Worst in HPV-Positive Head and Neck Cancer Christine H. Chung 9:12 AM 9:30 AM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract #

Oral Abstract Session Health Services Research, Clinical Informatics, and Quality of Care II Location: S404 8:00 AM 11:00 AM Chair - Health Services Research, Clinical Informatics, and Quality of Care II Faithlore Patrice Gardner 8:00 AM 8:12 AM The impact of routine ESAS use on overall survival: Results of a population-based retrospective Lisa Catherine Barbera 6509 matched cohort analysis. 8:12 AM 8:24 AM Phase III non-randomized controlled trial of PROMPT-Care, an eHealth intervention utilizing patient Afaf Girgis 6510 reported outcomes in routine clinical care: Impact on emergency department presentations.

8:24 AM 8:36 AM Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular Revlimid Celgene Gita Thanarajasingam 6511 lymphoma in ECOG-ACRIN 2408. 8:36 AM 8:48 AM Population-based cohort of prostate cancer patients on active surveillance (AS): guideline Sabrina Peterson 6512 adherence, conversion to treatment and decisional regret. 8:48 AM 9:00 AM Asking and Listening to Deliver Better Care Stewart Barry Fleishman 9:00 AM 9:12 AM Panel Question and Answer Panel Discussion 9:12 AM 9:24 AM Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Consolacion Molto 6513 Administration. 9:24 AM 9:36 AM The use of optimal evidence-based chemotherapy (chemo) regimens in physician offices versus Michael Jordan Fisch 6514 hospital outpatient facilities. 9:36 AM 9:48 AM On the Path to Effective, Patient-Centered Policy Veena Shankaran 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Integrating psychosocial care into routine cancer care: a stepped-wedge design cluster randomized Rodolfo Passalacqua 6515 controlled trial (SWD-RCT) to evaluate effectiveness of the HuCare Quality Improvement Strategy (HQIS) on health-related quality of life (HRQoL). 10:12 AM 10:24 AM Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) Dawn L. Hershman 6516 therapy in women with breast cancer: SWOG S1105. 10:24 AM 10:36 AM Impact of Electronically Accessible Pathways (EAPathways) on clinical trial enrollment at a large Jeryl Jean Villadolid 6517 multisite cancer center. 10:36 AM 10:48 AM Bringing Clinical Trials to Cancer Care Delivery Rachel A. Freedman 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Pediatric Oncology II Location: S504 8:00 AM 11:00 AM Chair - Pediatric Oncology II Sara Michele Federico

8:00 AM 11:00 AM Chair - Pediatric Oncology II Scott C. Borinstein 8:00 AM 8:12 AM Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or entrectinib Roche Giles W. Robinson 10009 refractory solid tumors including central nervous system (CNS) tumors. 8:12 AM 8:24 AM Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients. Vitrakvi Bayer Cornelis Martinus van 10010 Tilburg 8:24 AM 8:36 AM Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. Donald Williams 10011 Parsons 8:36 AM 8:48 AM On the Right TRK: Finding the Next Success in Pediatric Precision Oncology Daniel Alexander Morgenstern 8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM A revised children's oncology group (COG) neuroblastoma risk classification system: Report from the Meredith Irwin 10012 COG biology study ANBL00B1. 9:12 AM 9:24 AM Randomization of dose-reduced subcutaneous -2 (scIL2) in maintenance immunotherapy Qarziba EUSA Pharma Ruth Lydia Ladenstein 10013 (IT) with anti-GD2 antibody beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.

9:24 AM 9:36 AM Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without Qarziba EUSA Pharma Holger N. Lode 10014 subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. 9:36 AM 9:48 AM Neuroblastoma in 2019: Refining Classification and Therapy Barbara Hero 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A Xuexia Wang 10015 COG-ALTE03N1 and CCSS report. 10:12 AM 10:24 AM Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) Stephanie Dixon 10016 in the Childhood Cancer Survivor Study. 10:24 AM 10:36 AM Comparing late mortality risks among childhood cancer survivors: A report from the Childhood Miranda Marie Fidler 10017 Cancer Survivor Study and British Childhood Cancer Survivor Study. 10:36 AM 10:48 AM Global Application of Risk Stratification in Childhood Cancer Survivors 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Clinical Science Symposium Evidence, Care, Impact: Making Inroads Against Cancer Disparities Location: Hall D1 9:45 AM 11:15 AM Chair - Evidence, Care, Impact: Making Inroads Against Cancer Disparities Christopher S. Lathan

9:45 AM 9:57 AM Genetic predisposition to breast cancer among African American women. Julie R Palmer 104 9:57 AM 10:09 AM Ethnicity: Does It Influence One's Inheritable Cancer Risk and What Are the Implications for Care? Mark E. Robson

10:09 AM 10:21 AM The Affordable Care Act and cost-related medication non-compliance in cancer survivors. Justin Barnes 106 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 10:21 AM 10:33 AM Insurance status and survival of multiple myeloma (MM) patients. Kamal Chamoun LBA107 10:33 AM 10:45 AM Leveling the Playing Field: Health Policy and Cancer Disparities 10:45 AM 11:03 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Gastrointestinal (Noncolorectal) Cancer Location: Arie Crown Theater 9:45 AM 12:45 PM Chair - Gastrointestinal (Noncolorectal) Cancer Jennifer A. Chan 9:45 AM 12:45 PM Chair - Gastrointestinal (Noncolorectal) Cancer Vaibhav Sahai 9:45 AM 9:57 AM APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel Abraxane Celgene Margaret A. Tempero 4000 plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

9:57 AM 10:09 AM ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or Se Hoon Park 4001 chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). 10:09 AM 10:21 AM A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency Namiki Izumi 4002 ablation for small hepatocellular carcinoma (SURF trial). 10:21 AM 10:33 AM Integrating Therapies in Localized Cancer Jiping Wang 10:33 AM 10:45 AM Panel Question and Answer Panel Discussion 10:45 AM 10:57 AM ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) Angela Lamarca 4003 alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. 10:57 AM 11:09 AM Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for Keytruda Merck & Co. Richard S. Finn 4004 second line therapy in advanced hepatocellular carcinoma (HCC). 11:09 AM 11:21 AM Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive Votrient Novartis Emily K. Bergsland 4005 carcinoid tumors (CARC)(Alliance A021202). 11:21 AM 11:33 AM Advances in Advanced Disease William Proctor Harris

11:33 AM 11:45 AM Panel Question and Answer Panel Discussion 11:45 AM 11:57 AM Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer Peter S Hall 4006 (aGOAC): The GO2 phase III trial. 12:09 PM 12:21 PM S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed- Rui-hua Xu 4017 type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

12:21 PM 12:33 PM Expanding Options in GE Cancers Ian Chau 12:33 PM 12:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Hematologic Malignancies—Plasma Cell Dyscrasia Location: E451 9:45 AM 12:45 PM Chair - Hematologic Malignancies—Plasma Cell Dyscrasia Noopur S. Raje 9:45 AM 9:57 AM Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised Jesus San Miguel 8000 IMWG diagnostic criteria. 9:57 AM 10:09 AM E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with Revlimid Celgene Sagar Lonial 8001 asymptomatic high-risk smoldering multiple myeloma. 10:09 AM 10:21 AM Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly Kyprolis; Revlimid Celgene Francesca Gay 8002 diagnosed myeloma according to risk status: Results from the FORTE trial.

10:21 AM 10:33 AM Something Old, Something New: Evolving Paradigms in Untreated Multiple Myeloma Philip L. McCarthy 10:33 AM 10:45 AM Panel Question and Answer Panel Discussion 10:45 AM 10:57 AM Phase 3 randomized study of (DARA) + bortezomib/thalidomide/dexamethasone (D- Darzalex Amgen Philippe Moreau 8003 VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. 10:57 AM 11:09 AM A phase III randomized, open label, multicenter study comparing , pomalidomide, and low- isatuximab; Sanofi; Celgene Paul G. Richardson 8004 dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with Pomalyst relapsed/refractory multiple myeloma (RRMM). 11:09 AM 11:21 AM Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous Darzalex Amgen Maria-Victoria Mateos 8005 (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. 11:21 AM 11:33 AM The Many Faces of Monoclonal Antibody Targeting of CD38 Faith Davies 11:33 AM 11:45 AM Panel Question and Answer Panel Discussion 11:45 AM 11:57 AM First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with iberdomide Celgene Sagar Lonial 8006 dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

11:57 AM 12:09 PM Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R AMG 420 Amgen Max S. Topp 8007 multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. 12:09 PM 12:21 PM It's Not All About CAR T: What's New in Immunotherapy? Jesus G. Berdeja 12:21 PM 12:33 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Breast Cancer—Metastatic Location: Hall D2 11:15 AM 12:45 PM Chair - Breast Cancer—Metastatic Nicholas C. Turner 11:15 AM 12:45 PM Chair - Breast Cancer—Metastatic Sara M. Tolaney 11:15 AM 11:27 AM Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first- Tecentriq; Cotellic; Roche; Celgene Adam Brufsky 1013 line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast Abraxane cancer (mTNBC). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 11:15 AM 11:27 AM Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational Keytruda Merck & Co. Ajjai Shivaram Alva 1014 burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

11:15 AM 11:27 AM Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of Keytruda Merck & Co. David B. Page 1015 metastatic triple-negative breast cancer (mTNBC). 11:15 AM 11:27 AM Refining Immunotherapy Strategies in Breast Cancer Justin M. Balko 11:27 AM 11:37 AM Panel Question and Answer Panel Discussion 11:37 AM 11:49 AM Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2- advanced breast Kisqali; Afinitor Novartis Aditya Bardia 1016 cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

11:37 AM 11:49 AM A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- Verzenio Eli Lilly Carey K. Anders 1017 metastatic breast cancer (MBC). 11:37 AM 11:49 AM In-depth gene expression analysis of premenopausal patients with HR+/HER2- advanced breast Kisqali Novartis Yen-Shen Lu 1018 cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.

11:37 AM 11:49 AM Characterization of mutational processes in ER+ metastatic breast cancer. Jorge Buendia-Buendia 1019

11:37 AM 11:49 AM Advancing Our Knowledge in ER-Positive Breast Cancer Komal L. Jhaveri 11:49 AM 11:59 AM Panel Question and Answer Panel Discussion 11:59 AM 12:09 PM End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled Perjeta; Herceptin Roche Sandra M. Swain 1020 CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 11:59 AM 12:09 PM Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination Ogivri Mylan Cornelius F. Waller 1021 therapy: Final overall survival (OS) from the phase III HERITAGE Trial. 11:59 AM 12:09 PM HER2-Positive Disease: How Far We Have Come? Olwen Mary Hahn 12:09 PM 12:19 PM Panel Question and Answer Panel Discussion 12:19 PM 12:31 PM Genomic landscape of de novo stage IV breast cancer. Ana Christina Garrido- 1022 Castro 12:19 PM 12:31 PM Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). Jeffrey S. Ross 1023 12:19 PM 12:31 PM mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic Thomas Denis Bachelot 1024 breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.

12:19 PM 12:31 PM Letting Genomics Lead the Way Christos Sotiriou 12:31 PM 12:45 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: S406 11:15 AM 12:45 PM Chair - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Anne S. Tsao 11:15 AM 12:45 PM Chair - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Robert B. Cameron 11:15 AM 11:27 AM Randomized phase II study of adjuvant afatinib for three months versus two years in patients with Gilotrif Boehringer Jamie E. Chaft 8507 resected stage I-III EGFR mutant NSCLC. Ingelheim 11:15 AM 11:27 AM The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung Peng Xie 8508 cancer. 11:15 AM 11:27 AM NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell Mariano Provencio 8509 lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment. 11:15 AM 11:27 AM Building on the Standards for Operable Lung Cancer Don Lynn Gibbons 11:27 AM 11:37 AM Panel Question and Answer Panel Discussion 11:37 AM 11:49 AM Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus veliparib AbbVie David E. Kozono 8510 radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07).

11:37 AM 11:49 AM Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent Keytruda Merck & Co. Salma K. Jabbour 8511 chemoradiation for locally advanced, unresectable non-small cell lung cancer.

11:37 AM 11:49 AM Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced Tecentriq Roche Steven H. Lin 8512 non-small cell lung cancer. 11:37 AM 11:49 AM Adding to Chemoradiation in Locally Advanced NSCLC Kristin Ann Higgins 11:49 AM 11:59 AM Panel Question and Answer Panel Discussion 11:59 AM 12:11 PM Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316). Susanne M. Arnold 8513

11:59 AM 12:11 PM Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in adavosertib; AstraZeneca Sehhoon Park 8514 relapsed small cell lung cancer. vistusertib; accurin

11:59 AM 12:11 PM A randomized phase II study of tremelimumab and durvalumab with or without radiation for tremelimumab; AstraZeneca Taofeek Kunle 8515 patients with relapsed small cell lung cancer (SCLC). Imfinzi Owonikoko 11:59 AM 12:11 PM Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with rovalpituzumab AbbVie; Bristol Jyoti Malhotra 8516 2L+ extensive-stage (ED) SCLC. tesirine; Opdivo; Myers Squibb Yervoy 11:59 AM 12:11 PM Relapsed SCLC: A Difficult Path Ahead Jared Weiss 12:11 PM 12:21 PM Panel Question and Answer Panel Discussion 12:21 PM 12:33 PM Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients Alimta Eli Lilly Arkadiusz Z. Dudek 8517 (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).

12:21 PM 12:33 PM A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for Alimta Eli Lilly Seiki Hasegawa 8518 malignant pleural mesothelioma (Japan Mesothelioma Interest Group 1101 Trial). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 12:21 PM 12:33 PM Surgery and Maintenance Therapy for Mesothelioma Aaron Scott Mansfield

12:33 PM 12:45 PM Panel Question and Answer Panel Discussion

Plenary Session Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture Location: Hall B1 1:00 PM 4:00 PM Chair - Plenary Session Including the Distinguished Achievement Award and Science of Oncology Suzanne George Award Lecture 1:00 PM 4:00 PM Chair - Plenary Session Including the Distinguished Achievement Award and Science of Oncology Monica M. Bertagnolli Award Lecture 1:00 PM 1:02 PM Welcome and Introductory Remarks Monica M. Bertagnolli

1:02 PM 1:07 PM Presentation of the Distinguished Achievement Award Bruce E. Johnson 1:07 PM 1:10 PM Distinguished Achievement Award Recipient Robert J. Mayer 1:10 PM 1:15 PM Presentation of the Science of Oncology Award Bruce E. Johnson 1:15 PM 1:40 PM Science of Oncology Award Lecture: Tumor Cell Stress Management in Progression and Therapy Resistance 1:40 PM 1:45 PM Introduction to Plenary Session. Suzanne George 1:45 PM 2:00 PM Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer Blythe J.S. Adamson LBA1 treatment. 2:00 PM 2:15 PM Discussion - Plenary Session Including the Distinguished Achievement Award and Science of Yousuf Zafar Oncology Award Lecture 2:15 PM 2:30 PM Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or Xtandi Astellas Christopher Sweeney LBA2 without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. 2:30 PM 2:45 PM Discussion - Plenary Session Including the Distinguished Achievement Award and Science of Tanya B. Dorff Oncology Award Lecture 2:45 PM 3:00 PM ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin Lartruvo Eli Lilly William D. Tap LBA3 (dox) + versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

3:00 PM 3:15 PM Discussion - Plenary Session Including the Distinguished Achievement Award and Science of Jaap Verweij Oncology Award Lecture 3:15 PM 3:30 PM Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in Lynparza AstraZeneca Hedy L. Kindler LBA4 patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. 3:30 PM 3:45 PM Discussion - Plenary Session Including the Distinguished Achievement Award and Science of Wells A. Messersmith Oncology Award Lecture

Plenary Session Post-Plenary Discussion: Health Services Research (LBA1) Location: S100a 4:00 PM 4:45 PM Chair - Post-Plenary Discussion: Health Services Research (LBA1) Gabriel A. Brooks 4:00 PM 4:45 PM Panel Speaker Yousuf Zafar 4:00 PM 4:45 PM Panel Speaker Deborah Schrag 4:00 PM 4:45 PM Panel Speaker Blythe J.S. Adamson 4:00 PM 4:45 PM Panel Speaker Blase N. Polite

Plenary Session Post-Plenary Clinical Application and Discussion: Prostate Cancer (LBA2) Location: S100bc 4:15 PM 5:00 PM Chair - Post-Plenary Clinical Application and Discussion: Prostate Cancer (LBA2) Celestia S. Higano 4:15 PM 5:00 PM Panel Speaker Ian D. Davis 4:15 PM 5:00 PM Panel Speaker Christopher Sweeney

4:15 PM 5:00 PM Panel Speaker

Poster Discussion Session Breast Cancer—Local/Regional/Adjuvant Location: Hall D2 4:30 PM 6:00 PM Chair - Breast Cancer—Local/Regional/Adjuvant Erica L. Mayer 4:30 PM 6:00 PM Chair - Breast Cancer—Local/Regional/Adjuvant Eun-Sil Shelley Hwang

4:30 PM 4:42 PM Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast Sibylle Loibl 509 cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. 4:30 PM 4:42 PM Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Otto Metzger Filho 510 Results from BrighTNess phase III study. 4:30 PM 4:42 PM NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic Sandra M. Swain 511 complete response (pCR). 4:30 PM 4:42 PM Precision in Targeted Treatment Selection: New Advances Ruth O'Regan 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 Arlindo R. Ferreira 512 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.

4:52 PM 5:04 PM Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab Kadcyla Roche Andreas Schneeweiss 513 emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:52 PM 5:04 PM Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with Juliet Richman 514 early ER+ breast cancer. 4:52 PM 5:04 PM Quality and Quantity: Living Your Best Life Norah Lynn Henry 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant Abraxane Celgene Luca Gianni 515 nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2- negative high-risk breast cancer. 5:14 PM 5:26 PM Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus Priyanka Sharma 516 paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

5:14 PM 5:26 PM Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) Romualdo Barroso- 517 doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study. Sousa 5:14 PM 5:26 PM Neo/adjuvant Chemotherapy Optimization: Is This End of the Quest? Nadia Harbeck 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Association between tumor biology and occult lymph node metastases before and after primary Hans-Christian Kolberg 518 neoadjuvant therapy (NAT) for patients with early breast cancer. 5:36 PM 5:48 PM Adjuvant endocrine monotherapy (ET) versus adjuvant breast radiation (RT) alone in healthy older Anthony H. Bui 519 women with stage I, estrogen receptor-positive (ER+) breast cancer: An analysis of the National Cancer Database (NCDB). 5:36 PM 5:48 PM Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women's Health Rowan T. Chlebowski 520 Initiative randomized clinical trial. 5:36 PM 5:48 PM Local Therapy and Lifestyles: What's New? Lior Zvi Braunstein 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Central Nervous System Tumors Location: S404 4:30 PM 6:00 PM Chair - Central Nervous System Tumors Sani Haider Kizilbash 4:30 PM 6:00 PM Chair - Central Nervous System Tumors Phioanh Leia Nghiemphu 4:30 PM 4:42 PM NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain Vinai Gondi 2009 radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). 4:30 PM 4:42 PM A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients veliparib AbbVie Mustafa Khasraw 2011 (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM). 4:30 PM 4:42 PM Optimizing Efficacy and Safety of Radiation Therapy for Brain Tumors Monica Malik 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel Maximilian Knoll 2012 methylome based glioma subtypes. 4:52 PM 5:04 PM Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on Wolfgang Wick 2013 the methylation subgroup. 4:52 PM 5:04 PM Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC. Melinda D Willard 2014

4:52 PM 5:04 PM Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS Mihaela Aldea 2015 progression. 4:52 PM 5:04 PM Molecular Diagnostics and Precision Medicine for Brain Tumors Monika E. Hegi 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. Manmeet Singh 2016 Ahluwalia 5:14 PM 5:26 PM Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in Michael Lim 2017 patients with recurrent GBM. 5:14 PM 5:26 PM Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB- ofranergeneobaden VBL Therapeutics; Benjamin M. Ellingson 2018 111 with or without bevacizumab or bevacizumab monotherapy. ovec; Avastin Roche 5:14 PM 5:26 PM Exploring New Directions in Glioma Immunotherapy 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and Pedro R. Lowenstein 2019 FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system. 5:36 PM 5:48 PM Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent E. Antonio Chiocca 2020 glioblastoma. 5:36 PM 5:48 PM Incorporating Gene and Viral Therapies in Brain Tumor Treatment 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Lung Cancer—Non-Small Cell Metastatic Location: Hall D1 4:30 PM 6:00 PM Chair - Lung Cancer—Non-Small Cell Metastatic Robert Charles Doebele

4:30 PM 6:00 PM Chair - Lung Cancer—Non-Small Cell Metastatic Gilberto Lopes 4:30 PM 4:42 PM IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets). Mark A. Socinski 9012 4:30 PM 4:42 PM KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with Keytruda; Alimta Merck & Co.; Eli Lilly Shirish M. Gadgeel 9013 pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. 4:30 PM 4:42 PM A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated Opdivo; Yervoy Bristol Myers Squibb Lyudmila Bazhenova 9014 patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). 4:30 PM 4:42 PM Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Keytruda Merck & Co. Edward B. Garon LBA9015 Results from KEYNOTE-001. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 4:30 PM 4:42 PM Parsing the Data for Checkpoint Inhibitors in 2019 Kathryn Cecilia Arbour

4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in Imfinzi; AstraZeneca Naiyer A. Rizvi 9016 MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) tremelimumab NSCLC. 4:52 PM 5:04 PM Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint Lingzhi Hong 9017 blockade in non-small cell lung cancer (NSCLC). 4:52 PM 5:04 PM Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer. Hira Rizvi 9018 4:52 PM 5:04 PM Furthering Our Knowledge of Biomarkers for Checkpoint Inhibitors in NSCLC Marina Chiara Garassino 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced Lorbrena Pfizer Alice Tsang Shaw 9019 ALK-positive non-small cell lung cancer (NSCLC). 5:14 PM 5:26 PM Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator Tagrisso AstraZeneca Caicun Zhou 9020 EGFR-TKIs in the FLAURA trial. 5:14 PM 5:26 PM Dynamic Changes in Plasma: Ready for Prime Time? Benjamin Philip Levy 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation Mekinist Novartis Shirish M. Gadgeel 9021 positive (+) recurrent non-small cell lung cancer (NSCLC). 5:36 PM 5:48 PM A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair Talzenna Pfizer Taofeek Kunle 9022 deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). Owonikoko

5:36 PM 5:48 PM c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell telisotuzumab AbbVie Rebecca Suk Heist 9023 lung cancer. vedotin 5:36 PM 5:48 PM Old Targets, New Approaches Martin Edelman 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Plenary Session Post-Plenary Clinical Application and Discussion: Sarcoma (LBA3) Location: S100a 5:00 PM 5:45 PM Chair - Post-Plenary Clinical Application and Discussion: Sarcoma (LBA3) Rashmi Chugh 5:00 PM 5:45 PM Panel Speaker William D. Tap 5:00 PM 5:45 PM Panel Speaker Patrick Schoffski 5:00 PM 5:45 PM Panel Speaker Jaap Verweij 5:00 PM 5:45 PM Panel Speaker Patricia Keegan

Plenary Session Post-Plenary Clinical Application and Discussion: Pancreatic Cancer (LBA4) Location: S100bc 5:15 PM 6:00 PM Chair - Post-Plenary Clinical Application and Discussion: Pancreatic Cancer (LBA4) Vaibhav Sahai 5:15 PM 6:00 PM Panel Speaker Hedy L. Kindler 5:15 PM 6:00 PM Panel Speaker 5:15 PM 5:35 PM Panel Speaker 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Highlights of the Day Session Highlights of the Day Session II Location: Hall D1 7:30 AM 9:15 AM Chair - Highlights of the Day Session II Colin D. Weekes 7:30 AM 7:45 AM Developmental Immunotherapy and Tumor Immunobiology Mary L. Disis 7:45 AM 8:00 AM Health Services Research, Clinical Informatics, and Quality of Care Ronald C. Chen 8:00 AM 8:15 AM Gastrointestinal (Noncolorectal) Cancer Steven Ades 8:15 AM 8:30 AM Hematologic Malignancies—Plasma Cell Dyscrasia Noopur S. Raje

Oral Abstract Session Developmental Therapeutics and Tumor Biology (Nonimmuno) Location: S406 8:00 AM 11:00 AM Chair - Developmental Therapeutics and Tumor Biology (Nonimmuno) Irene Brana 8:00 AM 11:00 AM Chair - Developmental Therapeutics and Tumor Biology (Nonimmuno) Kyriakos P. Papadopoulos 8:00 AM 8:12 AM Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS belvarafenib Roche Tae Won Kim 3000 mutations: Phase I study. 8:12 AM 8:24 AM A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) LY3214996 Eli Lilly Shubham Pant 3001 patients (pts). 8:24 AM 8:36 AM Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the Tafinlar; Mekinist Novartis April K.S. Salama 3002 molecular analysis for therapy choice (MATCH) Arm H. 8:36 AM 8:48 AM Targeting MAPK Pathways: How Low Should We Go? Bob T. Li 8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a AMG-510 Amgen Marwan Fakih 3003 novel small molecule KRASG12C inhibitor, in advanced solid tumors. 9:12 AM 9:24 AM First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in ABBV-085 AbbVie George D. Demetri 3004 sarcomas and other advanced solid tumors. 9:24 AM 9:36 AM Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. ONC201 Oncoceutics Isabel Arrillaga 3005 9:36 AM 9:48 AM Breaking the Code: Drugging Difficult Targets and Tumors Sarina Anne Piha-Paul

9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type Talzenna Pfizer Joshua James Gruber 3006 patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. 10:12 AM 10:24 AM First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in BAY 1895344 Bayer Johann S. De Bono 3007 patients (pts) with advanced solid tumors. 10:24 AM 10:36 AM Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced FF-10502 Fujifilm Filip Janku 3008 cholangiocarcinoma and solid tumors. 10:36 AM 10:48 AM Expanding the Horizon of Synthetic Lethality Gregory Michael Cote

10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Genitourinary (Nonprostate) Cancer Location: Arie Crown Theater 8:00 AM 11:00 AM Chair - Genitourinary (Nonprostate) Cancer Samuel D. Kaffenberger

8:00 AM 11:00 AM Chair - Genitourinary (Nonprostate) Cancer Raquibul Hannan 8:00 AM 8:12 AM Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal Keytruda; axitinib Merck & Co; Brian I. Rini 4500 cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid Clearside Biomedical subgroups of the phase 3 KEYNOTE-426 study. 8:12 AM 8:24 AM A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + Opdivo Bristol-Myers Squibb Jianjun Gao 4501 ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). 8:24 AM 8:36 AM Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic Votrient Novartis Leonard Joseph 4502 renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG- Appleman ACRIN cancer research group (E2810). 8:36 AM 8:48 AM Evolving Front-Line Therapy in Metastatic Renal Cell Carcinoma Rana R. McKay 8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing Jonathan E. Rosenberg 4503 gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. 9:12 AM 9:24 AM Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first- Keytruda Merck & Co Matt D. Galsky 4504 line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.

9:24 AM 9:36 AM EV-201: Results of monotherapy for locally advanced or metastatic urothelial enfortumab vedotin Astellas Daniel Peter Petrylak 4505 cancer previously treated with platinum and immune checkpoint inhibitors.

9:36 AM 9:48 AM Novel Treatment Strategies in Metastatic Urothelial Carcinoma Andrea Necchi 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant Thomas W. Flaig 4506 chemotherapy for localized, muscle-invasive bladder cancer. 10:12 AM 10:24 AM Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced Mohamed S. Zaghloul 4507 bladder cancer after radical cystectomy. 10:24 AM 10:36 AM Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with Arnaud Mejean 4508 focus on intermediate IMDC-risk population. 10:36 AM 10:48 AM Integrating Local and Systemic Modalities in Bladder and Renal Cancers Alexander Kutikov 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Oral Abstract Session Lung Cancer—Non-Small Cell Metastatic Location: Hall B1 8:00 AM 11:00 AM Chair - Lung Cancer—Non-Small Cell Metastatic Hossein Borghaei 8:00 AM 11:00 AM Chair - Lung Cancer—Non-Small Cell Metastatic Ticiana Leal 8:00 AM 8:12 AM RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination Tarceva; Cyramza Roche; Eli Lilly Kazuhiko Nakagawa 9000 with (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

8:12 AM 8:24 AM Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin Iressa AstraZeneca Vanita Noronha 9001 chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). 8:24 AM 8:36 AM ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for Suresh S. Ramalingam 9002 advanced non-squamous NSCLC. 8:36 AM 8:48 AM A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed Takashi Seto 9003 after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L). 8:48 AM 9:00 AM Chemotherapy and Antiangiogenic Therapy in 2019: Who Needs It? Maurice Perol 9:00 AM 9:12 AM Panel Question and Answer Panel Discussion 9:12 AM 9:24 AM Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy capmatinib Novartis Juergen Wolf 9004 data from the phase II GEOMETRY mono-1 study. 9:24 AM 9:36 AM Phase II study of tepotinib in NSCLC patients with METex14 mutations. tepotinib Merck KGaA Paul K. Paik 9005 9:36 AM 9:48 AM MET inhibitor resistance in patients with MET exon 14-altered lung cancers. Robin Guo 9006 9:48 AM 10:00 AM New Drugs and Resistance: Have We MET Expectations? Karen L. Reckamp 10:00 AM 10:12 AM Panel Question and Answer Panel Discussion 10:12 AM 10:24 AM Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. TAK-788 Takeda Pasi A. Janne 9007 10:24 AM 10:36 AM Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients BLU-667 Blueprint Medicines Justin F. Gainor 9008 (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Corporation

10:36 AM 10:48 AM Emerging Therapies for New Targets Christine Marie Lovly 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Sarcoma Location: E450 8:00 AM 11:00 AM Chair - Sarcoma Angela C. Hirbe 8:00 AM 11:00 AM Chair - Sarcoma James Lin Chen 8:00 AM 8:12 AM Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical Alessandro Gronchi 11000 trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). 8:12 AM 8:24 AM STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery Sylvie Bonvalot 11001 versus surgery alone for patients with retroperitoneal sarcoma. 8:24 AM 8:36 AM Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Votrient Novartis Aaron R. Weiss 11002 A report from Children's Oncology Group (COG) and NRG Oncology. 8:36 AM 8:48 AM Neoadjuvant Strategies in Localized Disease: Dissecting the Results of Three Phase III Studies Raphael E. Pollock

8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid tazemetostat Epizyme Silvia Stacchiotti 11003 sarcoma (ES) (NCT02601950). 9:12 AM 9:24 AM Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. Verzenio Eli Lilly Mark Andrew Dickson 11004

9:24 AM 9:36 AM ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): ABI-009 AADi Andrew J. Wagner 11005 Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. 9:36 AM 9:48 AM Taking Aim at Histology-Specific Targets Winette T.A. Van Der Graaf 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of Cometriq Exelixis Patrick Schoffski 11006 imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST. 10:12 AM 10:24 AM Results of the first interim assessment of rEECur, an international randomized controlled trial of Martin G. McCabe 11007 chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

10:24 AM 10:36 AM Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced Neeta Somaiah 11008 soft tissue sarcoma (STS). 10:36 AM 10:48 AM Refining Strategies Across the Sarcoma Spectrum Jayesh Desai 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Symptoms and Survivorship Location: S102 8:00 AM 11:00 AM Chair - Symptoms and Survivorship Shoshana M. Rosenberg

8:00 AM 11:00 AM Chair - Symptoms and Survivorship Kevin C. Oeffinger 8:00 AM 8:12 AM A phase II RCT of high-dose supplementation and exercise for cancer treatment-induced Luke Joseph Peppone 11500 bone loss in breast cancer patients on aromatase inhibitors. 8:12 AM 8:24 AM A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents Xgeva Amgen Mark J. Clemons 11501 (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 8:24 AM 8:36 AM Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: Catherine H. Van 11502 SWOG S0702, NCT00874211. Poznak 8:36 AM 8:48 AM Give Me a Break: Optimizing Bone Care Silke Gillessen 8:48 AM 9:00 AM Panel Question and Answer Panel Discussion 9:00 AM 9:12 AM A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined Hironobu Hashimoto 11503 with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

9:12 AM 9:24 AM Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final Alexey Rumyantsev 11504 results of randomized phase II trial. 9:24 AM 9:36 AM Randomized controlled trial (RCT) of a patient navigation (PN) intervention to increase early access Enrique Soto Perez De 11505 to supportive care (SC) for patients with metastatic cancer in a resource-limited setting. Celis

9:36 AM 9:48 AM Supportive Care Is Global 9:48 AM 10:00 AM Panel Question and Answer Panel Discussion 10:00 AM 10:12 AM Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation Matteo Lambertini 11506 (mBRCA): Results of an international cohort study. 10:12 AM 10:24 AM Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer. Po-Ju Lin 11507

10:24 AM 10:36 AM Association of baseline cardiovascular risk factors and health care utilization and costs in elderly Dawn L. Hershman 11508 breast cancer patients enrolled in SWOG clinical trials. 10:36 AM 10:48 AM Navigating the Cancer Journey Beyond Breast Cancer Ellen Warner 10:48 AM 11:00 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Breast Cancer—Local/Regional/Adjuvant Location: Hall D2 9:45 AM 12:45 PM Chair - Breast Cancer—Local/Regional/Adjuvant Priyanka Sharma 9:45 AM 12:45 PM Chair - Breast Cancer—Local/Regional/Adjuvant Jacqueline Sara Jeruss

9:45 AM 9:57 AM Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T- Sara A. Hurvitz 500 DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. 9:57 AM 10:09 AM Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of Perjeta Roche Jonas C. S. Bergh 501 HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard? 10:09 AM 10:21 AM HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from Perjeta Roche Otto Metzger Filho 502 a prospective clinical trial. 10:21 AM 10:33 AM Anti-HER2 Therapy at the Forefront: Stepping Closer to De-escalation Mark D. Pegram 10:33 AM 10:45 AM Panel Question and Answer Panel Discussion 10:45 AM 10:57 AM Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast Joseph A. Sparano 503 cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. 10:57 AM 11:09 AM Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A Lucia Del Mastro 504 randomized, phase III study of Gruppo Italiano Mammella (GIM). 11:09 AM 11:21 AM Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence John Bartlett 505 (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial. 11:21 AM 11:33 AM Adjuvant Endocrine Therapy: Selecting the Optimal Path Vered Stearns 11:33 AM 11:45 AM Panel Question and Answer Panel Discussion 11:45 AM 11:57 AM GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison Peter A. Fasching 506 to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). 11:57 AM 12:09 PM TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in Erica L. Mayer 507 TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. 12:09 PM 12:21 PM Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III Patricia A. Ganz 508 study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. 12:33 PM 12:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Cancer Prevention, Hereditary Genetics, and Epidemiology Location: S100bc 9:45 AM 12:45 PM Chair - Cancer Prevention, Hereditary Genetics, and Epidemiology Zsofia Kinga Stadler 9:45 AM 12:45 PM Chair - Cancer Prevention, Hereditary Genetics, and Epidemiology John R. Goffin 9:45 AM 9:57 AM Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease. Andrea De Censi 1500

9:57 AM 10:09 AM Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive Julian Oliver Kim 1501 endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial. 10:09 AM 10:21 AM Tam 2.0: Tamoxifen Chemoprevention in the Modern Era Erin Wysong Hofstatter

10:21 AM 10:33 AM Panel Question and Answer Panel Discussion 10:33 AM 10:45 AM Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline Bhavana Sree Vangara 1502 mutations: A large, single-institutional experience. Chapman 10:45 AM 10:57 AM Risk of subsequent cancer diagnosis in patients treated with 3D conformal, intensity modulated, or Michael H. Xiang 1503 proton beam radiation therapy. 10:57 AM 11:09 AM Breast radiotherapy among ATM-mutation carriers. Leslie A. Modlin 1504 11:09 AM 11:21 AM Insights Into Radiation Therapy Risks and Benefits Lori J. Pierce 11:21 AM 11:33 AM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 11:33 AM 11:45 AM Relative risks of prostate cancer associated with different family cancer histories. Jennifer Lynn Beebe- 1505 Dimmer 11:45 AM 11:57 AM Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with Heather Symecko 1506 implementation of point of care (POC) testing. 11:57 AM 12:09 PM Improving Hereditary Risk Assessment Approaches: A Focus in Pancreas and Prostate Cancer Veda N. Giri

12:09 PM 12:21 PM Panel Question and Answer Panel Discussion

Clinical Science Symposium Using Real-World Data to Advance Research and Care Location: Hall D1 9:45 AM 11:15 AM Chair - Using Real-World Data to Advance Research and Care Mia Alyce Levy 9:45 AM 9:57 AM Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: R Donald Harvey LBA108 Real-world analysis. 9:57 AM 10:09 AM Can We Capture Every Patient? Sumithra J. Mandrekar

10:09 AM 10:21 AM A predictive model for survival in non-small cell lung cancer (NSCLC) based on electronic health Nathanael Fillmore 109 record (EHR) and tumor sequencing data at the Department of Veterans Affairs (VA).

10:21 AM 10:33 AM Utilizing Big Data to Advance Personalized Therapy Robert Charles Doebele

10:33 AM 10:45 AM Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and Sean Khozin 110 autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs). 10:45 AM 10:57 AM Using Big Data to Identify Outcomes of Uncommon Population: Are We Ready? David E. Kozono 10:57 AM 11:15 AM Panel Question and Answer Panel Discussion

Clinical Science Symposium Emerging Combinations in Sarcoma Immunotherapy Location: S100a 11:30 AM 1:00 PM Chair - Emerging Combinations in Sarcoma Immunotherapy Christina Lynn Roland

11:30 AM 1:00 PM Chair - Emerging Combinations in Sarcoma Immunotherapy Juneko E. Grilley-Olson

11:30 AM 11:42 AM A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with Keytruda Merck & Co. Seth Pollack 11009 metastatic/unresectable sarcoma. 11:54 AM 12:06 PM Pilot study of NKTR214 and nivolumab in patients with sarcomas. bempegaldesleukin; Nektar Sandra P. D'Angelo 11010 Opdivo Therapeutics; Bristol- Myers Squibb

12:06 PM 12:18 PM Can We Find a Sweet Spot in Dual Immuno-Stimulation? Antoine Italiano 12:18 PM 12:30 PM A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft CMB305; Tecentriq Merck & Co.; Roche Sant P. Chawla 11011 tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.

12:42 PM 1:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Gastrointestinal (Colorectal) Cancer Location: Arie Crown Theater 11:30 AM 1:00 PM Chair - Gastrointestinal (Colorectal) Cancer Ritesh Rathore 11:30 AM 1:00 PM Chair - Gastrointestinal (Colorectal) Cancer Fotios Loupakis 11:30 AM 11:42 AM A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS Filippo Pietrantonio 3509 mutated metastatic colorectal cancer (mCRC) patients. 11:30 AM 11:42 AM A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 Zhen Zhang 3510 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).

11:30 AM 11:42 AM Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Vectibix Amgen Michael Geissler 3511 versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC). 11:30 AM 11:42 AM Can We Hit the Targets in Colorectal Cancer? Jennifer Rachel Eads 11:42 AM 11:52 AM Panel Question and Answer Panel Discussion 11:52 AM 12:04 PM CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and Imfinzi; AstraZeneca Eric Xueyu Chen 3512 tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best tremelimumab supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). 11:52 AM 12:04 PM Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with Franck Pages 3513 oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

11:52 AM 12:04 PM A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic Opdivo Bristol-Myers Squibb Aparna Raj Parikh 3514 colorectal adenocarcinoma (mCRC). 11:52 AM 12:04 PM Immuno-Oncology: Managing Expectations Joleen Marie Hubbard

12:04 PM 12:14 PM Panel Question and Answer Panel Discussion 12:14 PM 12:26 PM A randomized controlled trial of the conventional technique versus the no-touch isolation technique Yasumasa Takii 3515 for primary tumor resection in patients with colon cancer: Primary analysis of Japan Clinical Oncology Group study JCOG1006. 12:14 PM 12:26 PM Long-term survival after laparoscopic versus open resection for colorectal liver metastases. Asmund Avdem LBA3516 Fretland 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 12:14 PM 12:26 PM Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish Pia J. Osterlund 3517 metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).

12:14 PM 12:26 PM Surgery: Techniques and Teamwork Y. Nancy You 12:26 PM 12:36 PM Panel Question and Answer Panel Discussion 12:36 PM 12:48 PM A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in Jeanne Tie 3518 early stage colorectal cancer (CRC). 12:36 PM 12:48 PM Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A Jean Francois Delattre 3519 post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR). 12:36 PM 12:48 PM Relative contribution of clinical and molecular features to outcome within low and high risk T and N Frank A. Sinicrope 3520 groups in stage III colon cancer (CC). 12:36 PM 12:48 PM Prognostic Markers for Early-Stage Disease Richard H. Wilson 12:48 PM 1:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Location: E450 11:30 AM 1:00 PM Chair - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Nina D. Wagner- Johnston 11:30 AM 1:00 PM Chair - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Manali K. Kamdar 11:30 AM 11:42 AM Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, Jithma P. Abeykoon 7509 cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). 11:30 AM 11:42 AM Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic Imbruvica AbbVie Paul M. Barr 7510 lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.

11:30 AM 11:42 AM Second cancer incidence in CLL patients receiving BTK inhibitors. David Alan Bond 7511 11:30 AM 11:42 AM Promises, Promises: Informing Long-term Expectations in WM and CLL William G. Wierda 11:42 AM 11:52 AM Panel Question and Answer Panel Discussion 11:52 AM 12:04 PM Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular ME-401 MEI Pharma Andrew David Zelenetz 7512 lymphoma (FL). 11:52 AM 12:04 PM MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory David Jacob Andorsky 7513 indolent non-Hodgkin lymphoma. 11:52 AM 12:04 PM Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in Revlimid Celgene John G. Gribben 7514 patients with R/R indolent NHL (AUGMENT). 11:52 AM 12:04 PM Evolving Options in Follicular Lymphoma Carla Casulo 12:04 PM 12:14 PM Panel Question and Answer Panel Discussion 12:14 PM 12:26 PM Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell lisocabtagene Celgene Jeremy S. Abramson 7515 non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL maraleucel 001. 12:14 PM 12:26 PM Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma lisocabtagene Celgene Michael Wang 7516 (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. maraleucel

12:14 PM 12:26 PM Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from Yescarta Gilead Jay Y. Spiegel 7517 the US lymphoma CAR-T consortium. 12:14 PM 12:26 PM CAR T: The Good, the Bad, and the Ugly Leslie Popplewell 12:26 PM 12:36 PM Panel Question and Answer Panel Discussion 12:36 PM 12:48 PM Managing release syndrome (CRS) and neurotoxicity with step-fractionated dosing of Nancy L. Bartlett 7518 mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).

12:36 PM 12:48 PM Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B- Calquence; Keytruda AstraZeneca, Merck Thomas E. Witzig 7519 cell lymphoma (DLBCL). & Co. 12:36 PM 12:48 PM Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with Imfinzi AstraZeneca Grzegorz S. 7520 previously untreated, high-risk DLBCL. Nowakowski 12:36 PM 12:48 PM Awakening the Immune System in DLBCL Justin Paul Kline 12:48 PM 1:00 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Central Nervous System Tumors Location: S102 1:15 PM 4:15 PM Chair - Central Nervous System Tumors Evanthia Galanis 1:15 PM 4:15 PM Chair - Central Nervous System Tumors Timothy Francis Cloughesy 1:15 PM 1:27 PM Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON Martin J. Van Den Bent 2000 trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.

1:27 PM 1:39 PM Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of Carmen Balana 2001 temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial. 1:39 PM 1:51 PM Temozolomide: How Much Is Enough? Stuart A. Grossman 1:51 PM 2:03 PM Panel Question and Answer Panel Discussion 2:03 PM 2:15 PM Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within Erica Hlavin Bell 2002 the high-risk treatment arms of NRG Oncology/RTOG 9802. 2:15 PM 2:27 PM A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low- Tibsovo; AG-881 Agios Ingo K. Mellinghoff 2003 grade glioma: Results from cohort 1. Pharmaceuticals 2:27 PM 2:39 PM Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or DS-1001 Daiichi Sankyo Atsushi Natsume 2004 progressive IDH1 mutant gliomas. 2:39 PM 2:51 PM IDH: From Target to Therapies Riccardo Soffietti 2:51 PM 3:03 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 3:03 PM 3:15 PM Efficacy and safety of selinexor in recurrent glioblastoma. selinexor Karyopharm Andrew B. Lassman 2005 Therapeutics 3:15 PM 3:27 PM Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central Vitrakvi Bayer Alexander E. Drilon 2006 nervous system tumors. 3:27 PM 3:39 PM Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Yondelis Johnson & Johnson Matthias Preusser 2007 Brain Tumor Group (EORTC-1320-BTG). 3:39 PM 3:51 PM A phase I study of convection-enhanced delivery of 124I-8H9 radio-labeled monoclonal antibody in omburtamab Y-mAbs Mark M. Souweidane 2008 children with diffuse intrinsic pontine glioma: An update with dose-response assessment. Therapeutics

3:51 PM 4:03 PM The Rationale for New Brain Tumor Treatments: How Can We Do Better? Peter A. J. Forsyth 4:03 PM 4:15 PM Panel Question and Answer Panel Discussion

Clinical Science Symposium Education Research and Workplace Inequities Location: S100bc 1:15 PM 2:45 PM Chair - Education Research and Workplace Inequities Leora Horn 1:15 PM 2:45 PM Chair - Education Research and Workplace Inequities David L. Graham 1:15 PM 1:27 PM Feasibility of implementing a resident oncology video curriculum. Sam Brondfield 10500 1:27 PM 1:39 PM Which factors are influencing good digital education? Analysis on ecancer programs from major Danny Burke 10501 international congresses. 1:39 PM 1:51 PM Enhancing Education Through Technology Douglas Edward Ney 1:51 PM 2:03 PM Survey of sexual harassment and gender disparities among gynecologic oncologists. Marina Stasenko LBA10502 2:03 PM 2:15 PM Evaluating unconscious bias: Speaker introductions at an international oncology conference. Narjust Duma 10503

2:15 PM 2:27 PM Gender Bias and Discrimination Christina Hunter Chapman 2:27 PM 2:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Gynecologic Cancer Location: S406 1:15 PM 4:15 PM Chair - Gynecologic Cancer Elizabeth Louise Dickson

1:15 PM 4:15 PM Chair - Gynecologic Cancer Rachel N. Grisham 1:15 PM 1:27 PM A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in Matthew A. Powell 5500 chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial. 1:27 PM 1:39 PM Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) Imfinzi AstraZeneca Yoland Catherine Antill 5501 status: The phase II PHAEDRA trial (ANZGOG1601). 1:39 PM 1:51 PM Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), Bavencio Merck KGaA Panagiotis A. 5502 microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent Konstantinopoulos endometrial cancer (EC). 1:51 PM 2:03 PM Uterine Cancer: Match or Mismatch? Vicky Makker 2:03 PM 2:15 PM Panel Question and Answer Panel Discussion 2:15 PM 2:27 PM Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Gemma Kenter 5503 Ib2-IIb cervical cancer, EORTC 55994. 2:27 PM 2:39 PM Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical Shitanshu Uppal 5504 hysterectomy: A multi-institutional analysis of 700 cases. 2:39 PM 2:51 PM The Shifting Winds of Cervical Cancer Treatment Patricia J. Eifel 2:51 PM 3:03 PM Panel Question and Answer Panel Discussion 3:03 PM 3:15 PM Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent Zejula GlaxoSmithKline Mansoor Raza Mirza 5505 platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO- AVANOVA2/ENGOT-OV24. 3:15 PM 3:27 PM Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum- Lynparza AstraZeneca Richard T. Penson 5506 sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

3:27 PM 3:39 PM Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum- Lynparza AstraZeneca Adriaan Vanderstichele 5507 resistant ovarian cancer. 3:39 PM 3:51 PM EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy Claire Falandry 5508 regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

3:51 PM 4:03 PM Old Standards and New Tricks for Ovarian Cancer Don S. Dizon 4:03 PM 4:15 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Hematologic Malignancies—Plasma Cell Dyscrasia Location: E450 1:15 PM 2:45 PM Chair - Hematologic Malignancies—Plasma Cell Dyscrasia Agne Paner 1:15 PM 2:45 PM Chair - Hematologic Malignancies—Plasma Cell Dyscrasia 1:15 PM 1:27 PM Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac Amandeep Godara 8009 involvement. 1:15 PM 1:27 PM Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain Ping Zhou 8010 genes in patients with MGUS or smoldering multiple myeloma. 1:15 PM 1:27 PM Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation Abdullah Al Saleh 8011 with three or more organs involved. 1:15 PM 1:27 PM No Reason to Fear, New Treatments Are Here: Amyloidosis Suzanne Lentzsch 1:27 PM 1:37 PM Panel Question and Answer Panel Discussion 1:37 PM 1:49 PM Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. BION-1301 Aduro Biotech William Bensinger 8012 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 1:37 PM 1:49 PM Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in Chunrui Li 8013 relapsed/refractory multiple myeloma. 1:37 PM 1:49 PM Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple selinexor Karyopharm Paul G. Richardson 8014 class refractory-multiple myeloma (TCR-MM). Therapeutics 1:37 PM 1:49 PM To BCMA and Beyond Nina Shah 1:49 PM 1:59 PM Panel Question and Answer Panel Discussion 1:59 PM 2:11 PM Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group Brian G. Durie 8015 (IMWG) multicenter study. 1:59 PM 2:11 PM Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed Darzalex; Revlimid Johnson & Johnson; Aurore Perrot 8016 multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, Celgene lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. 1:59 PM 2:11 PM Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant- Darzalex; Velcade Johnson & Johnson; Herve Avet-Loiseau 8017 eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) Takeda status: Analysis of the CASSIOPEIA trial. 1:59 PM 2:11 PM Beyond the M Spike: Diagnostic and Monitoring Platforms Andrew Jenho Yee 2:11 PM 2:21 PM Panel Question and Answer Panel Discussion 2:21 PM 2:33 PM Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia Imbruvica AbbVie Alessandra Tedeschi 8018 (WM): Results from iNNOVATE. 2:21 PM 2:33 PM Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. Ninlaro; Revlimid Takeda; Celgene Angela Dispenzieri 8019 2:21 PM 2:33 PM Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma Angela Dispenzieri 8020 (SMM). 2:21 PM 2:33 PM There's More Than Multiple Myeloma: Other Plasma Cell Dyscrasias Jens Hillengass 2:33 PM 2:45 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Gastrointestinal (Noncolorectal) Cancer Location: Arie Crown Theater 3:00 PM 4:30 PM Chair - Gastrointestinal (Noncolorectal) Cancer Bradley G. Somer 3:00 PM 4:30 PM Chair - Gastrointestinal (Noncolorectal) Cancer Manisha Palta 3:00 PM 3:12 PM Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) Keytruda Merck & Co. Zev A. Wainberg 4009 in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059. 3:00 PM 3:12 PM Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase Keytruda Merck & Co. Manish A. Shah 4010 3 KEYNOTE-181 study. 3:00 PM 3:12 PM First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive Keytruda Merck & Co. Yelena Yuriy Janjigian 4011 metastatic esophagogastric adenocarcinoma. 3:00 PM 3:12 PM Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced Opdivo Bristol-Myers Squibb Thomas Yau 4012 hepatocellular carcinoma (aHCC): Results from CheckMate 040. 3:00 PM 3:12 PM Checking Up on Checkpoint Inhibitors Osama E. Rahma 3:12 PM 3:30 PM Panel Question and Answer Panel Discussion 3:30 PM 3:42 PM Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC- veliparib AbbVie E. Gabriela Chiorean 4014 737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

3:30 PM 3:42 PM Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) veliparib AbbVie Michael J. Pishvaian 4015 in patients (pts) with metastatic pancreatic cancer (mPDAC). 3:30 PM 3:42 PM Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a Xarelto Johnson & Johnson Saroj Vadhan-Raj 4016 prespecified subgroup analysis of the CASSINI study. 3:30 PM 3:42 PM PDA: Target or Not? Eric Andrew Collisson

3:42 PM 4:00 PM Panel Question and Answer Panel Discussion 4:00 PM 4:12 PM PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the Sylvie Lorenzen 4018 prospective MEMORI trial. 4:00 PM 4:12 PM Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring Clarisse Eveno 4019 cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

4:00 PM 4:12 PM Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal Hitoshi Katai 4020 dissection for clinical stage IA/IB gastric cancer (JCOG0912). 4:00 PM 4:12 PM Pushing the Frontiers in GE Cancers Yoon-Koo Kang 4:12 PM 4:30 PM Panel Question and Answer Panel Discussion

Clinical Science Symposium Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes Location: S404 3:00 PM 4:30 PM Chair - Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes 3:00 PM 4:30 PM Chair - Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes Tina Hsu 3:00 PM 3:12 PM Predictive factors of grade 3-5 toxicity in older patients with cancer treated with chemotherapy: A Jaime Feliu Batlle 11509 prospective multicenter study. 3:12 PM 3:24 PM Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men Shabbir M.H. Alibhai 11510 receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents. 3:24 PM 3:36 PM Tools of the Trade: Predicting Toxicity in Geriatric Oncology Heidi D. Klepin 3:36 PM 3:48 PM Outcomes that matter to patients: The Geriatric Oncology Surgical Assessment and Functional Isacco Montroni 11511 rEcovery after Surgery (GOSAFE) study—Analysis of 471 patients. 3:48 PM 4:00 PM Reduced 90-day postoperative mortality through geriatric comanagement after cancer surgery. Armin Shahrokni 11512

4:00 PM 4:12 PM Improving Surgical Outcomes With Team-Based Care 4:12 PM 4:30 PM Panel Question and Answer Panel Discussion

Poster Discussion Session 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Cancer Prevention, Hereditary Genetics, and Epidemiology Location: S103 4:30 PM 6:00 PM Chair - Cancer Prevention, Hereditary Genetics, and Epidemiology Noelle K. LoConte 4:30 PM 6:00 PM Chair - Cancer Prevention, Hereditary Genetics, and Epidemiology Joanne M. Jeter 4:30 PM 4:42 PM Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. Madison Conces 1507

4:30 PM 4:42 PM Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia. Nicholas S. Moore 1508 4:30 PM 4:42 PM Effect of germline ATM mutations on clonal hematopoiesis. Thomas Paul Slavin 1509 4:30 PM 4:42 PM CHIP-ing Away at Heme Malignancies Catherine Callaghan Coombs 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Antiviral therapy to reduce hepatocellular carcinoma recurrence in patients with low HBV-DNA Gang Huang 1510 levels: A randomized controlled trial. 4:52 PM 5:04 PM Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel Alicia Latham 1511 adenocarcinoma (SBA). 4:52 PM 5:04 PM New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening Maria Fernanda Montiel 1512 program. 4:52 PM 5:04 PM Gastrointestinal Malignancies Nataliya Volodymyrivna Uboha

5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene Allison W. Kurian 1513 sequencing in the Women's Health Initiative. 5:14 PM 5:26 PM Racial and ethnic differences in the results of multigene panel testing of inherited cancer Siddhartha Yadav 1514 predisposition genes in breast cancer patients. 5:14 PM 5:26 PM Adequacy of self-reported family history in electronic health record for genetic risk assessment for Mala Pande 1515 Lynch syndrome. 5:14 PM 5:26 PM Who Should We Be Testing? Susan M. Domchek 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Genome-wide association study using whole-genome sequencing to identify a novel locus associated Yadav Sapkota 1516 with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach. 5:36 PM 5:48 PM Gliomas in the context of Li-Fraumeni syndrome: An international cohort. Orli Michaeli 1517 5:36 PM 5:48 PM "Hearts and Brains": Pediatric Cancer Survivorship Eric Jessen Chow 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Genitourinary (Nonprostate) Cancer Location: Hall D2 4:30 PM 6:00 PM Chair - Genitourinary (Nonprostate) Cancer Tian Zhang 4:30 PM 6:00 PM Chair - Genitourinary (Nonprostate) Cancer Ulka N. Vaishampayan

4:30 PM 4:42 PM A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial RC48-ADC Rongchang Xinan Sheng 4509 carcinoma. Biopharmaceutical

4:30 PM 4:42 PM Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association infigratinib BridgeBio Nazli Dizman 4510 with comprehensive genomic profiling/cell-free DNA results. 4:30 PM 4:42 PM FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with vofatamab Rainier Therapeutics Arlene O. Siefker- 4511 pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. Radtke 4:30 PM 4:42 PM Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma Yohann Loriot 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic Tecentriq Roche Brian I. Rini 4512 renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.

4:52 PM 5:04 PM CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC Opdivo Britol-Myers Squibb David F. McDermott 4513 intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. 4:52 PM 5:04 PM Efficacy of immune checkpoint inhibitors (ICI) & genomic characterization of sarcomatoid and/or Ziad Bakouny 4514 rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). 4:52 PM 5:04 PM Sarcomatoid RCC: Defining a New Treatment Paradigm? James Brugarolas 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with Tecentriq Roche Sumanta K. Pal 4515 bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).

5:14 PM 5:26 PM Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Igal Kushnir 4516 Cancer information system (CKCis). 5:14 PM 5:26 PM Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell Opdivo Britol-Myers Squibb Hamid Emamekhoo 4517 carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

5:14 PM 5:26 PM Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma Neeraj Agarwal 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies Opdivo Britol-Myers Squibb Bradley Alexander 4518 (BCVH). McGregor 5:36 PM 5:48 PM Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of Tecentriq Roche Cora N. Sternberg 4519 atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. 5:36 PM 5:48 PM Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial Andrea Necchi 4581 carcinoma reveals opportunities for therapeutic and biomarker development. 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 5:36 PM 5:48 PM Classification and Management of Infrequent Genitourinary Malignancies Samuel Aaron Funt 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Location: E450 4:30 PM 6:00 PM Chair - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Laura Christian Michaelis 4:30 PM 6:00 PM Chair - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Milos Miljkovic

4:30 PM 4:42 PM The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine Hu5F9-G4 Forty Seven David Andrew Sallman 7009 in AML and MDS patients: Initial phase 1b results. 4:30 PM 4:42 PM Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid B. Douglas Smith 7010 leukemia: Long-term analysis of a phase 2 randomized trial. 4:30 PM 4:42 PM Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly Tibsovo Agios Courtney Denton 7011 diagnosed acute myeloid leukemia (ND AML). Pharmaceuticals Dinardo 4:30 PM 4:42 PM Hitting the Bull's-eye With Targeted Treatments in AML 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) Bosulif Pfizer Carlo Gambacorti- 7012 chronic myeloid leukemia (CML). Passerini 4:52 PM 5:04 PM Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic Tasigna Novartis Francis J. Giles 7013 myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

4:52 PM 5:04 PM Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab Lumoxiti Innate Pharma Robert J. Kreitman 7014 pasudotox-tdfk. 4:52 PM 5:04 PM Follow-up and Safety in the Chronic Leukemias Kerry Anne Rogers 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Inferior survival after microbiota injury: A multicenter allo-HCT study. Jonathan U. Peled 7015 5:14 PM 5:26 PM Development and validation of a novel disease risk model for patients with AML receiving allogeneic Piyanuch Kongtim 7016 hematopoietic cell transplantation. 5:14 PM 5:26 PM Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell Richard Jirui Lin 7017 transplantation. 5:14 PM 5:26 PM Novel Cooperating Factors of Allogeneic Transplant Outcomes Lyndsey Runaas 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 5:36 PM 5:48 PM Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients. Gaurav Goyal 7018

5:36 PM 5:48 PM Correlation of BRAF V600E mutation with cardiac involvement assessed by heart imaging in a Marine Bravetti 7019 monocentric series of 205 patients with Erdheim-Chester disease. 5:36 PM 5:48 PM Clinical features, molecular aberrations, treatments, and outcomes in histiocytic sarcoma. Gordon Ruan 7020

5:36 PM 5:48 PM Histocytes Front and Center 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Melanoma/Skin Cancers Location: E451 4:30 PM 6:00 PM Chair - Melanoma/Skin Cancers Sunandana Chandra 4:30 PM 6:00 PM Chair - Melanoma/Skin Cancers Geoffrey Thomas Gibney 4:30 PM 4:42 PM Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus Braftovi; Mektovi Array Biopharma Gabriella Liszkay 9512 binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. 4:30 PM 4:42 PM Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma Allison Betof Warner 9513 (mel). 4:30 PM 4:42 PM Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced Keytruda Merck & Co. Georgina V. Long 9514 melanoma: Initial analysis of KEYNOTE-029 cohort 1C. 4:30 PM 4:42 PM Long-term Clinical Outcomes in Advanced Melanoma Douglas Buckner Johnson 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:52 PM 5:04 PM Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients spartalizumab; Novartis Reinhard Dummer 9515 (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + Tafinlar; Mekinist dabrafenib (D) + trametinib (T). 4:52 PM 5:04 PM Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment. Arissa Young 9516

4:52 PM 5:04 PM Circulating PD-L1-exosomes to monitor tumor response in melanoma patients. Charlee Nardin 9517 4:52 PM 5:04 PM Peripheral Blood and Tumor Microenvironment Considerations for Immunotherapy Jason J. Luke 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 5:14 PM 5:26 PM Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients Claus Garbe 9518 with AJCC v8 stage II cutaneous melanoma (CM). 5:14 PM 5:26 PM Three-year survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression Eddy C. Hsueh 9519 profile (31-GEP) test for cutaneous melanoma (CM). 5:14 PM 5:26 PM One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of Reinhard Dummer 9520 neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). 5:14 PM 5:26 PM Searching for a Crystal Ball: Biomarkers in Melanoma Management Joshua Matthew Varghise Mammen 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Monday, June 3 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 5:36 PM 5:48 PM A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin Xieqiao Yan 9521 plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).

5:36 PM 5:48 PM Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). Opdivo Bristol-Myers Squibb Meredith Pelster 9522

5:36 PM 5:48 PM Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral and association IMCgp100 Immunocore Mark R. Middleton 9523 with overall survival in patients with advanced melanoma. 5:36 PM 5:48 PM Updates for the Treatment of Rare Melanoma Subtypes Sophie Piperno Neumann 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion

Poster Discussion Session Symptoms and Survivorship Location: S102 4:30 PM 6:00 PM Chair - Symptoms and Survivorship Ishwaria Mohan Subbiah 4:30 PM 6:00 PM Chair - Symptoms and Survivorship Winson Y. Cheung 4:30 PM 6:00 PM Impact of cancer on physical and mental activities of daily living in young adult (YA) survivors. Tyler Garrett Ketterl 11517

4:30 PM 6:00 PM Effects of a structured intervention program to improve physical activity (PA) of adolescents and Jannike Lisa Salchow 11518 young adult cancer survivors (AYAs): Final results of the randomized Motivate AYA–MAYA trial.

4:30 PM 6:00 PM Predictors of suicide risk in adolescent and young adults (AYA) with cancer. Jeremy Howard Lewin 11519

4:30 PM 4:42 PM Attention Gen AYA Tara M. Brinkman 4:42 PM 4:52 PM Panel Question and Answer Panel Discussion 4:30 PM 6:00 PM Candidate SNPs enhance prediction of cognitive impairment after blood or marrow transplantation Noha Sharafeldin 11520 (BMT) for hematologic malignancy (HM). 4:30 PM 6:00 PM Cognitive rehabilitation program to improve cognition of cancer patients treated with Mélanie Dos Santos 11521 chemotherapy: A randomized controlled multicenter trial. 4:30 PM 6:00 PM Acupuncture versus cognitive behavioral therapy for cognitive impairment in cancer survivors with Jun J. Mao 11522 insomnia: Implications for personalized medicine. 4:52 PM 5:04 PM Train the Brain Michelle Christine Janelsins 5:04 PM 5:14 PM Panel Question and Answer Panel Discussion 4:30 PM 6:00 PM Improving person-centered communication of goals, proxy, and advance directives in older patients Marie Anne Flannery 11523 with advanced cancer: Secondary analysis from a University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT).

4:30 PM 6:00 PM Prognostic understanding in hematologic malignancies: A multicenter longitudinal study. Kah Poh Loh 11524

4:30 PM 6:00 PM Comparing nonverbal synchrony in racially concordant and racially discordant oncology interactions. Lauren M. Hamel 11525

5:14 PM 5:26 PM Talk to Me: Communication in Cancer Care Anthony Back 5:26 PM 5:36 PM Panel Question and Answer Panel Discussion 4:30 PM 6:00 PM Accelerated sarcopenia and outcomes in older adults with cancer: The Health ABC Study. Grant Richard Williams 11526

4:30 PM 6:00 PM Age disparities among cancer clinical trial participants: The role of industry sponsorship. Ethan B. Ludmir 11527

4:30 PM 6:00 PM Cumulative burden of new-onset chronic health conditions (CHCs) among older cancer survivors. Kelly Kenzik 11528

5:36 PM 5:48 PM New Solutions to Old(er) Problems Gretchen Genevieve Kimmick 5:48 PM 6:00 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Tuesday, June 4 - Oral Presentations

Start End Title Drug Company Presenter Abstract # Highlights of the Day Session Highlights of the Day Session III Location: Hall D1 7:30 AM 9:15 AM Chair - Highlights of the Day Session III Tatiana Michelle Prowell 7:30 AM 7:45 AM Gynecologic Cancer Rachel N. Grisham 7:45 AM 8:00 AM Lung Cancer—Non-Small Cell Metastatic Jhanelle Elaine Gray 8:00 AM 8:15 AM Breast Cancer—Local/Regional/Adjuvant Nancy E. Davidson 8:15 AM 8:30 AM Developmental Therapeutics and Tumor Biology (Nonimmuno) Geoffrey Shapiro 8:30 AM 8:45 AM Genitourinary (Nonprostate) Cancer Michiel Simon Van Der Heijden 8:45 AM 9:00 AM Sarcoma - Highlights of the Day Session III Shreyaskumar Patel 9:00 AM 9:15 AM Symptoms and Survivorship Martin R. Stockler

Clinical Science Symposium The Who, What, and Where of CAR T Location: S406 8:00 AM 9:30 AM Chair - The Who, What, and Where of CAR T Matthew I. Milowsky 8:00 AM 9:30 AM Chair - The Who, What, and Where of CAR T James L. Gulley 8:00 AM 8:12 AM The Who, What, and Where of CAR T Christopher Austin Klebanoff 8:12 AM 8:24 AM Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and CAR-CLD18 T CARsgen Xianbao Zhan 2509 pancreatic adenocarcinoma. Therapeutics 8:24 AM 8:36 AM Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) Nirav Niranjan Shah 2510 modified T cells for relapsed, refractory, non-Hodgkin lymphoma. 8:36 AM 8:48 AM Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary Mesothelin-targeted Atara Prasad S. Adusumilli 2511 efficacy in combination with anti-PD-1 agent. CAR T Program Biotherapeutics

8:48 AM 9:00 AM The Challenges of CAR T for Solid and Liquid Tumors 9:00 AM 9:12 AM The Opportunities of CAR T for Solid and Liquid Tumors Marco L. Davila 9:12 AM 9:30 AM Panel Question and Answer Panel Discussion

Oral Abstract Session Breast Cancer—Metastatic Location: Hall D1 9:45 AM 12:45 PM Chair - Breast Cancer—Metastatic Virginia G. Kaklamani

9:45 AM 12:45 PM Chair - Breast Cancer—Metastatic Erika Paige Hamilton 9:45 AM 9:57 AM SOPHIA primary analysis: A phase 3 (P3) study of (M) + chemotherapy (C) versus margetuximab; MacroGenics; Roche Hope S. Rugo 1000 trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior Herceptin anti-HER2 therapies (Tx). 9:57 AM 10:09 AM Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously pyrotinib Jiangsu Hengrui Zefei Jiang 1001 treated with trastuzumab and taxanes: A randomized phase III study. Medicine Co. 10:09 AM 10:21 AM Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast Nerlynx; Tykerb Puma Cristina Saura 1002 cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, Biotechnology; randomized, phase III NALA trial. Novartis 10:21 AM 10:33 AM Target Practice: HER2 Blockade in Metastatic Breast Cancer Carlos H. Barrios 10:33 AM 10:45 AM Panel Question and Answer Panel Discussion 10:45 AM 10:57 AM IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo- Tecentriq; Abraxane Roche; Celgene Peter Schmid 1003 controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

10:57 AM 11:09 AM Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone Halaven; Keytruda Eisai; Merck & Co. Sara M. Tolaney 1004 receptor-positive (HR+) metastatic breast cancer (MBC). 11:09 AM 11:21 AM Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression capivasertib; AstraZeneca Robert Hugh Jones 1005 on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double- Faslodex blind, placebo-controlled, phase II trial. 11:21 AM 11:33 AM Novel Therapeutics in Breast Cancer: Crossing the Subtype Divide Cesar Augusto Santa- Maria 11:33 AM 11:45 AM Panel Question and Answer Panel Discussion 11:45 AM 11:57 AM A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine Ibrance Pfizer Yeon Hee Park 1007 in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746). 11:57 AM 12:09 PM Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer Kisqali Novartis Sara A. Hurvitz LBA1008 (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

12:09 PM 12:21 PM CDK4/6 Inhibitors: Optimizing Care in ER-Positive Breast Cancer Angelo Di Leo 12:21 PM 12:33 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Location: E451 9:45 AM 12:45 PM Chair - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Matthew Steven Davids

9:45 AM 12:45 PM Chair - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Nancy L. Bartlett 9:45 AM 9:57 AM Acalabrutinib with (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic Calquence; Gazyva AstraZeneca; Roche Jennifer Ann Woyach 7500 lymphocytic leukemia (CLL): Three-year follow-up. 2019 ASCO Annual Meeting Planner Tuesday, June 4 - Oral Presentations

Start End Title Drug Company Presenter Abstract # 9:57 AM 10:09 AM TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene lisocabtagene Celgene Tanya Siddiqi 7501 maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with maraleucel relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

10:09 AM 10:21 AM Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and Venclexta; Gazyva AbbVie; Roche Kirsten Fischer 7502 rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

10:21 AM 10:33 AM CLL: The Future Is Now Matthew Steven Davids

10:33 AM 10:45 AM Panel Question and Answer Panel Discussion 10:45 AM 10:57 AM First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for Norbert Shmitz 7503 consolidation—Final results of the AATT study. 10:57 AM 11:09 AM Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): A multicenter, single- sintilimab Innovent Biologics Rong Tao 7504 arm, phase 2 trial (ORIENT-4). 11:09 AM 11:21 AM Chipping Away at T-cell Lymphomas Neha Mehta-Shah 11:21 AM 11:33 AM Panel Question and Answer Panel Discussion 11:33 AM 11:45 AM (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with polatuzumab Roche; Celgene Catherine Diefenbach 7505 relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial. vedotin; Gazyva; Revlimid 11:45 AM 11:57 AM Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory umbralisib TG Therapeutics Nathan Hale Fowler 7506 marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

11:57 AM 12:09 PM Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Rituxan Roche Elly J. Lugtenburg 7507 Results from a randomized HOVON-Nordic Lymphoma Group phase III study.

12:09 PM 12:21 PM Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with Rituxan; Revlimid; Roche; Celgene; Jason Westin 7508 chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. Imbruvica AbbVie

12:21 PM 12:33 PM Toward Targeting NHL Subsets Jasmine M. Zain 12:33 PM 12:45 PM Panel Question and Answer Panel Discussion

Oral Abstract Session Melanoma/Skin Cancers Location: S406 9:45 AM 12:45 PM Chair - Melanoma/Skin Cancers Alexander Christopher Jonathan Van Akkooi

9:45 AM 12:45 PM Chair - Melanoma/Skin Cancers April K.S. Salama 9:45 AM 9:57 AM Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) Gerald Fogarty 9500 following local treatment of 1-3 melanoma brain metastases (MBMs). 9:57 AM 10:09 AM Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with Opdivo; Yervoy Bristol-Myers Squibb Hussein Abdul-Hassan 9501 symptomatic melanoma brain metastases (CheckMate 204). Tawbi 10:09 AM 10:21 AM A New Era for the Treatment of Brain Metastases in Melanoma Harriet M. Kluger 10:21 AM 10:33 AM Panel Question and Answer Panel Discussion 10:33 AM 10:45 AM A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. Carina N. Owen 9502 10:45 AM 10:57 AM Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from Alexander M. Menzies 9503 the International Neoadjuvant Melanoma Consortium (INMC). 10:57 AM 11:09 AM United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 Yervoy Bristol-Myers Squibb Ahmad A. Tarhini 9504 mg/kg) versus high-dose -α2b for resected high-risk melanoma. 11:09 AM 11:21 AM Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg Michael Weichenthal 9505 melanoma registry. 11:21 AM 11:33 AM Rethinking Melanoma Treatment Pre- and Postsurgery Kenneth F. Grossmann

11:33 AM 11:45 AM Panel Question and Answer Panel Discussion 11:45 AM 11:57 AM Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of Cabometyx Exelixis Daniel Olson 9506 cabozantinib (cabo) versus chemotherapy (chemo). 11:57 AM 12:09 PM Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with Tafinlar; Mekinist Novartis Paul D. Nathan 9507 BRAF V600–mutant unresectable or metastatic melanoma. 12:09 PM 12:21 PM FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in Christy Osgood 9508 patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

12:21 PM 12:33 PM Optimizing Targeted Therapy in Melanoma Paul B. Chapman 12:33 PM 12:45 PM Panel Question and Answer Panel Discussion 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Developmental Immunotherapy and Tumor Immunobiology Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double- Alexander M. M. 2512 blind phase 3 randomized trial. Eggermont CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX- Aung Naing 2513 072. A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced Laura Quan Man Chow 2514 malignancy. Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB). Natalie Vokes 2515

Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United Flora Mulkey 2516 States Food and Drug Administration (FDA). Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC Alexander M. M. 2517 1325/KEYNOTE-054 pembrolizumab versus placebo trial. Eggermont Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic Amod Sarnaik 2518 melanoma patients who progressed on multiple prior therapies including anti-PD-1. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. Karlo Perica 2520 First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody Alexandra Leary 2521 acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose- Shota Fukuoka 2522 expansion phase 1b trial (REGONIVO, EPOC1603). A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid Howard A. Burris 2523 tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy. Suman Paul 2524 First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin Malaka Ameratunga 2525 (EnaV) in solid tumors. A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or Lin Shen 2526 lymphomas. A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal Emiliano Calvo 2527 antibody, in patients (pts) with advanced solid tumors. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal Yung-Jue Bang 2528 junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. Jasgit C. Sachdev 2529 Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY- Mikiya Ishihara 2530 ESO-1-targeting TCR-redirected T cell transfer. Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel Blake T. Aftab 2532 (tab-cel) infusion in patients with EBV-driven disease. Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors. Maxim Yankelevich 2533 Efficacy and safety of CAR19/22 t-cell “cocktail"• therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma. Liang Huang 2534

The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition Lu Han 2535 domain. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with Carlos Roberto Becerra 2536 cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD). Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses Marcus O. Butler 2537 and CRS. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, Amir A. Jazaeri 2538 metastatic, or persistent cervical carcinoma. Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) Paolo Fabrizio Caimi 2539 transmembrane domain. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from Kartik Anand 2540 FAERS. Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly Arjun Khunger 2541 associated with response to CTLA4 blockade-based immunotherapy. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent Marco Adelmo James 2542 pembrolizumab (P). Iafolla Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population Natalia Palazon-Carrion 2543 cohort. Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational Rui Wang 2544 pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC). CD4+ T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy. Kyoichi Kaira 2545 Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic Matthew David Hellmann 2546 stable disease. ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. Everett J Moding 2547 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer Karen A. Autio 2548 (MBC) or metastatic castration-resistant prostate cancer (MCRPC). Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib Anna Maria Di Giacomo 2549 NIBIT-M4 study. An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic Steven O'Day 2550 triple-negative breast cancer (mTNBC). Community and academic partnerships: Moving a new generation of clinical trials in NCI community oncology research program Worta J. McCaskill- 2551 (NCORP) into community oncology practices. Stevens Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer Roberto Carmagnani 2552 who signed consent but were not treated in early-phase immunotherapy (IO) trials. Pestana Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. Nataliya Volodymyrivna 2553 Uboha Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in Jermaine Coward 2554 subjects with advanced solid tumors. Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM). Miguel Angel Villalona- 2555 Calero Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC). Siyang Wang 2556

Association between MDM2/MDM4 amplification and PD-1/PD-L1 inhibitors-related hyperprogressive disease: A pan-cancer analysis. Weiqiang Ju 2557

Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung Ruth Perets 2558 cancer (NSCLC): Updated interim results from a phase I study. Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 Alessio Cortellini 2559 study. IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± Nashat Y. Gabrail 2560 bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer. Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis. Gol Minoo Golshani 2561 Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced Manish R. Patel 2562 solid tumors. Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune- Chris Morehouse 2563 checkpoint inhibitors (ICIs). Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell Kyung Hwan Kim 2564 profiles. Association between past medical history (PMH) of autoimmune events and adverse events of special interest (AESI). Jamie Renee Brewer 2565

Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO's CancerLinQ. Wendy S. Rubinstein 2566 Understanding contribution and independence of multiple biomarkers for predicting response to atezolizumab. Parantu K. Shah 2567 Cardiovascular complications of immune checkpoint inhibitor therapy. Samip R. Master 2568 Organ dysfunction (dys) and clinical outcomes in patients (pts) treated with immune checkpoint inhibitors (ICIs). QI LIU 2569 A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, Oliver Klein 2570 neuroendocrine, and gynecological malignancies. Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced Yinghong Wang 2571 colitis. Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, Roberto Pili 2572 renal, and prostate carcinoma patients. Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and Yunfang Yu 2573 OAK): A combined analysis of two multicenter, randomized, phase II/III trials. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Joshua Dean Horton 2574 Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with Charlotte L. Zuur 2575 advanced head and neck cancer (the IMCISION trial, NCT03003637). Effect of exonic microsatellite instability of B2M on the predictability of MSI/dMMR for immunotherapy. Jia Wei 2576 Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. Hamzah Abu-Sbeih 2577 Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination. Arsen Osipov 2578

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal Philippe Alexandre 2579 adenocarcinoma (PDAC) and colorectal cancer (CRC). Cassier Patient survival with immune checkpoint inhibitors and targeted agents in phase 1 trials: A propensity score weighted analysis. Itziar Gardeazabal 2580

Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients. Paul Johannet 2581

High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis. Shilpa Grover 2582

Overcoming genetically-based resistance mechanisms to PD-1 blockade. Davis Yuri Torrejon 2584 Measuring the long-term “tail of curve"• survival benefits in oncology trials: A comparison of the ASCO Value Framework and the Louis Everest 2585 ESMO Magnitude of Clinical Benefit Scale. Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors. Noha Abdel-Wahab 2586 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American Neil J. Shah 2587 descent, poor ECOG performance status, and chronic viral infections. Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy- Prateek Prasanna 2588 treated non-small cell lung cancer (NSCLC): A multi-site multi-agent study. Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden. Xiaodong Jiao 2589

Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell Ehsan Ghorani 2590 lung cancer. Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance. Rahul Parulkar 2591 Can serum IL-6 levels predict sarcopenia and poor outcome in relapsed/refractory gynecologic cancer patients? Tomoyuki Yoshikawa 2592 Association of an inflammatory gene signature with CD8 expression by immunohistochemistry (IHC) in multiple tumor types. Peter M Szabo 2593

CD8+ T cells in tumor parenchyma and stroma by image analysis (IA) and gene expression profiling (GEP): Potential biomarkers for Peter M Szabo 2594 immuno-oncology (I-O) therapy. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell Jason Zhu 2595 carcinoma (mRCC). Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) Alessandro Russo 2596 during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

Application of artificial intelligence to predict a new class of novel synthetic lethal targets. Spyro Mousses 2598 A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid Rosalyn A. Juergens 2599 malignancies. First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced Colin Bier 2600 solid tumors. Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced Michael Rahman 2601 NSCLC. Shafique Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial Anthony B. El-Khoueiry 2602 tumors with evidence of tumor regression and immune activation. THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2). Marcos E Milla 2603 AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with John D. Powderly 2604 advanced tumors: Preliminary results from ongoing phase I studies. 2D and 3D thermally bioprinted human MCF-7 breast cancer cells: A promising model for drug discovery. Aleli Campbell 2605 Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial. Peter A. Kaufman 2606

Immune profiling of tumor-infiltrating T cells using mass cytometry. David Roumanes 2607 Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid Jian-Ming Xu 2608 tumors in China. Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Toshio Shimizu 2609 Japanese patients with advanced solid tumors. Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) Takayuki Nakayama 2610 for advanced solid tumor patients (pts). A phase 1/2a study of GEN-009, a neoantigen based on autologous peptide immune responses. Roger B. Cohen 2611 A donor-dependent in vivo model for single agent and drug combination cytokine release syndrome safety evaluation. James G. Keck 2612

Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood Xabier Mielgo 2613 (GETHI021). Gut microbiota and clinical outcomes treated with nivolumab in Chinese non-small cell lung cancer. Shun Lu 2614 Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer. Ying L Liu 2615 Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. Daniel H. Johnson 2616 Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors Vaia Florou 2617 (ICI) in a pancancer analysis. Pan-tumor prognostic value of multiple immune protein expressions. Tiphaine Lambert 2618 Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor Khanh Tu Do 2619 AT7519M in patients with advanced solid tumors. Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Kirstin Perdrizet 2620 Integrating expanded genomic sequencing into the Canadian publicly funded health care model. Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction. Kaushal Parikh 2621 Breast cancer with insertion or deletion exhibits the immunogenic phenotype. Yongmei Yin 2622 Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Michael E. Hurwitz 2623 TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project. Diana M. Merino 2624

Tissue immune response in epithelial ovarian carcinoma. Jon Henriksen 2625 Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC). Abdul Rafeh Naqash 2626

Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC. Sushma Jonna 2627 The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a Carine El Sissy 2628 “Watch and Wait"• strategy. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in Tony Navas 2629 FFPE tissues. Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. Emily Castellanos 2630 Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I- Julia Dianne Wulfkuhle 2631 SPY 2 Trial. Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage. Jan Budczies 2632 Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer. Martin D. Berger 2633

Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden Kirsten Timms 2634 analysis. Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated Amy Lauren Cummings 2635 with immunotherapy. Effect of subcutaneous multi-peptide active antigen-specific immunotherapy at lymph nodes and tumor sites on clinical outcomes in Juan Pablo Marquez- 2636 progressive tumors. Manriquez Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell Robert O. Dillman 2637 . Preliminary results of a phase I clinical trial using an autologous dendritic cell targeting HER2 in patients with Hoyoung M. Maeng 2639 metastatic cancer or operated high-risk bladder cancer (NCT01730118). Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to Julie Marie Collins 2640 express brachyury and costimulatory molecules in advanced solid tumors. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and ANA Maria Arance 2641 immunogenicity. Fernandez Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse Luis Teixeira 2642 transcriptase (hTERT) in patients with advanced solid tumors. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the Gal Cafri 2643 autologous cancer. A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in Sonia Quaratino TPS2644 patients with selected advanced malignancies. Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Maria Pia Morelli TPS2645 A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI- Mehrdad Mobasher TPS2646 444, and in combination with pembrolizumab in adult patients with advanced cancers. A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors. David Henry Michael TPS2647 Steffin A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors. Jason Alan Chesney TPS2648 Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with Ulka N. Vaishampayan TPS2649 advanced solid tumors. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. Rodabe Navroze Amaria TPS2650

The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of Daniel Wilhelm Mueller TPS2651 subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities. A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed Timothy A Yap TPS2652 on prior PD-1/PD-L1 therapy. A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate Jeffrey Yachnin TPS2653 the safety of intravenously administered ATOR-1015. A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors. Matthew David Hellmann TPS2654

A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in Rui-hua Xu TPS2655 patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as Jian-Ming Xu TPS2656 first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

A phase I study evaluating COM701 in patients with advanced solid tumors. Drew W. Rasco TPS2657 SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. Sandip Pravin Patel TPS2658 Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: Salvatore Siena TPS2659 The ARETHUSA trial. JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors David Michael Hyman TPS2660 with a BRCA1/2 or ATM defect. A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 Jason J. Luke TPS2661 and CTLA-4 in patients with unresectable or metastatic neoplasms. The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, Rohit K. Jain TPS2662 determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity. A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and Raanan Alter TPS2663 advanced/recurrent endometrial cancer. Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy Tira Jing Ying Tan TPS2664 (MET4-IO). 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Phase 1/1b multicenter trial of tpst-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent Ginna Laport TPS2665 (SA) or in combination in patients with advanced solid tumors. An open label, multicenter, phase 1b/2 study of rebastinib (DCC‑2036) in combination with carboplatin to assess safety, tolerability, Anthony W. Tolcher TPS2666 and pharmacokinetics in patients with advanced or metastatic solid tumors. A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with Julio Antonio Peguero TPS2667 advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC). A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in Aung Naing TPS2668 patients with epithelial tumors (FORTITUDE). Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. Matthew Reilley TPS2669

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti- Shubham Pant TPS2670 PD-1 therapy. An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid Mark R. Middleton TPS2671 tumors.

Developmental Therapeutics and Tumor Biology (Nonimmuno) A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial Mihaela C. Cristea 3009 ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC). Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid Anthony W. Tolcher 3010 tumors likely to express NaPi2b. Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non- D. Ross Camidge 3011 small cell lung cancer by EGFR mutation status. A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent Priya Kumthekar 3012 glioblastoma patients. Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. Mark J. Ratain 3013 Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients Timothy A Yap 3014 (pts) with advanced solid tumors. Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Victor Moreno 3015

Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network. James V. Tricoli 3016 Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three Salvatore Siena 3017 clinical trials. Genome-wide cell-free DNA fragmentation profiling for early cancer detection. Alessandro Leal 3018 Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final Jean-Yves Pierga 3019 results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study.

Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration- Ugo De Giorgi 3020 resistant prostate cancer (mCRPC): Results of a phase II clinical trial. A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors. Nancy Chan 3021 Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Rahul Raj Aggarwal 3022 Long-term follow-up of a phase 1b study. Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF Jeeyun Lee 3023 and DLL4 in metastatic gastrointestinal (GI) cancer. The dynamic detection of drug area under curve (AUC) guides clinical usage of docetaxel in solid tumors. Yan Zhang 3024 A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer patients. Deqiang Wang 3025

A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid Florence Atrafi 3026 tumors. Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with Nagla Fawzy Abdel Karim 3027 advanced solid tumors. Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for Theodore John Wigle 3028 fluoropyrimidine-based chemotherapy on adverse events and hospital costs. PDX validation of a 3D microtumor platform. Ellen Sampson 3029 Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent. Sarah Patricia Blagden 3030

Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors. Dana Backlund Cardin 3031 A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A. Antonio Jimeno 3032

Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors. Anan Abdelmoti Abu 3033 Rmilah Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors. Jaffer A. Ajani 3034

Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic Brendan John Guercio 3035 colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung Yong Song 3036 cancer cohort. Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring. Benoit You 3037 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into Lorenzo Gerratana 3038 organ tropism in metastatic breast cancer (MBC)? Development and analytical validation of a 523-gene clinical assay for cell-free DNA. Robin Harrington 3039 Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and Charu Aggarwal 3040 progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced Andrew A. Davis 3041 tumors. A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders Andrew A. Davis 3042 to cancer treatment. NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors. Bo Zhang 3043 Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction Yumi Kim 3044 monitoring-based mass spectrometry. Circulating bacterial DNA as a tool towards noninvasive biomarkers for colorectal adenocarcinoma and adenoma. Ke-Feng Ding 3045 Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among Yuichi Kumaki 3046 MET amps in diverse advanced cancer types. Tumor specific DNA in bronchial lavage as a new diagnostic tool in lung cancer. Caroline Brenner 3047 Thomsen Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data Francesca Battaglin 3048 from TRIBE, MAVERICC, and FIRE-3 phase III trials. Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance. Minetta C. Liu 3049 CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts). Howard I. Scher 3050

Identification and validation of a serum microRNA panel for detection of early-stage breast cancer. Ruiyang Zou 3051 Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients Nuzzo Pier Vitale 3052 with clear cell renal cell carcinoma (ccRCC). Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients Daniel Adams 3053 undergoing definitive radiotherapy. Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) Gabriela C. Lobato 3054 patients. Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive Laura Mezquita 3055 non-small cell lung cancer (NSCLC) patients (pts). Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. Tyler J. Moss 3056

Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer. Anna Hartwig 3057

Changes in DNA hydroxymethylation for the detection of multiple cancers in plasma cell-free DNA. Anna Bergamaschi 3058 Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Junning Cao 3059 Australian patients with advanced solid tumors. Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective? Pauline Corbaux 3060 A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib Hongming Pan 3061 (EOC315) in Chinese patients with advanced solid tumors. Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety Martijn P. Lolkema 3062 and proof of mechanism. First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with Debbie Robbrecht 3063 advanced solid tumors. Rethinking about the dose limiting toxicities (DLTs): They can be equivocal! Wei Zhong 3064 Effectiveness of ASCO's adverse event reporting decision aid: Results from an interventional study. Kathryn Finch Mileham 3065

The i3+3 design for phase I clinical trials. Yuan Ji 3066 Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in Arjun Mittra 3067 patients with refractory solid tumors. Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100. Floris Jan Voskuil 3068

Radiomics features to identify distinct subtypes of triple-negative breast cancers. Haruka Itakura 3069 [18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with Rohini Sharma 3070 platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study. A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients. Shumei Kato 3071

Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective Linda R. Mileshkin 3072 study: Experience of the first two years. No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial Marc Ryan Matrana 3073 enrollment. Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program. Pradeep Poonnen 3074

Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant Carsten Denkert 3075 GeparX trial. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Utility of somatic mutation panel testing in patients with advanced cancer receiving treatment in an Irish teaching hospital. Hadia Khan 3076

Proteomic profile of high-risk luminal A early breast cancers. Nawale Hajjaji 3077 MET kinase domain rearrangements across 10 cancer types. Jun Zhao 3078 An artificial intelligence approach to variant calling of ALK resistance mutations. Jochen K Lennerz 3079 Whole transcriptome sequencing in metastatic cancer: A review of expression outliers in 113 metastatic breast cancer patients. Nathalie LeVasseur 3080

Transcriptome-based cancer type prediction for tumors of unknown origin. Jack Michuda 3081 Observational, multicenter, prospective study to assess the impact on patients' outcome of a systematic screening of oncogenic Carmen Beato 3082 drivers in advanced cancer: The GETHI XX-16 study. Machine learning algorithm analysis using a commercial 592-gene NGS panel to accurately predict tumor lineage for carcinoma of Jim Abraham 3083 unknown primary (CUP). Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast Padma Sheila Rajagopal 3084 cancer. First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with Judy Sing-Zan Wang 3085 relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data. c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas. Rami Al-Rohil 3086 PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in Juanita Suzanne Lopez 3087 patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination. Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting Angelika Terbuch 3088 outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial Lorena Farinas-Madrid 3089 cancer and squamous cell lung carcinoma. Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving Kuo-Ming Yu 3090 anticancer treatment. A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3- David S. Hong 3091 kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

Preclinical testing of ultra-rapid FLASH total abdominal irradiation demonstrates survival benefit and decreased gastrointestinal Karen Levy 3092 toxicity compared to conventional external beam radiation. First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 Iris H.C. Miedema 3093 PET/CT. A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer. Elizabeth Ruth Plummer 3094

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with Udai Banerji 3095 advanced cancer. Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in Florence Atrafi 3096 patients with solid tumors. A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors. Safi Shahda 3097 A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors. Melissa Lynne Johnson 3098

FGFR2: A pan-genomic target. Russell Madison 3099 A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early Miguel Quintela-Fandino 3100 HER2-negative breast cancer (E-HERNEBC). Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic Hao Xie 3101 gastrointestinal (mGI) cancer patients. Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC. Marcelo Vailati Negrao 3102

The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments. Darya Filippova 3103 First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative Jeeyun Lee 3104 pathologic-genomic analysis and the final results. Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative Valentino Cattori 3105 xenograft models of castration-resistant prostate cancer (CRPC). The landscape of RET alterations from 56,970 adult patients with cancer: Clinical implications. Alexander Andreev- 3106 Drakhlin Host transcriptomic signatures associated with dysbiosis in a preclinical model of lung cancer. Mariam El-Ashmawy 3107 Prediction of olaparib sensitivity for variants of unknown significance in homologous repair genes. Sandy Chevrier 3108 Cell-specific upregulation of lung “cancer signature genes"• in the small airway epithelium of asymptomatic smokers. Mahboubeh Rostami 3109 Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma Sebastiao N. Martins- 3110 (LUAD). Filho Integrative analyses of signaling and DNA damage repair pathways in patient-derived xenograft (PDX) models from NCI's patient- Biswajit Das 3111 derived models repository (PDMR). Genomic somatic alterations of human epidermal growth factor-2 (HER2) gene: A pan-cancer analysis. Xinha Zhu 3112 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to Martin Eduardo 3113 pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer. Richardet

Development and clinical validation of Lantern Pharma's AI engine: Response algorithm for drug positioning and rescue (RADR). Umesh Kathad 3114

A modeling and simulation study of less frequent dosing of nivolumab 480 mg. Cody J. Peer 3115 Correlation between NDRG1 gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the Nicla Maria La Verde 3116 PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment). Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring Stefanie L. Groenland 3117 program. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced Jill J.J. Geenen 3118 cancer. Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients. Stefanie L. Groenland 3119 Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab Masahide Fukudo 3120 (Pembro) in real-world practice. Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients Benoit Rousseau 3121 treated with regorafenib (REGO). Larotrectinib efficacy and safety in adult TRK fusion cancer patients. David S. Hong 3122 Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in Eoghan Ruadh Malone 3123 patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS). A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. Xing Zhang 3124 A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients Drew W. Rasco 3125 with advanced solid tumors. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. Drew W. Rasco 3126 A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy Filippo G. De Braud 3127 and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors. Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer. Simon Johnston 3128 Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study. Alison M. Schram 3129 Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC). Alberto Puccini 3130 Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors. Tony Navas 3131

Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Arielle Lutterman Heeke 3132

HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 Julia Dianne Wulfkuhle 3133 TRIAL. Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal William Herrick 3134 protein S6 in needle biopsies. Machine learning methods with salivary metabolomics for breast cancer detection. Takeshi Murata 3135 The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and Subotheni 3136 less common cancers. Thavaneswaran The whole genome landscape of adult metastatic sarcoma. Eric Yang Zhao 3137 Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts). Jun Zhao 3138 A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer. Chang Gong 3139

Prediction of biomarker status, diagnosis and outcome from histology slides using deep learning-based hypothesis free feature Eldad Klaiman 3140 extraction. MET exon 14 skipping analogs: Rare but potentially clinically actionable. Rebecca Feldman 3141 Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial). Saranya Chumsri 3142 Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric Alessandra Raimondi 3143 cancer (mGC): The VERA study. Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology Katherine Geiersbach 3144 and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory. BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab Madiha Naseem 3145 (bev): Results from phase III TRIBE and FIRE-3 trials. First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or Vincent Chung TPS3146 lymphoma. A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701). Hagen P Schwenzer TPS3147

Trial in progress abstract phase I trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in patients with advanced solid tumors. M. Cecilia Monge B. TPS3148

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile. Jade Maxime van Berge TPS3149 Henegouwen A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in Gary Edward Richardson TPS3150 patients with advanced solid tumors. Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected Irene Brana TPS3151 populations with advanced solid tumors. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. Rosalyn A. Juergens TPS3152 TROPHY-U-01: A phase II open-label study of (IMMU-132) in patients with advanced urothelial cancer after Scott T. Tagawa TPS3153 progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. A phase II study for prostate cancer monitoring using 18F-DCFPyL and blood-based biomarkers. Emerson A. Lim TPS3154 Clinical Trial in Progress: The FLEX Big Data Platform explores new gene expression profiles and investigator-initiated protocols in Sarah Untch TPS3155 early-stage breast cancer. TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for Tomoko Jogo TPS3156 advanced solid malignancies with FGFR alterations identified by circulating tumor DNA. FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. David Michael Hyman TPS3157

A phase I open label study evaluating VT1021 in patients with advanced solid tumors. Michael Cieslewicz TPS3158 Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected Olivia Le Saux TPS3159 response to targeted therapies in patients with solid tumors. SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors. David S. Hong TPS3160

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Kyriakos P. Papadopoulos TPS3161

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer Patrick Schoffski TPS3162 and medullary thyroid cancer. A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced Erkut Hasan Borazanci TPS3163 solid tumors. Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent Martin Kelly Nicholas TPS3164 malignant glioma. A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies. Mohammad Telfah TPS3165 A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or Curtis Robert Chong TPS3166 metastatic solid tumors. A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors. Peter F. Gallagher TPS3167 A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with Sarina Anne Piha-Paul TPS3168 advanced solid tumors. Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors. Johanna C. Bendell TPS3169

Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity Stephen K. L. Chia TPS3170 and resistance—A compLEEment-1 Canadian correlative sub-study. Prospective observational study for treatment resistance-related gene screening using plasma circulating tumor DNA in the third Akihiro Tamiya TPS3171 generation EGFR TKI osimertinib therapy elucidator.

Pediatric Oncology Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS Pablo Berlanga 10018 experience. Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud. Scott Newman 10019 Participant hopes and expectations regarding outcomes of genomic sequencing research in pediatric oncology. Jonathan M Marron 10020 Population-based cancer predisposition testing as a component of newborn screening: A cost-effectiveness analysis. Jennifer Yeh 10021 Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from Furqan Shaikh 10022 the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy. Adriana Fonseca 10023 High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident Brian H. Kushner 10024 primary refractory metastases in bone marrow (BM). Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study. Jaume Mora 10025

Frailty among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS). Samah Hayek 10026 Impact of protein supplementation on lean muscle mass in adult survivors of childhood cancer engaged in resistance training. Matthew R Krull 10027

Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation sensitivity syndrome genes: A report from Lindsay M. Morton 10028 the Childhood Cancer Survivor Study. The promoting resilience in stress management (PRISM) intervention for parents of children with cancer: A randomized controlled Mallory R. Taylor 10029 trial. A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors Purnima Singh 10030 (CCS): A COG ALTE03N1 report. Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study. Charlotte M. Niemeyer 10031

A phase II trial testing interventions to shorten time to diagnosis and reduce abandonment of treatment of children with Burkitt Sandra Langat 10032 lymphoma in Kenya. Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in Lauren K. Meyer 10033 pediatric T-cell acute lymphoblastic leukemia. Poverty and survival in targeted immunotherapy clinical trials. Kira O'Neil Bona 10034 A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary Jason R. Fangusaro 10035 brain tumors. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell Allison Frances O'Neill 10036 international consortium. Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas. Neela Lakshmi 10037 Penumarthy Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, Douglas James Harrison 10038 rhabdomyosarcoma, and Ewing sarcoma in vivo models. Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults. Byung-Kiu Park 10040

What is the best therapy for grossly resected synovial sarcoma? Experience of the CWS Study Group. Monika Scheer 10042 Late toxicities, especially second malignancies, with GWAS analysis in hepatoblastoma cases treated in the Japanese study group for Eiso Hiyama 10043 pediatric liver tumor protocol-2. Sponsorship of pediatric oncology interventional trials. Dylan Neel 10044 First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers. Ulrike Gerdemann 10045 ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma. Sharon L. Gardner 10046 AcSé-ESMART: “European Proof of Concept Therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory Tumors Susanne Andrea Gatz 10047 in children and adolescents" –ARM D: Olaparib and Irinotecan. Renal function after treatment for childhood cancer: A report from the St. Jude Lifetime Cohort Study. Daniel M. Green 10048 Patient-reported outcomes (PROs) in adult survivors of childhood hematopoietic cell transplant (HCT): A report from the St. Jude Neel S. Bhatt 10049 lifetime cohort study. Male fertility preservation (FP) at pediatric cancer centers: A report from the Children's Oncology Group (COG). Jennifer Levine 10050 Long term morbidity and mortality among survivors of infant neuroblastoma: A report from the Childhood Cancer Survivor Study Danielle Novetsky 10051 (CCSS). Friedman Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors: A report from the Childhood Cancer Matthew J. Ehrhardt 10052 Survivor Study (CCSS). Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from Lene H. S. Veiga 10053 the childhood cancer survivor study (CCSS). Long-term health status of high-risk neuroblastoma survivors treated with high-dose chemotherapy and hematopoietic stem cell Sandrine Haghiri 10054 transplantation. Incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: A Sumit Gupta 10055 population-based study. Emergency department (ED) visits and hospitalizations in survivors of childhood cancer in the Childhood Cancer Survivor Study. Valerie Arsenault 10056

Progression of frailty in young adult survivors of childhood cancer: St. Jude Lifetime Cohort. Kirsten K. Ness 10057 Cardiac events in survivors of childhood cancer treated in more recent eras: A report from the Childhood Cancer Survivor Study. Daniel A. Mulrooney 10058

Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and childhood Zhaoming Wang 10060 cancer survivor study (CCSS). New insights in cisplatin and radiation-induced ototoxicity: A French Childhood Cancer Survivors Study (FCCSS). Brice Fresneau 10061 Morbidity and mortality in a national cohort of pediatric patients with hemophagocytic lymphohistiocytosis. Steven William Allen 10062 Educational attainment in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). Lisa Bashore 10063

Performance of FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric hodgkin lymphoma (HL) Sharon M. Castellino 10064 patients. INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with Cornelis Martinus van TPS10065 refractory high-risk malignancies: INFORM2 NivEnt. Tilburg A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers. Steven G. DuBois TPS10066

Sarcoma Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open Jie Xu 11012 label, phase Ib/II trial (NCT03416517). Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A Lu Xie 11013 prospective, open label, phase II trial. A three-gene signature to predict survival in pediatric osteosarcoma (OS) to follow patients toward liquid biopsy: A collaborative Natacha Entz-Werle 11014 work in OS2006 protocol. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma Melissa Amber Burgess 11015 (LPS): Final results of SARC028 expansion cohorts. SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line Erlinda Maria Gordon 11016 treatment of advanced soft tissue sarcoma. A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal Arun S. Singh 11017 stromal tumor(GIST). Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma Shiraj Sen 11018 patients on phase 1 trials. Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived Shibu Thomas 11019 liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D).

Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis. Mark A. Eckardt 11020 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) Nicolas Penel 11021 with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ). Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). Michael C. Heinrich 11022 ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of Desmond Yip 11023 metastatic gastrointestinal stromal tumor (GIST). Secondary genomic alterations in Ewing sarcoma. An Uche 11024 Interval-compressed vincristine, doxorubicin, cyclophosphamide (VAC), alternating with ifosfamide and etoposide (IE) for adults with Eric Lu 11025 Ewing or Ewing-like sarcoma. Outcomes of extra-skeletal versus skeletal Ewing sarcoma patients treated with standard chemotherapy protocol. Samer Salah 11027 Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS). Nam Bui 11028 Clinical characteristics of nonosteogenic, non-Ewing's sarcoma of the bone: Experience at the Toronto Sarcoma Program. Zachary William Neil 11029 Veitch Multidisciplinary treatment of 99 adult osteosarcoma (OST) patients (pts) with synchronous and metachronous metastases (mets): A Elise Lavit 11030 retrospective series of the French Sarcoma Group (FSG). Depletion of mutant IDH1 impairs chondrosarcoma growth by downregulating integrins. Luyuan Li 11031 Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor). Silvia Gasperoni 11032 Clinical characterization of patients with SDHC epimutation in gastrointestinal stromal tumors. Maran Ilanchezhian 11033 Correlation of imatinib plasma trough concentrations with adverse reaction in Chinese gastrointestinal stromal tumors patients. Yanzhe Xia 11034

Neurofibromatosis 1 (NF1) and gastrointestinal stromal tumors (GISTs): Five-year experience from a regional center in United Venkata Ramesh Bulusu 11035 Kingdom. Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST. Ciara Marie Kelly 11036 Racial disparity in incidence and survival for gastrointestinal stromal tumors (GIST): An analysis of SEER database. Mark Bilinyi Ulanja 11037 Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Josefina Cruz Jurado 11038 Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). Margaret von Mehren 11039 Immune signature and molecular profiling of radiation-induced sarcoma (RIS). Eoghan Ruadh Malone 11040 Retroperitoneal soft tissue sarcoma (RPS): Recent outcome improvement and refinement of treatment strategies at a single Marco Fiore 11041 institution. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 Hans Gelderblom 11042 PLX108-01 (TGCT cohort) studies. Identification of genomic alterations by circulating tumor DNA in leiomyosarcoma: A molecular analysis of 73 patients. Junaid Arshad 11044

Determinants of secondary alterations in WWTR1-CAMTA1 fusion epithelioid hemangioendothelioma. Nathan David Seligson 11045 Angiosarcoma of bone: A European Muscoloskeletal Oncology Society (EMSOS) multicenter, retrospective study. Emanuela Palmerini 11046 Metagenomic discovery of a distinct inflammatory subtype of human angiosarcoma associated with human herpesvirus 7. Jason Yongsheng Chan 11047

DNA damage response pathway alterations and clinical outcome in leiomyosarcoma. Evan Rosenbaum 11048 A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Ciara Marie Kelly 11049 Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of Yoshihiro Nishida 11050 relationship between efficacy and various factors. Complete remission of patients with heavily pretreated uterine sarcomas by weekly bevacizumab and temozolomide. Kazuki Takasaki 11051

Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT). Salvatora tindara Miano 11052

Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients. Marianna Silletta 11053 Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma? Mudit Chowdhary 11054

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented Gulam Abbas Manji 11055 villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas. Improved local relapse-free and overall survival with secondary surgery after a first R1 or R2 resection in soft tissue sarcoma (STS) of Francois Gouin 11056 the limbs or trunk wall: An analysis 10,931 patients (pts) in NETSARC. A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), Erlinda Maria Gordon 11057 liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: Preliminary efficacy and safety results.

Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma. Achal Awasthi 11058 ARST1321: Pazopanib neoadjuvant trial in non-rhabdomysarcoma soft tissue sarcomas: A report of major wound complications. Thomas Scharschmidt 11059

Pathologic response rates after neoadjuvant therapy for sarcoma. Gautam A. Shrivastava 11060 A single-center retrospective study of patients treated with trabectedin (TRB) with long-term follow up. Brett A. Schroeder 11061 Prognostic factors and therapeutic options for epithelioid hemangioendothelioma (EHE): A multicenter analysis of a series of fifty- Aurore Vozy 11062 seven cases. Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel Shiraj Sen 11063 immunotherapies. A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS). Alona Zer 11064 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Noemi Simeone 11065 Network (RTR). Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional Roberta Sanfilippo 11066 referral center experience in advanced disease. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic Claudia Maria Valverde 11067 liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study. Morales

Solitary fibrous tumor: A Brazilian cohort analysis. Marcelle Goldner Cesca 11068

Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk Dennis Strassmann 11069 prediction during multimodal therapy (MT)? Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation Yen-Lin Chen 11070 or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas. Frequent mutations of genes predisposing to Rho GTPase signal activation and autophagy inhibition in metastatic soft tissue sarcoma Katsuhito Takahashi 11071 unveiled by paired somatic and germline genomic analyses. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Jomjit Chantharasamee 11072

Efficacy and dosimetry prognostic factors of image guided 125I seed implantation for locally recurrent soft tissue sarcoma. Weijuan Jiang 11073

Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for Mikiya Ishihara TPS11074 patients with refractory soft tissue sarcoma. A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft Viktor Grünwald TPS11075 tissue sarcoma (MEDISARC, AIO-STS 0415). MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study Meng XU WELLIVER TPS11076 (NRG-DT001). CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on Gregory Michael Cote TPS11077 doxorubicin. Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC). Antoine Italiano TPS11078

A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma. Brian Andrew Van Tine TPS11079 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Education Research and Professional Development Gender-based analysis of pre-residency research productivity among a current United States radiation oncology resident class. Shearwood McClelland 10504

Humanism in global oncology curricula: An emerging priority. Meredith Elana Giuliani 10505

Integrating concept maps into a medical student oncology curriculum. Sam Brondfield 10506 Development of an “Art of Oncology"• curriculum to mitigate burnout and foster solidarity among hematology/oncology fellows. Daniel R. Richardson 10507

Mindful fellows: Study results from a pilot wellness curriculum in hematology oncology. Monica Sheila Chatwal 10508 Management of muscle-invasive bladder cancer with bladder preservation in Russia: A survey-based analysis of current practice and Natalia Dengina 10509 the impact of an educational workshop on clinical expertise. Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). Bhavana Pendurthi Singh 10510

Evaluation of Colorado oncology providers on the use of medical marijuana. Ashley Elizabeth Glode 10511

The higher school of oncology: An educational program adopting the western oncology experience in Russia. Ekaterina Baron 10512 Burnout and level of mental functioning in oncology staff. Adelina Alcorta-Garza 10513 Implementation of competency-based medical education in a Canadian medical oncology training program: Lessons from our first Anna T. Tomiak 10514 year. ASCO Direct GU: A multistakeholder blended-learning project to make global education local. Kurt Miller 10515 TeamX integrative oncology scholars: Harnessing the potentials of students in shaping oncological care. Kin Wai (Tony) Hung 10516 Cross-cultural validation of a medical leadership competencies survey in Latin-American physicians: A multinational study. Max S. Mano 10517

Support structures for female physicians: Motivations and barriers to gender-specific conferences and symposia. Shikha Jain 10518 Innovation, education, and research: A multidisciplinary survivorship care model. Hira Latif 10519 It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical Mudit Chowdhary 10520 oncology (SO) program leadership positions. Medical oncologists' experience with returning molecular tumor profiling to patients. Subotheni 10521 Thavaneswaran Developing an inspired leader: How to maximize human talent to maximize operating results. Aimee Greeter 10522 From presentation to paper: Gender disparities in oncological research. Willemieke P.M. 10523 Dijksterhuis Creation and development of the National Cancer Control Plan in Russia. Alexander Petrovsky 10524 Working together in cancer care: An academic community partnership for a diverse patient population. Naomi Ko 10525 Training of oncologists: Results of a global survey. Divyanshi Jalan 10526 Oncology fellows' knowledge and current practice regarding outpatient oncology and palliative care. Amy Johnson 10527 Choosing oncology as specialization: Medical students' perception after clinical rotation in cancer center. Omar Orlando Castillo 10528 Fernandez Satisfaction of general versus specialized continuity clinic in hematology oncology fellowship training: A survey. Sama Imran Ilyas 10529 A novel qualitative methodology study to characterize discrimination and inclusion among hematology/oncology trainees. Rahma M. Warsame 10530

Targeting B-cell malignancies: Impact of an educational curriculum on BTK inhibitors. Lauren Willis 10531 Enhancing evidence-based medicine skills in oncology training with cognitive technology. Chun-You Chen 10532 Online education about immunotherapy for melanoma: Outcomes over time. Kinjal Parikh 10533 Non-oncologist physician knowledge of radiation therapy at an urban community hospital. Evan Siau 10534 Collaborative learning workshops to optimize integration of cancer immunotherapies in the community setting. Latha Shivakumar 10535 Medical oncology trainees' perceptions of their education and preparedness for independent practice. Geordie Linford 10536 FitFirms: A wellness option for oncology trainees. Bhavana Pathak 10537 Believe the H.I.P.E.: Hematology-Oncology Inter Professional Education to improve provider collaboration at an inpatient tertiary Richard Lewis Martin 10538 medical center. Using blended learning to improve education on clinical pathways for breast cancer management in Nigeria: Preliminary results. Kelechi Ngozi Eguzo 10539

Implementing a quality improvement curriculum for medical oncology residents: A pilot study at the Ottawa Hospital Cancer Centre. Stephanie Yasmin Brule 10540

Simulated patient encounter to assess and improve fellows' ability to manage chemotherapy infusion reactions. Danielle Elise Zimmerman TPS10541

Genitourinary (Prostate) Cancer PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate Susan Halabi 5021 cancer (mCRPC). External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate Susan Halabi 5022 cancer (mCRPC). Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration- Eric Jay Small 5023 resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) Julie Nicole Graff 5024 with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with YaoYao Guan Pollock 5025 apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone Neal D. Shore 5026 (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer Evan Y. Yu 5027 (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study. RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer. Jeremie Calais 5028 Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with Christophe Massard 5029 metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after Syed A. Hussain 5030 progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with Wassim Abida 5031 metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients. Edwin Lin 5032 Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, Masanori Noguchi 5033 double-blind, placebo-controlled, phase III trial. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic Horst-Dieter Hummel 5034 castration-resistant prostate cancer (mCRPC). Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant A. Oliver Sartor 5035 prostate cancer (mCRPC): Final PROCEED analysis. Interlesional response assessment with 18F-sodium fluoride (18F-NaF) PET/CT in men with chemotherapy-naive bone metastatic Christos Kyriakopoulos 5036 castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA). Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with Glenn Liu 5037 PSA-recurrent prostate cancer. Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. Jose Mauricio Mota 5038 Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer Vincenza Conteduca 5039 (mCRPC). A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve Enrique Grande 5040 metastatic castration-resistant prostate cancer. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the Jingsong Zhang 5041 adaptive abiraterone (abi) study (NCT02415621). Impact of enzalutamide and sequential flutamide and enzalutamide therapy for castration-resistant prostate cancer after Taro Iguchi 5042 bicalutamide-combined androgen blockade therapy onoverall survival: A follow-up study of randomized phase 2 trial (OCCU-CRPC study). Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer Andrew W Hahn 5043 (mCRPC) by circulating tumor DNA (ctDNA). Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer Arnulf Stenzl 5044 (mHSPC) from the ARCHES study. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after Emmanuel S. Antonarakis 5045 prostatectomy, with integrated biomarker analysis. Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive Carsten Henning 5046 castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634). Ohlmann Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer Manish Kohli 5047 (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival.

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive Andrew J. Armstrong 5048 prostate cancer (mHSPC). Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in Gautam Gopalji Jha 5049 metastatic castration resistant prostate cancer (mCRPC). A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for Orazio Caffo 5050 patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study. Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC). Gustavo Rubio Romero 5051

Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). Ana Aparicio 5052

Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study. Maria Jose Mendez-Vidal 5053

Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC). Mamta Parikh 5054

Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and Brian Francis Chapin 5055 prolonged responders to initial systemic treatment. Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic Vsevolod Borisovich 5056 hormone-naïve prostate cancer: A single center analysis. Matveev 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Marcus W. Moses 5058 high-dose testosterone. A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration- Pai-Chi Teng 5059 resistant prostate cancer. Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical Patrick Leo 5060 prostatectomy: A multisite study. Risk of depression following prostate cancer work-up: A nationwide study. Anne Sofie Friberg 5061 Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer. Alexandria Mara 5062 Evolving natural history of metastatic prostate cancer. Nellie Nafissi 5063 Ductal (PDC), acinar (PAC) and neuroendocrine (PNC) carcinomas of the prostate: A comparative comprehensive genomic profiling Gennady Bratslavsky 5064 (CGP) study. SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based Vincenza Conteduca 5065 chemotherapy (PLT). Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer Dong Shen 5066 (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D).

Clinical outcomes and genomic analysis in patients with very high-risk clinically localized prostate cancer treated by radical Pedro Isaacsson Velho 5067 prostatectomy. WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC). Pedro Isaacsson Velho 5068

ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay. Emmanuel S. Antonarakis 5069

Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer. Semini Sumanasuriya 5070 Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage Iris Yeong- Fung Sheng 5071 migration. Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC). Simon Yuen Fai Fu 5072 Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer. Panagiotis J. 5073 Vlachostergios The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world Harshraj Leuva 5074 data from the Veterans Administration Medical Centers (VAMCs). Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR- Howard I. Scher 5075 V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC). Clinical and safety outcomes of Talapro-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) Neeraj Agarwal 5076 in metastatic castration-resistant prostate cancer (mCRPC). Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom. Pandora Rudd 5077 Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) Amado J. Zurita 5078 presenting with lymph node (LN) metastasis. CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with James Andrew Eastham 5079 clinically localized, high-risk prostate cancer (CLHRPC). Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate Karen A. Autio 5080 plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized Laura Graham 5081 prostate cancer (PC). Contemporary trends in treatment for low-risk prostate cancer. Jason Frankel 5082 Human prostate cancer immune phenotypes after androgen deprivation therapy. Matthew Dallos 5083 IMRT pelvic radiotherapy with simultaneous integrated boost in high-risk prostate cancer: Results after 10 years. Christian Ekanger 5084 Is there a role for testosterone replacement therapy in reducing biochemical recurrence following radical prostatectomy? Linda Edward Huynh 5085

Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a Simon Chowdhury TPS5086 circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer Sumit Kumar Subudhi TPS5087 (NCT03431350). Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II Stéphane Supiot TPS5088 trial (POSTCARD - GETUG-P13). An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with Johann S. De Bono TPS5089 advanced solid/metastatic tumors. Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES). Yien Ning Sophia Wong TPS5090

IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations. Melissa Andrea Reimers TPS5091

TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic Neeraj Agarwal TPS5092 castration-resistant prostate cancer (mCRPC). A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected Michael J. Morris TPS5093 recurrence of prostate cancer (CONDOR). 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: the CHAARTED 2 Christos Kyriakopoulos TPS5094 Trial: A trial of the ECOG-ACRIN Cancer Research Group (EA8153). High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency Julia Chen TPS5095 (HRD). Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial. Zachery Reichert TPS5096 A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA Tian Zhang TPS5097 recurrent prostate cancer (PC) after radical prostatectomy (STARTAR). Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP). Julie Van TPS5098 VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of A. Oliver Sartor TPS5099 patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation Mary-Ellen Taplin TPS5100 therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning Jeremie Calais TPS5101 [PSMA-SRT].

Gynecologic Cancer Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for Munetaka Takekuma 5524 residual cervical disease. Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study. Jiayao Lei 5525 Clinically significant discrepancy between clinical and pathologic stage of early-operable cervical cancer. Jennifer Gibbs 5526 Feasibility of visual inspection with acetic acid (VIA) screening for cervical cancer in Tanzania with emphasis on special populations. Justine Chinn 5527

Comparative benefit of interstitial needles in addition to intracavitary applicators in the treatment of locally advanced cervical Dorothy Chilambe Lombe 5528 cancer. Prognostic significance of the number of pelvic lymph-nodes resection in patients with cervical adenocarcinoma: An analysis from Yuji Ikeda 5529 JGOG 1070S study. Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV. Jianjun Zhiang 5530 Cervical cancer harboring a Rb1 mutation may sensitize to cisplatin via PI3K/AKT pathway by regulating apoptosis. Peng Luo 5531 Safety and efficacy of and concurrent intensity-modulated radiation therapy and chemotherapy for locally advanced Ang Qu 5532 cervical squamous cell cancer. PD-L1 expression, DNA mismatch repair genes, and HPV types in cervical squamous cell carcinoma. Tahmineh Haidary 5533 Comparison of definitive cervical cancer management with concurrent chemotherapy and radiation between two centers with Francis Adumata 5534 variable resources and opportunities for improved treatment delivery. Asamoah Recurrence and survival after robotic-assisted radical hysterectomy (RRH) for early-stage cervical cancer (CC): Experience may Christine K. Fitzsimmons 5535 matter. Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience. Shiru Lucy Liu 5536

A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and Ignace Vergote 5537 carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Wendy M Swetzig 5538 Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA Nicoletta Colombo 5539 mutation (BRCAm): Phase III SOLO1 trial. Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life Isabelle Laure Ray- 5540 ambispective study. Coquard Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and Cara Amanda Mathews 5541 a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: Association of favorable response rates in a phase I/II study Yael Chava Cohen 5542 with an immunotherapeutic effect. Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer. Yang Xiang 5543 First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid Toshio Shimizu 5544 tumors. SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent Juliet Elizabeth Wolford 5545 ovarian carcinoma among women with germline BRCA mutations (gBRCAmut). Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in Patrick Robelin 5546 ovarian cancer patients: Data from CHIVA trial (a GINECO study). Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence. Melinda Louie-Gao 5547 Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment. Shannon Neville Westin 5548

How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian Felicia Roncolato 5549 cancer (ROC). Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m2 and 40 mg/m2 in patients with platinum- Akira Yabuno 5550 resistant Müllerian carcinoma (JGOG3018). Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the Michael Friedlander 5551 phase III SOLO1 trial. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Ying L Liu 5552 Molecular stratification of endometrioid ovarian carcinomas. Barbara Stanley 5553 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced Lingying Wu 5554 ovarian cancer (OC): SOLO1 China cohort. Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study. Florence Joly 5555 Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. Ross Harrison 5556 Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and Rebecca Ann Previs 5557 peritoneal cancer after progression. Patient preferences for maintenance PARP therapy in ovarian cancer treatment. Laura Jean Havrilesky 5558 Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials. Bradley Corr 5559 Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous Marta Llaurado 5560 ovarian cancer. Fernandez Impact of BRCA mutation status and time to platinum resistance on patients with advanced ovarian cancer. Alexandra Tyulyandina 5561

Real life efficacy and safety data of bevacizumab-based front line treatment in advance or metastatic ovarian cancer patients: Focus Michail Nikolaou 5562 on patients with malignant ascites—A phase IV study. Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta- Michele Bartoletti 5564 analysis (NMA). Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era. Catherine S. John 5565 Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment. Frederique C. van der 5566 Scheun Everolimus plus letrozole treatment of recurrent gynecologic cancers. Kenneth David Miller 5567 Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis. Mansoor Raza Mirza 5568 Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian Melissa Kristen Frey 5569 cancer. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer. Nicole D. Fleming 5570

Comprehensive genomic analysis of mucinous ovarian cancer reveals unique therapeutic vulnerabilities. Dane Anthony Cheasley 5571

BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. Caterina Fumagalli 5572

T cell trafficking within the peritoneal tumor environment and ovarian cancer progression. Sharina Palencia Desai 5573 The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA Allen Lee Cohn 5574 signals. DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with Janos Laszlo Tanyi 5576 advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression.

Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer. J.P. P. Grabowski 5577 Real-world bevacizumab utilization and outcomes in first-line ovarian cancer. Matthew J. Monberg 5578 Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients. David Garofalo 5579 Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer. Luisa Bonilla 5580 Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study. Emil Lou 5581 A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and Maria M Rubinstein 5582 endometrial carcinosarcoma. Association of total hysterectomy with survival among newly diagnosed uterine cancer patients with distant organ metastasis. Yuefeng Wang 5583

A phase II, open labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer: Kensuke Hori 5584 KCOGG1303 study. Lynch-like syndrome in endometrial cancer: Features of a growing population. Sushmita Gordhandas 5585 Mismatch repair deficiency as a predictor of adjuvant radiotherapy response in endometrioid endometrial carcinoma. Stefan Kommoss 5586

Impact of non-compliance with guidelines in early type 1 endometrial cancers management, study from FRANCOGYN group. Hélene Costaz 5587

Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma. Katie Lee Hwang 5588 The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade, and serous endometrial cancers. Vance Broach 5589

Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial Katherine Cynthia Fuh 5590 cancer. Trends of endometrial cancer incidence from 2000 to 2015 in the United States. V V Pavan Kedar 5591 Mukthinuthalapati p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE- Linn Lena Woelber 5592 translational study group. Use of nivolumab as salvage therapy in heavily pretreated patients with gynecologic malignancies. Heather Williams 5593 Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer. Anna Jo Smith LBA5563 BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel Ana Oaknin TPS5594 chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx). KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line Ronnie Shapira-Frommer TPS5595 treatment of persistent, recurrent, or metastatic cervical cancer. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, Kamran A. Ahmed TPS5596 or metastatic cervical cancer. CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women Bradley J. Monk TPS5597 with locally advanced cervical cancer-A phase III, randomized, double-blind, multicenter study. DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by Philipp Harter TPS5598 maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

ENGOT-Ov41/ GEICO-69-O/ ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or Antonio Gonzalez-Martin TPS5599 without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.

ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR- Anne-Claire Hardy- TPS5600 042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial Bessard ovarian cancer (OC). AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and Frederik Marme TPS5601 chemotherapy in recurrent ovarian cancer (ROC). Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208). Haider Mahdi TPS5602 ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus Ignace Vergote TPS5603 chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary Anna Tinker TPS5604 peritoneal or fallopian tube epithelial carcinoma. EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with Nicole Concin TPS5605 carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination- chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.

Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to Emily Hinchcliff TPS5606 gynecologic malignancy. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial Vicky Makker TPS5607 cancer. AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel Nicoletta Colombo TPS5608 and carboplatin in women with advanced/recurrent endometrial cancer. NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of Helen Mackay TPS5609 cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.

Head and Neck Cancer Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous Ye Guo 6024 cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.

CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell Julie E. Bauman 6025 carcinoma (HNSCC). Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 Kevin J. Harrington 6026 prior radiation treatment (RT) and disease state. Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by Felix Keil 6027 radiotherapy with cetuximab for locally ad•vanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial. Safety and antitumor activity of accelerator-based boron neutron capture therapy in patients with inoperable recurrent and locally Katsumi Hirose 6028 advanced head and neck cancer: A phase II study. Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint Salvatore Alfieri 6029 inhibitors (ICI). Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, Wei Jiang 6030 phase II trial. Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC. Konrad Friedrich 6031 Klinghammer A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head Caroline Even 6032 and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group. An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with Assuntina Gesualda Sacco 6033 recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.

Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma Panagiota 6034 (HNSCC). Economopoulou Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and Caroline Even 6035 neck. A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by Jingjing Miao 6036 induction chemotherapy and chemoradiotherapy. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Metformin treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients induces an anti-tumorigenic Vidhya Karivedu 6037 immune response. High-dose, short-duration, intra-arterial cisplatin therapy for oral cancer. Masatoshi Ohmae 6038 Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve Ezra E.W. Cohen 6039 patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Personalized TPF induction chemotherapy on the basis of stathmin expression in patients with locally advanced oral squamous cell Lai-Ping Zhong 6040 carcinoma. Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with Yao Yu 6041 nivolumab. COX-2 expression and mesenchymal-transition status on circulating tumor cells to predict survival in patients with nasopharyngeal Yongjiang Li 6042 carcinoma: A prospective analysis. Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epstein–Barr virus Fo-Ping Chen 6043 DNA and TNM stage: A “Big data"• analysis of 9,160 endemic cases. Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) Kedar Kirtane 6044 inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Role of the oral and gut microbiota as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma (ROMA LA- Marc Oliva Bernal 6045 OPSCC). Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally-advanced nasopharyngeal carcinoma (LA-NPC) treated with Marc Oliva Bernal 6046 definitive chemoradiotherapy. Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients. Pernille Lassen 6047 Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic Xiang Guo 6048 head and neck squamous cell carcinoma. Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase Dong Moon Shin 6049 inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck. Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell Bouchra Tawk 6050 carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Racial disparities in outcome among head and neck cancer patients in the United States: An analysis using SEER-Medicare linked Ikumi Suzuki 6051 database. Pretreatment obesity prolongs survival in elderly patients (≥65 years) with head and neck cancer (HNC). Parth Anil Desai 6052 Association of single nucleotide polymorphisms within genes in NF-κB, TGF-β, and JNK signaling pathways with the risks of Hanyi Zhang 6053 nasopharyngeal carcinoma in Chinese Han. A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma Sudhir Vasudevan Nair 6054 (OSCC): Erlo-Xib Study. Immune signatures associated with response to neoadjuvant PD-1 blockade in oral cavity cancer. Hannah Knochelmann 6055 Risk of mortality varies by type of fat consumed in a longitudinal cohort of head and neck cancer patients. Hania M. Taha 6056 Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models. Devraj Basu 6057 Depth of invasion in early oral cancers: Is it an independent prognostic factor. Harsh Dhar 6058 Prophylactic gabapentin decreases fatigue and swallowing difficulty in patients undergoing concurrent chemo-radiation (CCR) for Barbara A. Murphy 6059 head and neck cancer (HNC): Interim results from a randomized controlled trial. Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142). Amanda Psyrri 6060

Prognostic impact of baseline circulating tumor cells (CTCs) detected by the isolation by size of epithelial tumor cells (ISET) in locally Thiago Bueno Oliveira 6061 advanced head and neck squamous cell carcinoma (LAHNSCC): Results of a prospective study. Tumor volume, circulating tumor cells, and cfDNA changes during radiotherapy in patients with head and neck cancer. Sweet Ping Ng 6062

Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) Sean Matthew McBride 6063 head and neck squamous cell carcinoma (HNSCC). Safety and efficacy of docetaxel combined with cisplatin as induction chemotherapy followed by cisplatin concurrent Zhi Hui Wang 6064 chemoradiotherapy plus gemcitabine as adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A prospective and multicenter phase II trial. Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and Loren K. Mell 6065 neck cancer with a contraindication to cisplatin: NRG-HN004. A randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a Paul Swiecicki 6066 novel Bcl-xL inhibitor. Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for Xiuning Le 6067 surgical resection. Impact of smoking cessation in locally advanced head and neck cancers undergoing radiation. Ruth Lauren Sacks 6068 Hafnium oxide nanoparticles NBTXR3 activated by radiotherapy as a new therapeutic option for elderly/frail HNSCC patients. Christophe Le Tourneau 6069

Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of Jennifer Maria Johnson 6070 the head and neck (LA SCCHN). Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and Katharine Andress Rowe 6071 neck squamous cell carcinoma (HNSCC). Price Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal Robert S. Siegel 6072 squamous cell carcinoma (OPSCC)—An update and retrospective review of non-study patients. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high- Maura L. Gillison 6073 risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.

Is there a benefit of adding surveillance imaging to frequent history and physical exams in patients treated definitively for head and Jeffrey Chi 6074 neck squamous cell carcinoma? Cost-effectiveness analysis of chemoradiation compared to radiation alone in the treatment of nonmetastatic oropharyngeal cancer. Husam Albarmawi 6075

Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human Anthony Hee Kong 6076 papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.

Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and Signe Friesland 6077 cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.

Impact of antiviral prophylaxis in HSV positive patients treated with concurrent chemoradiotherapy for head and neck cancer. Nathalie Letarte 6078

A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell Vatche Tchekmedyian 6079 carcinoma of the oropharynx. Outcomes of post-operative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell Jessica Lyn Geiger 6080 carcinoma (OCSCC): A multi-institutional collaboration. Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes Lori J. Wirth 6081 in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic Jonathan Daniel 6082 carcinoma. Schoenfeld NISCAHN: A Phase II, multicenter nonrandomized trial aiming at evaluating Nivolumab (N) in two cohorts of patients (pts) with Jerome Fayette 6083 recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Vatche Tchekmedyian 6084

Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma. Jelena Lukovic 6085 PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer. Samuel Rack 6086

Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy. Lori J. Wirth 6087 Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy Eric Jeffrey Sherman 6088 (SBRT) to treat metastatic anaplastic thyroid cancer (ATC). A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine Yunpeng Yang TPS6089 and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with Ravindra Uppaluri TPS6090 resectable, locally advanced head and neck squamous cell carcinoma. EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab Martin David Forster TPS6091 relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer. Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)- Lillian L. Siu TPS6092 positive nasopharyngeal carcinoma (EBV+NPC). Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary Chia-Jung Busch TPS6093 radiochemotherapy for oropharyngeal cancer (TopROC). A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician's choice Merrill A. Biel TPS6094 standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs Chia-Jung Busch TPS6095 standard follow-up in surgical resectable HNSCC after adjuvant therapy. Roman: Reduction in oral mucositis with avasopasem manganese (GC4419)—Phase 3 trial in patients receiving chemoradiotherapy Jon Holmlund TPS6096 for locally-advanced, non-metastatic head and neck cancer. A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)- Marcia S. Brose TPS6097 refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.

ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic Renata Ferrarotto TPS6098 carcinoma (ACC) with Notch activating mutations (Notchact mut).

Health Services Research, Clinical Informatics, and Quality of Care Evaluation of a risk-based approach to follow-up care for breast cancer survivors: From oncology specialist to primary care provider Kathleen Keenan 6529 (PCP). Association of providers' prescribing patterns with postsurgical opioid use among cancer patients undergoing curative-intent surgery. Yuan Xu 6530

Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians. Suanna S. Bruinooge 6531 The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province. Ravi Ramjeesingh 6532 A Prospective blinded study of 1000 cases analyzing the role of artificial intelligence: Watson for oncology and change in decision S.P. Somashekhar 6533 making of a Multidisciplinary Tumor Board (MDT) from a tertiary care cancer center. 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Leveraging a conversational agent to support adherence to oral anticancer agents: A usability study. Bethany Mooney Berges 6534

Risk stratification and daily symptom monitoring for oncology patients. Robert Michael Daly 6535 Evaluation of quality of life, satisfaction and cost of care in metastatic colorectal cancer patients receiving ambulatory chemotherapy. Phichai Chansriwong 6536

Proactive, multidisciplinary approach to supportive medicine: Improving health outcomes and care utilization. Brooke Worster 6537 Deployment and integration of a cognitive technology in China: Experiences and lessons learned. Tianle Li 6538 Capacity to provide specialized care for older adults in community oncology practices: Results of the NCI Community Oncology Grant Richard Williams 6539 Research Program (NCORP) Landscape survey. Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials (RCTs). Caroline Savage Bennette 6540

Delay in receipt of newly prescribed oral anticancer drugs. Daniel O'Neil 6541 Safety and outcomes of a cancer patient urgent care clinic. Jack S Bevins 6542 Validation of an oncology-specific instrument to measure cancer patients' perception of care coordination. Izumi Okado 6543 Nurse Navigators telephone and web application follow-up intervention for patients treated with oral anticancer medication: an Marie Ferrua 6544 optimization of oncologists' medical time. Watson for oncology applied to teaching and remote consulting model. Juemin Fang 6545 Creation of a virtual cancer care network for remote oncology treatment. Vida Almario Passero 6546 National lung cancer screening utilization trends in the Veterans Health Administration. Jennifer A. Lewis 6547 Active search for toxicity reduces delay on chemotherapy. Juliana Souza 6548 Prospective comparative effectiveness trial of multidisciplinary lung cancer (LC) care. Raymond U. 6549 Osarogiagbon Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC). Di Maria Jiang 6550

Trends in the use of proton beam therapy among newly diagnosed cancer patients in the United States. Leticia Maciel Nogueira 6551

The diagnosis and outcomes when the outpatients receiving chemotherapy visited the emergency room: A tertiary referral center Takatsugu Ogata 6552 retrospective study of 734 cases. A blinded evaluation of a clinical decision-support system at a regional cancer care center. Suthida Suwanvecho 6553 A framework for building a clinically relevant risk model. Robert Michael Daly 6554 Reasons for discordance in treatment approaches between oncology practice and clinical decision support in China. Jun Liang 6555 Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients. Smita Agrawal 6556 Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC). Davendra Sohal 6557

Use of machine learning to identify relevant research publications in clinical oncology. Fernando Jose Suarez Saiz 6558

Patient reported outcomes and predictors of distress. Patrick Leland Meadors 6559

Impact of travel time on healthcare costs and resource utilization by phase of care for older cancer patients. Gabrielle Betty Rocque 6560

Esophageal cancer in Hispanic patients: A demographic analysis of the National Cancer Database. Juan Ricardo 6561 Access to care and financial burden for patients with breast cancer in Ghana, Kenya, and Nigeria. Majid Twahir 6562 Racial comparisons in receipt of timely guideline-based colon cancer treatment in an equal-access health system. Yvonne L Eaglehouse 6563 Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. Kelly Faulk 6564

Development of a financial navigation program to ease the burden of financial toxicity. Melissa Monak 6565 Unique perspectives from the transgender community: A retrospective chart review of cancer care needs for transgender patients. Carolyn Moloney 6566

Effectiveness of mobile computerized tomographic (CT) lung scanning unit for early diagnosis of lung cancer in under-served Derek Raghavan 6567 populations. Australian population-based study of single- versus multi-fraction palliative radiotherapy for bone metastases. Wee Loon Ong 6568 Clinical impact of the Mexican healthcare system "Seguro Popular" on breast cancer survival. Luis Antonio Cancel 6569 Impact of race/ethnicity in the clinical presentation and outcomes of patients with multiple myeloma in an underserved urban Christian Torres 6570 population. Forecasting the global need for high-dose methotrexate to prevent and mitigate shortages. Scott C. Howard 6571 Cervical cancer screening in incarcerated women: An experience from the first cervical cancer screening campaign in a southern Ingporn Jiamset 6572 Thailand correctional facility. A novel patient-centric approach between sites, CRO, and sponsor to accelerate FPI and drive more patients into oncology protocols. Krystyna Kowalczyk 6573

Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Gerneiva Parkinson 6574 Diagnostic and treatment delays in young women with breast cancer. Philip D Poorvu 6575 Association of diagnosing physician and hospital characteristics with the use of radical cystectomy among patients with muscle- Hemalkumar B Mehta 6576 invasive bladder cancer. Disparities in lung cancer outcomes for veterans with comorbid mental disorders. Jacob E Berchuck 6577 Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence. Ryan Nguyen 6578 Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer. Vikram Jairam 6579 Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer? Andrew Johns 6580 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Low nationwide utilization of adjuvant chemotherapy (AC) in elderly patients with localized non-small cell lung cancer (NSCLC). Kaushal Parikh 6581

Self-reported health and survival in older patients diagnosed with multiple myeloma. Nadia Azmi Nabulsi 6582 Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO's Li Chen 6583 CancerLinQ database. Caveat medicus: Harrowing experiences of clinicians who identify and publish near-fatal oncology associated adverse drug reactions. Ashley Caitlin Godwin 6584

Can high-volume surgeons achieve optimal outcomes at low-volume hospitals? Implications for the Leapfrog Initiative and Christopher Thomas 6585 regionalization of high-risk surgical oncology procedures. Aquina Impact of cardiovascular comorbidities on mortality in patients admitted for neutropenic fever in 2016. Suheil Albert Atallah- 6586 Yunes Prospective study of pain outcomes associated with contralateral prophylactic mastectomy in women with nonhereditary breast Demetria Joy Smith- 6587 cancer. Graziani Analysis of racial distribution amongst patients in phase III cancer clinical trials. Swathi Gopishetty 6588 Real-world effectiveness of approved anticancer agents among Medicare beneficiaries. Angela Green 6589 Reporting of patient reported outcome (PRO) in clinical trials: A systematic review of clinical trials. Liat Vidal-Fisher 6590 Hormone replacement therapy (HRT) and risk of distant recurrence in newly diagnosed ER+, node-negative (N-) breast-cancer (BC) Ariel Hammerman 6591 patients: A retrospective population-based matched-cohort study. Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials. Fang Yang 6592

Clinical utility and reimbursement for expanded genomic panel testing in adult oncology. Susan Jean Hsiao 6593 Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT). Surbhi Sidana 6594 Incidence and outcome of interval breast cancer among women participating in the provincial population based screening program in Saroj Niraula 6595 manitoba, Canada. A living systematic review of immune checkpoint inhibitors in cancer patients: A novel platform for evidence synthesis in oncology. Irbaz Bin Riaz 6596

Association between age, risk of severe (Grade 3-4) immune-related adverse events (sirAE), and mortality in patients receiving Asrar Alahmadi 6597 immune checkpoint inhibitors (ICI). Impact of timing of lung resection on survival for clinical stage I and II lung cancer. Isabel M Emmerick 6598 Online advertising and marketing claims by providers of proton beam therapy: Are they guideline based? Mark Thomas Corkum 6599 Mortality within 30 days of immunotherapy (checkpoint inhibitors) in metastatic cancer patients treated at Australian tertiary cancer Hiren A. Mandaliya 6600 center. Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers? Julia Rachel Trosman 6601

Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) Shivaani Kummar 6602 fusion cancer receiving larotrectinib. Where's my doctor? the impact of the primary oncologist's visit with their hospitalized patients. Brianna R. Bakow 6603 The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. Joseph M. Unger 6604 Survivorship care: Improving delivery of care plans for hematology patients at the Washington Cancer Institute (WCI). Hira Latif 6605

Multi-institution quality improvement in supportive oncology: Results of the Coleman Supportive Oncology Collaborative (CSOC). Paramjeet Khosla 6606

Utilization of value stream mapping to improve chimeric antigen receptor (CAR) T-cell patient experience at an academic medical Julie Porter 6607 center (AMC). Venous thromboembolism (VTE) in patients with ALK-rearranged non-small cell lung cancer (ALK-LC): A population-based cohort. Alona Zer 6608

Characterization of oncologic patient visits at the emergency department (ED) at an Austrian tertiary care center. Christoph Minichsdorfer 6609

A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid Tina Hsu 6610 premedication for docetaxel chemotherapy. QOL assessment integrated into the clinical care of cancer survivors to identify needs and direct care. Christian S. Adonizio 6611 Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based Lotte Keikes 6612 study. Impact of cancer in pulmonary embolism presentation and outcomes: A large academic center study. Cherry Au 6613 Impact of specialist palliative care delivered over three months prior to death on a colorectal cancer patient's risk of experiencing Aynharan Sinnarajah 6614 aggressive end-of-life care. Impact of an oncology urgent care clinic on emergency department rates. Tannaz Sedghi 6615 Quality control system of Watson for oncology: Artificial intelligence for supporting clinical decisions in oncology. Juemin Fang 6616 Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized Guillermo de Velasco 6617 clinical trials. Adherence to the guidelines: A comparison of biomarker testing implementation in metastatic non-squamous, non-small cell lung Sufana Shikdar 6618 cancer in university versus community institutions. Qualifying sites for oncology clinical trials. Dax Kurbegov 6619 Impact of Oncology Care Model (OCM) reporting requirements on quality of care. Emily Castellanos 6620 Decreasing postoperative opioid prescriptions in ambulatory extended recovery patients. Nkechi Fearon 6621 Virtual visits for children, adolescents, and young adults with cancer. Peter Meade Anderson 6622 2019 ASCO Annual Meeting Planner Saturday, June 1 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Evaluating the impact of telephonic nurse care management during high toxicity chemotherapy treatment. Craig A Hunter 6623 Evaluating the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks for Sophie Feng 6624 Food and Drug Administration (FDA) approved checkpoint inhibitors (CIs). Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective? Naomi RM Schwartz 6625 Relationship of emergency department use pre- and post-cancer diagnosis in safety-net adults. Arthur Hong 6626 A weighted criterion-based approach to value assessment of oncology drugs. Doreen Anuli Ezeife 6627 Followup mammography after breast conservation therapy: Is 3D Tomosynthesis(3DT) worth it? Shaakir Hasan 6628 Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada. Ying Wang 6629 Economic impact of the 31-gene expression profile test in the Medicare-eligible population with cutaneous melanoma. Federico A. Monzon 6630

Cost of oral cancer drugs: Trends in the United States Medicare population in 2013 and 2015. Kira Rose-Madison Seiger 6631

Sustaining the gains in cancer care from the oncology care model. Valerie P Csik 6632 Identifying and predicting the most costly patients in oncology. Mark Raymond Waddle 6633

Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting. Sienna Durbin 6634 The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology Stephen Matthew 6635 network. Schleicher Clinical and economic outcomes of pegfilgrastim in metastatic colorectal cancer. Lalan S. Wilfong 6636 Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin Jeremy S. Abramson 6637 lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001. Clinical benefit and prices of cancer drugs in the United States and Europe. Kerstin Noelle Vokinger 6638

A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma. Ambika Parmar 6639 Desire to address costs at time of treatment decisions among patients with metastatic breast cancer. Yvonne Y. Lei 6640 Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits. Ambika Parmar 6641

Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy. Alexander Kuhlmann 6642 Progression free survival (PFS) benefits of immuno-oncology agents (IOs) and implications for market cost-sharing inefficiencies. Syed Muhammad 6643 Mushtaq Ashraf Cost-effectiveness of CHOP in treating DLBCL in Malawi. Matthew Painschab 6644 Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (Febrile) neutropenia and Weijia Wang 6645 expanded access based on budget neutral basis. Scope of practice of advanced practice providers (APP) in US community oncology. Andrew Klink 6646 National cancer expenditure analysis in the United States Medicare population, 2013. Emily S Ruiz 6647 Total cost of care for patients (pts) with stage II colon cancer (CC-II): A SEER-Medicare analysis. Afsaneh Barzi 6648 Reproductive health in cancer. Erika K Radeke TPS6649 Patient related outcomes in cancer patients in Croatia. Dragan Trivanovic TPS6650 Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi- Gillian Gresham TPS6651 STEPS). Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal Veena Shankaran TPS6652 cancer (mCRC). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Breast Cancer—Local/Regional/Adjuvant Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the Sibylle Loibl 509 translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase Otto Metzger Filho 510 III study. NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR). Sandra M. Swain 511

Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A Arlindo R. Ferreira 512 prospective patient-reported outcomes (PRO) analysis. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus Andreas Schneeweiss 513 trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer. Juliet Richman 514

Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus Luca Gianni 515 paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I- Priyanka Sharma 516 III triple-negative breast cancer (NCT02413320). Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide Romualdo Barroso-Sousa 517 (AC)-T regimen: A prospective study. Association between tumor biology and occult lymph node metastases before and after primary neoadjuvant therapy (NAT) for Hans-Christian Kolberg 518 patients with early breast cancer. Adjuvant endocrine monotherapy (ET) versus adjuvant breast radiation (RT) alone in healthy older women with stage I, estrogen Anthony H. Bui 519 receptor-positive (ER+) breast cancer: An analysis of the National Cancer Database (NCDB). Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women's Health Initiative randomized clinical trial. Rowan T. Chlebowski 520

Impact of the extent of resection on primary breast angiosarcoma survival. Timur Mitin 521 Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis. Paul Stewart 522

Adherence to adjuvant endocrine therapy after breast cancer in Sweden 2008-2010: A nationwide survey. Anne Andersson 523 De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A Hadar Goldvaser 524 systemic review and meta-analysis. Effect of tart cherry on aromatase inhibitor-induced arthralgia (AIA) in nonmetastatic hormone-positive breast cancer patients: A Mina Shenouda 525 randomized double-blind placebo-controlled trial. Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer. Jinani Jayasekera 526 Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast Luca Gianni 527 cancer: The NA-PHER2 Michelangelo study. A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel Jiani Wang 528 plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.

The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial Isabel Pimentel 529 of metformin versus placebo in addition to standard therapy. Prognostic value of a new clinical-genomic model to predict 10-year risk of recurrence in patients with operable breast cancer. Lei Lei 530

Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care. Xiao Xu 531 EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity. Lauren A Marcath 532 Influence of competing risks on estimates of recurrence risk and breast cancer-specific mortality in analyses of the Early Breast Ramy Saleh 533 Cancer Trialists Collaborative Group. Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study. Ivana Sestak 534 Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR- Darran O'Connor 535 positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland. Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). Tessa Gerjanne 536 Steenbruggen Breast cancer-specific survival outcomes among patients based on 21-gene recurrence score. Wade T. Swenson 537 Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group Jose Pablo Leone 538 (BIG) 1-98 sub-analyses. Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two Lee S. Schwartzberg 539 phase III trials in breast cancer patients. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Jose Pablo Leone 540 Results (SEER) Registry. Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Jessica Scott 541 Operable Breast Cancer: A Randomized Controlled Trial (RCT). A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node- Takeo Fujii 542 negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients. Bo Chen 543 PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant Pier Franco Conte 544 chemotherapy plus trastuzumab in the ShortHER trial. The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer. Sara Bravaccini 545

Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC. Tiffany A. Traina 546 Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Zeina A. Nahleh 547 Database. Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II Carlos Hernando 548 CONTROL trial. Barcenas Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center. Katya Losk 549

Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast Ioannis Zerdes 550 cancer. Prediction of neoadjuvant chemotherapeutic efficacy by CTC and cfDNA in patients with locally advanced breast cancer. Ge Ma 551

Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast Darya Kizub 552 cancer metastases as part of the SWOG 0307 trial. Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A Theodoros Foukakis 553 secondary analysis of the phase III PANTHER trial. Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H). Adrienne Gropper Waks 554

Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node-positive (N+) Dennis Sgroi 555 breast cancer patients with one to three positive nodes (N1). Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab Jessica Campf 556 versus trastuzumab alone to prevent recurrence. Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study. Hans-Christian Kolberg 557

Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics. Neelima Vidula 558 A prospective validation cohort study of a prediction model on non-sentinel lymph node involvement in early breast cancer. Xingfei Yu 559

Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort. Allison W. Kurian 560 Cognitive impairment in breast cancer patients before surgery?: Results of a subgroup of the French CANTO cohort. Marie Lange 561 Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety Christine B. Weldon 562 net and non-safety net centers? TARGIT E(lderly): Prospective phase II trial of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. Frederik Wenz 563

No relationship of axillary total tumor load (TTL) by PCR (OSNA) in early breast cancer and local and distant clinical outcomes. Jose Ales-Martinez 564

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis. Marissa K. Srour 565

Prediction of occult axillary metastases in treatment-naïve patients with breast cancer: A transSENTINA analysis. Cornelia Kolberg-Liedtke 566

Screening for cancer-related distress among women with newly diagnosed breast cancer (BC). Lauren Z. Rynar 567 Risk stratification in earl- stage luminal breast cancer patients treated with and without RT. Charlotta Wadsten 568 Clinical pharmacogenomic testing impacts therapy decisions and supportive medication choices in breast cancer. Kathleen Kiernan 569 Harnden Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P). Vera Martins 570 Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical Aranzazu Fernandez- 571 trials. Martinez Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor- Nour Abuhadra 572 infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). Esther Pohl-Rescigno 573

On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Stephen James Luen 574

Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with Miguel J. Gil Gil 575 long follow-up. Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal Jisun Kim 576 breast cancer [METEOR Study]. Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA). Giacomo Pelizzari 577

Race and response to neoadjuvant chemotherapy according to MammaPrint risk. Raquel Nunes 578 Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients. Ning Liao 579

Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with Xavier Pivot 580 HER2-positive early breast cancer at three-year follow-up. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab Yvonne Brandberg 583 emtansine as neoadjuvant treatment of HER2-positive breast cancer. Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal Emre Koca 584 growth factor receptor type 2 (HER2)-negative breast cancer-ANETT. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage Evthokia Hobbs 585 breast cancer patients with a BRCA mutation. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Sahil Seth 586 Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).

A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive Soong June Bae 587 breast cancer. Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple- Barbara Seliger 588 negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases. Wim Verhaegh 589 Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical Tarek Mohamed Ahmed 590 changes which guides the optimal adjuvant therapy. Abdel-Fatah CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab William M. Sikov 591 (Bev) in triple-negative breast cancer (TNBC). Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). Elizabeth Anne Comen 592 Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from Manasa Vulchi 593 pretreatment breast MRI. Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in Luca Cavallone 594 triple-negative breast cancer (TNBC). Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. Sahil Seth 595 ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus Nadia Harbeck TPS596 chemotherapy in intermediate-risk HR+/HER2- early breast cancer. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), Dennis J. Slamon TPS597 human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple- Heather L. McArthur TPS598 negative breast cancer. ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. Wendy Y. Chen TPS599

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post Eleftherios P. Mamounas TPS600 mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy Fatima Cardoso TPS601 and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2-) breast cancer. Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). Wendy R. Parulekar TPS602

The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). Chizuko Kanbayashi TPS603 Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer. Maryann J. Kwa TPS604 NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with Charles E. Geyer TPS605 atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Breast Cancer—Metastatic Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for Adam Brufsky 1013 patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from Ajjai Shivaram Alva 1014 the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer David B. Page 1015 (mTNBC). Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2- advanced breast cancer postprogression on a CDK4/6 Aditya Bardia 1016 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). Carey K. Anders 1017

In-depth gene expression analysis of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib- Yen-Shen Lu 1018 containing therapy in the Phase III MONALEESA-7 trial. Characterization of mutational processes in ER+ metastatic breast cancer. Jorge Buendia-Buendia 1019

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) Sandra M. Swain 1020 pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) Cornelius F. Waller 1021 from the phase III HERITAGE Trial. Genomic landscape of de novo stage IV breast cancer. Ana Christina Garrido- 1022 Castro Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). Jeffrey S. Ross 1023 mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with Thomas Denis Bachelot 1024 everolimus-exemestan: Results from the SAFIRTOR study. Effect of HER2/neu 655 polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. Isabel Blancas 1025

A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + Binghe Xu 1026 H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with Laura Spring 1028 metastatic HER2-positive breast cancer. Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort. Elena Shagisultanova 1029 High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc- Jeffrey L. Nordstrom 1030 enhanced anti-HER2 monoclonal antibody (mAb). Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ Prashanth Reddy Moku 1031 metastatic breast cancer. Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A Abby Statler 1032 National Cancer Database Analysis. Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Abby Statler 1033 Database analysis. Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic Zachary William Neil 1034 breast cancer (MBC): A multi-institutional analysis. Veitch Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer Fei Ma 1035 patients: A phase I clinical trial. Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, Qiang Zhang 1036 and prognosis in stage III/IV breast cancer (BCa). Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with Inna Y. Gong 1037 clinical trial outcomes. Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal Dejan Juric 1038 growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth Ingrid A. Mayer 1039 factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal Hope S. Rugo 1040 growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the Michelino DeLaurentiis 1041 treatment of HR+/HER2– advanced breast cancer (ABC). Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2- Erika Paige Hamilton 1042 negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data. A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer Pierre Heudel 1043 patients. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline Sami Diab 1044 BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.

A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with Joline Si Jing Lim 1045 hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC). Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone Claudia Omarini 1046 receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic Romualdo Barroso-Sousa 1047 breast cancer (MBC). Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line Peter A. Fasching 1048 chemotherapy: Data from the German PRAEGNANT registry. Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) Mark Jesus Mendoza 1049 receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance). Magbanua Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER- Paolo Nuciforo 1050 positive/HER2-negative early-stage breast cancer from the LORELEI trial. PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and Javier Pascual 1051 fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC. Vicki Rimkunas 1052 A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC). Carlos Henrique dos 1053 Anjos 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with Aditya Bardia 1054 ER+/HER2- metastatic breast cancer (mBC). Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). Cynthia Huang Bartlett 1055

Lasofoxifene as a potential treatment for ER+ metastatic breast cancer. Muriel Laine 1056 A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- Seth Andrew Wander 1057 metastatic breast cancer (MBC). Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated Madeline Cook 1058 with CDK4/6 inhibitor based therapies. Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, Erika Paige Hamilton 1059 HER2-negative breast cancer (HR+ BC). Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3). Hiroji Iwata 1060

RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast Arnd Nusch 1061 cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis.

The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients. Urvi Patel 1062 Effect of metformin on PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 expression in triple-negative breast Ye Han 1063 cancer. AL101 mediated tumor inhibition in notch-altered TNBC PDX models. Esther Channah Broner 1064

Association of SOX9 expression with sensitivity to CDK7 inhibition and overall survival in triple-negative breast cancer. Xiaoxiang Guan 1065

Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer. Jieqiong Liu 1066

Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic Sylvia Adams 1067 triple-negative breast cancer (mTNBC). IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)- Andreas Schneeweiss 1068 naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen Jin Sun Lee-Bitar 1069 receptor-positive triple-negative breast cancer. Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD). Fumikata Hara 1070

Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) Johannes Ettl 1071 and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with Amy Jo Chien 1072 advanced triple-negative breast cancer (TNBC). Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in Chaitanya Ramanuj 1073 multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB). Acharya Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer. Haven Garber 1074 Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in Mafalda Oliveira 1075 metastatic breast cancer (MBC). A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer. Nanlin Hu 1076 First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 Carlos Jara Sanchez 1077 (RegistEM). First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced Joyce O'Shaughnessy 1078 breast cancer (ABC): MONALEESA-2 long-term safety results. Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic Paul W. Sperduto 1079 assessment (Breast-GPA). Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) Lawrence G. Lum 1080 metastatic breast cancer. ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) Veronica Mariotti 1082 inhibitors in breast cancer (BC). Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase Reiki Nishimura 1083 III studies (SELECT BC-CONFIRM and SELECT BC). Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. Ming-Shen Dai 1084 Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in Adrienne Gropper Waks 1085 patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO). Tira Jing Ying Tan 1086 Association of secondary somatic mutations in BRCA1/2 with clinical resistance to PARP inhibitors and chemotherapy. Lingjun Zhu 1087

Differences in breast cancer outcomes amongst Black United States-born and Caribbean-born immigrants. Priscila Barreto Coelho 1088 Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation. Joshua Z. Drago 1089 Gaps in metastatic breast cancer patient knowledge and understanding in Mexico. Cynthia Villarreal-Garza 1090

TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in Cecile Vicier 1091 HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with Anne Patsouris 1092 homologous recombination deficiency (HRD). Survival outcomes of premenopausal patients diagnosed with invasive lobular carcinoma. Hee Jeong Kim 1093 Development and validation of novel microenvironment-based immune molecular subtypes of breast cancer: Implications for Yunfang Yu 1094 immunotherapy. Clinical characteristics and outcome of metaplastic breast cancer: A retrospective tertiary care center experience. Bicky Thapa 1095 A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative Ami N. Shah 1096 endocrine-refractory metastatic breast cancer (MBC). Measuring on-treatment genome-wide tumor copy number alterations in cell-free DNA (cfDNA) in plasma is highly prognostic in Adriana Aguilar 1097 metastatic breast cancer. Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients. Damien Mikael Hansra 1098 Patients with metastatic breast cancer enrolled in phase I clinical trials: Clinical outcomes and cohort trends. Jennifer Weiss 1099 A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced Akihiko Shimomura TPS1100 stage HER2-positive breast cancer: (JCOG1607 HERB TEA study). B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of Martine J. Piccart- TPS1101 HER2-positive advanced or metastatic breast cancer. Gebhart A phase III, multicenter, randomized, open label trial of [fam-] (DS-8201a) versus investigator's choice in Shanu Modi TPS1102 HER2-low breast cancer. XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone Peter Schmid TPS1103 receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non- visceral involvement. EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator's Aditya Bardia TPS1104 choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.

Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen Aditya Bardia TPS1105 receptor-positive (ER+)/HER2- metastatic breast cancer. A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production David B. Page TPS1106 and immunotherapy response in metastatic breast cancer (MBC). CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in Joyce O'Shaughnessy TPS1107 patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic Geoffrey J Lindeman TPS1108 breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.

A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus Jami Aya Fukui TPS1109 for the treatment of advanced triple-negative breast cancer. SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line Hyo S. Han TPS1110 treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.

A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. Zahi Ibrahim Mitri TPS1111 VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with Andrew Tutt TPS1112 olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in Sarah Sammons TPS1113 platinum responsive advanced triple-negative breast cancer (aTNBC). A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic Leonel Fernando TPS1114 triple-negative breast cancer (mTNBC). Hernandez-Aya Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. Romualdo Barroso-Sousa TPS1115

KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor Gerardo Antonio TPS1116 response of oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer Umanzor Funez (MBC). NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical Steven J. Chmura TPS1117 ablation for newly oligometastatic breast cancer (NCT02364557).

Central Nervous System Tumors NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus Vinai Gondi 2009 memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT Mustafa Khasraw 2011 (uMGMT) glioblastoma (GBM). Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes. Maximilian Knoll 2012

Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. Wolfgang Wick 2013

Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC. Melinda D Willard 2014 Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression. Mihaela Aldea 2015 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. Manmeet Singh 2016 Ahluwalia Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Michael Lim 2017

Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without Benjamin M. Ellingson 2018 bevacizumab or bevacizumab monotherapy. First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly Pedro R. Lowenstein 2019 diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.

Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma. E. Antonio Chiocca 2020 Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and Warren P. Mason 2021 radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive Wolfgang Wick 2022 glioblastoma patients. DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma. Nicholas A. Butowski 2023 Barriers to accrual and enrollment in brain tumor trials. Eudocia Quant Lee 2024 Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or Juanita Suzanne Lopez 2025 recurrent glioblastoma (GBM) or high-grade glioma. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter Christine Cordova 2026 mutation-specific droplet digital PCR assays. Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM). Roy E. Strowd 2027

Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements. Enrico Franceschi 2028 Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a Estela Pineda 2029 homogenously treated cohort: GLIOCAT project. Study of tumor infiltrating immune CELLS and vasculature in human gliomas: Differences in IDH1/2 mutant versus IDH1/2WT tumors. Maria Cruz Martin 2030 Soberon Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Jing Wu 2031

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed David A. Reardon 2032 unmethylated MGMT glioblastoma (new unmeth GBM). A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed Jiayi Huang 2033 glioblastoma. GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma. Bart Neyns 2034 Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without Emily Nash Nash Smyth 2035 brain metastases (BM). Effect of grade on survival in IDH-mutant grade II and grade III gliomas. Giuseppe Lamberti 2036 Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results. Giuseppe Lamberti 2037 Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology Juan Manuel Sepulveda- 2038 (GEINO) trial. Sanchez MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. Dina Randazzo 2039 Cancer differentiation analysis technology as a novel technology for cerebral cancer screening. Hongmei Tao 2040 A gene signature of response to radiotherapy in patients with grade II-III oligodendrogliomas. Elizabeth Moyal 2041 Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide Hao-Wen Sim 2042 (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM). Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An Giuseppe Lombardi 2043 observational study. A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed Denise Fabian 2044 glioblastoma utilizing global microRNA expression data. Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib Giuseppe Lombardi 2045 activity in relapsed glioblastoma patients. Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma. Yang Liu 2046 EGFR amplification predicted selective sensitivity to PARP inhibitors with high PARP-DNA trapping potential in human GBM. W. K. Alfred Yung 2047

Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM). Andrew B. Lassman 2048 Evaluating the capacity of connectome analysis to predict survival in high-grade astrocytoma. Rebecca A. Harrison 2049 Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma. Mitsuaki Shirahata 2050 The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma. Robert H. Press 2051 Correlation of systemic and local inflammation with survival prognosis in glioma patients. Pegah Mir Seyed Nazari 2052

Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. Rimas Vincas Lukas 2053 Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence. Sotirios Bisdas 2054

Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma. Suriya A. Jeyapalan 2055 Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study Michael Weller 2056 (EORTC 1419). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re- Maximilian Knoll 2057 irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK- ROG). Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact. Michael Fusco 2058 Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II Stephanie E Combs 2059 CINDERELLA trial. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of Annick Desjardins 2060 survivors from the phase I trial. Are patients with oligodendroglioma at higher risk for radiation neurotoxicity? Haroon Ahmad 2061 A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for Andrew E. Sloan 2062 newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit. Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment. Christopher Ray Trevino 2063

Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab Brandon Konkel 2064 versus bevacizumab alone. Phase I/II study of (ABT-414) monotherapy or combination with temozolomide in Japanese patients Yoshitaka Narita 2065 with/without EGFR-amplified recurrent glioblastoma. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. Benjamin Y. Lu 2066

Stereotactic radiosurgery for resected brain metastases: Does the surgical corridor need to be treated? Siyu Shi 2068 Insight into the brain metastasis journey: Initial survey results from patients and caregivers. Nicole Willmarth 2069 A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy Priya Kumthekar 2070 (WBRT). Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients Mark Rosenthal TPS2071 with recurrent or newly diagnosed disease. EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus Patrick Roth TPS2072 standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

A phase I/II study of nivolumab plus or minus ipilimumab in combination with multifraction stereotactic radiosurgery for recurrent Jiayi Huang TPS2073 high-grade radiation-relapsed meningioma. Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma. Adilia Hormigo TPS2074

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated Sani Haider Kizilbash TPS2075 diffuse astrocytoma and anaplastic astrocytoma (NCT03528642). Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II Wolfgang Wick TPS2076 study: NCT03750071.

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant Jamie E. Chaft 8507 NSCLC. The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer. Peng Xie 8508 NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II Mariano Provencio 8509 multicenter exploratory study—Final data of patients who underwent surgical assessment. Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage David E. Kozono 8510 III non-small cell lung cancer (NSCLC) (M14-360/AFT-07). Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally Salma K. Jabbour 8511 advanced, unresectable non-small cell lung cancer. Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. Steven H. Lin 8512

Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316). Susanne M. Arnold 8513 Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. Sehhoon Park 8514

A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung Taofeek Kunle 8515 cancer (SCLC). Owonikoko Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. Jyoti Malhotra 8516

Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural Arkadiusz Z. Dudek 8517 mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).

A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for malignant pleural mesothelioma Seiki Hasegawa 8518 (Japan Mesothelioma Interest Group 1101 Trial). Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. Ranjan Pathak 8519 Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with Myung-Ju Ahn 8520 neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results. The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence. Maya Khalil 8521 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: A validation study in Chinese patients. Chen Chen 8522

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without Athanassios Argiris 8523 veliparib in stage III non-small cell lung cancer (NSCLC). Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response. Joshua E. Reuss 8524

Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer. Atsushi Kamigaichi 8525 Three-year overall survival update from the PACIFIC trial. Jhanelle Elaine Gray 8526 Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for Kana Watanabe 8527 locally advanced unresectable stage III non-squamous non-small-cell lung cancer: NJLCG1001. Identifying actionable somatic mutations in lung cancer using cell-free DNA from bronchial washing fluid. Xin Zhang 8528 Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally Atsushi Horiike 8529 advanced non-small cell lung cancer. Alteration in tumor immune microenvironment after chemo-radiotherapy for locally advanced non-small cell lung cancer. Kazue Yoneda 8530

Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC). Ning Li 8531

T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with Alexandre Reuben 8532 ipilimumab (NEOSTAR trial). Neutrophil-to-lymphocyte ratio and subsequent recurrence of non-small cell lung cancer patients in remission. Abigail Sy Chan 8533 Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475- Jair Bar 8534 223. Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for Melissa Yan 8535 unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081. 10-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea Keunchil Park 8536 real-time automatically updated data warehouse in health care (UNIVERSE - ROOT study). Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC. Fotinos-Ioannis D. 8537 Dimtrakopoulos EGFR L858R mutation as a possible target for individual-independent immunotherapy in Chinese population. Yu Chen 8538 The spatiotemporal evolution of early-stage non-small-cell lung cancer. Siwei Wang 8539 Comprehensive genomic profiling in Chinese patients with lung squamous cell carcinoma. Zuping Lian 8540 Mutational landscapes and PD-L1 expression in non-small cell lung cancer. Kang Zhang 8541 Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Taymeyah E. Al-Toubah 8542

Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage Sayedmohammad 8543 IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial. Hasheminasab

Immune landscape of the tumor microenvironment to predict prognosis and DNA mutations in patients with lung adenocarcinoma. Sunyoung S. Lee 8544

Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Meaghan Dendy Case 8545

Lung cancer diagnosed by an incidental lung nodule program or lung cancer screening. Matthew Smeltzer 8546 Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study. Maria Pagano 8547 Outcome of neo-adjuvant chemotherapy in 225 surgical candidates with malignant pleural mesothelioma. Nobuyuki Kondo 8548 Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). Deepti Venkatraman 8549 Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant Federica Grosso 8551 pleural mesothelioma (MPM). Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy. Marjorie Glass Zauderer 8552

Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy. Yutao Liu 8553

Development of a prognostic risk model for small cell lung cancer: Identification of high-, intermediate-, and low-risk cohorts based Fatemeh Ardeshir-Larijani 8554 on clinical-genomic data. Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer. Hironori Yoshida 8555

Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung Wei-Chu Victoria Lai 8556 cancer. Phase I study on preliminary safety and efficacy of in Japanese patients (pts) with advanced, recurrent small Hiroaki Akamatsu 8557 cell lung cancer (SCLC). Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker Satoshi Oizumi 8558 study in LC-SCRUM-Japan. Impact of large-scale nationwide genomic screening project for small cell lung cancer (LC-SCRUM-Japan). Naoki Furuya 8559 Thoracic twice-daily radiotherapy and brain metastasis in patients with small cell lung cancer. Haiyan Zeng 8560 RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 Luis G. Paz-Ares 8562 dose-defining phase. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate Rieke Nila Fischer 8563 biomarkers predictive for response—Preliminary results from the SCLC cohort. 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Phase II study of S-1 in patients (pts) with previously treated Invasive thymoma (IT) and thymic carcinoma (TC): North Japan Lung Kyoji Tsurumi 8564 Cancer Study Group Trial 1203. Progression free survival and time to local failure after radiosurgery of pleural metastases in twenty-two patients with thymomas. Giulia Pasquini 8565

Clinical application of circulating cell-free DNA for monitoring the biological course of thymic epithelial tumors. Margaret Ottaviano 8566 Anti-EGFR target therapy in advanced thymic epithelial tumors. Mario Giuliano 8567 The risk of second primary malignancy in patients with localized thymoma: A U.S. population-based study. Dipesh Uprety 8568 ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma Benjamin J. Solomon TPS8569 kinase-positive (ALK+) non-small cell lung cancer (NSCLC). CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer Edward B. Garon TPS8570 (NSCLC). The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT). Nitin Ohri TPS8571 Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) Yi-Long Wu TPS8572 non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).

PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III Jeffrey D. Bradley TPS8573 NSCLC. Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally Luis G. Paz-Ares TPS8574 advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).

Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, Salma K. Jabbour TPS8575 locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799. Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small Lauren Averett Byers TPS8576 cell lung cancer (SCLC). Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with Marie-Anne Damiette TPS8577 small cell lung cancer (SCLC). Smit NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for Vinai Gondi TPS8578 small cell lung cancer.

Lung Cancer—Non-Small Cell Metastatic IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets). Mark A. Socinski 9012 KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with Shirish M. Gadgeel 9013 pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous Lyudmila Bazhenova 9014 cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. Edward B. Garon LBA9015

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± Naiyer A. Rizvi 9016 tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung Lingzhi Hong 9017 cancer (NSCLC). Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer. Hira Rizvi 9018 Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung Alice Tsang Shaw 9019 cancer (NSCLC). Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. Caicun Zhou 9020

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small Shirish M. Gadgeel 9021 cell lung cancer (NSCLC). A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV Taofeek Kunle 9022 squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). Owonikoko c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer. Rebecca Suk Heist 9023 Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer. Rodney E Wegner 9024

A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation Sunita Patruni 9025 with and without immunotherapy. Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial. Myung-Ju Ahn 9026 Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Tom Stinchcombe 9027 Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with Adam Jacob Schoenfeld 9028 EGFR-mutant lung cancers. Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer Mark M. Awad 9029 (NSCLC). Acquired resistance to MET inhibition in MET driven NSCLC. Richard Riedel 9030 Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients Isamu Okamoto 9031 with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M Yuankai Shi 9034 mutation advanced or recurrent NSCLC. Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients Yong He 9035 with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced Lecia V. Sequist 9036 non-small cell lung cancer (NSCLC). Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study. Myung-Ju Ahn 9037 The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with Kentaro Ito 9038 NSCLC harboring ALK-rearrangement (WJOG9516L). Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, Libor Havel 9039 randomized, multicenter trial. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Eugene R Ahn 9041 Profiling Utilization Registry (TAPUR) Study. Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint Bassel Nazha 9042 inhibitor (ICI): Our institutional experience. Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients. Yan Wang 9043 Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS). Kartik Anand 9044 Brigatinib in pretreated patients with ALK-positive advanced NSCLC. Renaud Descourt 9045 The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring Kiyotaka Yoh 9046 oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan. Variation in the assessment of immune-related adverse event occurrence, grade, and timing. David Hsieh 9047 Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Edward B. Garon 9048 Results from MYSTIC. Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant Nitin Roper 9049 NSCLC. Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes. Stephanie J. Yaung 9050

First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors. Jacob Sands 9051 ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade. Kathryn Cecilia Arbour 9052 Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III Rafal Dziadziuszko 9053 ALEX trial. First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC. David Planchard 9054

Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution. Jillian Bracht 9055 Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset Hiroe Kayatani 9056 analysis. Osimertinib (Osi) plus (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study. Jonathan W. Riess 9057

Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC). Abdel-Ghani Azzouqa 9058

Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Michael Leapman 9059

Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome Terufumi Kato 9060 screening in Japan (LC-SCRUM-Japan). Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were Thierry Landre 9061 PD-L1 negative or less than 1 %. Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive Gregory J. Riely 9062 NSCLC. Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions. Sai-Hong Ignatius Ou 9063 Prognostic significance of radiologic features of pneumonitis induced by anti-PD-1 therapy. Satoshi Watanabe 9065 Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical Sebastian Yves Friedrich 9066 trial–Updated report on progression-free and overall survival. Michels Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK Jessica Jiyeong Lin 9067 TKIs. Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors. Ibiayi Dagogo-Jack 9068 Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI). Zofia Piotrowska 9069 Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy Robert Charles Doebele 9070 analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.

Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term Enriqueta Felip 9071 benefit to immune checkpoint inhibitors (ICIs). First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of Anas Gazzah 9072 patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC). Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results. Andreas Nicholas Saltos 9073 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Christian Grohé 9074 Preliminary efficacy and safety results of the non-interventional study VARGADO. Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG- Saiama Naheed Waqar 9075 MAP sub-study S1400K (NCT03574753). Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after Celine Mascaux 9076 comprehensive genomic profiling (CGP): A real-world study. DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed Biagio Ricciuti 9077 death 1 axis inhibition in non-small cell lung cancer. Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers. Michael Offin 9078

Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer Alexis B. Cortot 9079 (NSCLC) patients (IFCT-1503 ACE-Lung). Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes. Alexandra Pender 9080

NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry. Michael Duruisseaux 9081

Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non- Biagio Ricciuti 9082 small cell lung cancer. Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. Joel W. Neal 9083 Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in Rosario Garcia Campelo 9084 advanced ALK+ non-small cell lung cancer (NSCLC). Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228. Paul K. Paik 9085 A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers. Helena Alexandra Yu 9086

Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials. Mark Doherty 9087

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum- Thomas A. Hensing 9088 based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation. Guanghui Gao 9089

Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results Tejas Patil 9090 from a single-center retrospective study. Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M Qing Zhou 9091 positive non-small cell lung cancer (NCSLC). Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK- Takashi Seto 9092 positive non-small cell lung cancer (ALK+ NSCLC). Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two Julie R. Brahmer 9093 phase 1 studies. Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer. Sehhoon Park 9094

Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a Li Zhang 9095 randomized, double-blind, phase III study. A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors. Claudia Proto 9096 Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate Akhila Ganeshi 9097 synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer. Wimalasingham A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced Enriqueta Felip 9098 NSCLC: OS for stage I and preliminary stage II efficacy. Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell Sofia Agelaki 9099 lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung Hirva Mamdani 9100 cancer (NSCLC). Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer. Lan Shen 9101

Determinants of early discontinuation of first-line chemotherapy, and associated outcomes among elderly with advanced non-small Pramit Nadpara 9102 cell lung cancer. Early mortality in metastatic lung cancer: A SEER population data analysis. Opher Globus 9103 Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer. James William Welsh 9104

Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials. Michael E. Menefee 9105 Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology. Diego Signorelli 9106 Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) Roberto Ferrara 9107 upon PD-(L)-1 blockade (IO). Non-small cell lung cancer (NSCLC) case study examining whether results in a randomized control arm are replicated by a synthetic Ruthie Davi 9108 control arm (SCA). 2019 ASCO Annual Meeting Planner Sunday, June 2 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor Daniel Morgensztern 9109 treatment failure. Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint Sean Khozin 9110 inhibitor. Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%. Elizabeth Jimenez Aguilar 9111

Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced non-squamous NSCLC with wild"•type EGFR Caicun Zhou 9112 and ALK. Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas. Sam Whipple 9113

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing Myung-Ju Ahn TPS9114 advanced non-small cell lung cancer (NSCLC). Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non–small cell lung cancer Edward S. Kim TPS9115 (NSCLC) that progressed on alectinib or ceritinib. TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma. Alice Davies TPS9116

Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II Martin Gutierrez TPS9117 KEYNOTE-495/KeyImPaCT study. Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in Rina Hui TPS9118 patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006. SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced Geoffrey R. Oxnard TPS9119 or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib. A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial Yoshiro Nakahara TPS9120 chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833. ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non- Enriqueta Felip TPS9121 small cell lung cancer (NSCLC) patients. Prospective study of germline and somatic alterations for Early Onset LUNG cancer patients (EOLUNG MASTER protocol). Maria Jove TPS9122

MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus Fortunato Ciardiello TPS9123 gemcitabine and cisplatin in patients with advanced squamous NSCLC. The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC). Luis G. Paz-Ares TPS9124 A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab Yoshimasa Shiraishi TPS9125 for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab Myung-Ju Ahn TPS9126 alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC). Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed Anne-Marie C. TPS9127 with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923). Dingemans 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Gastrointestinal (Colorectal) Cancer A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer Filippo Pietrantonio 3509 (mCRC) patients. A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation Zhen Zhang 3510 of locally advanced rectal cancer (CinClare). Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line Michael Geissler 3511 treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC). CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a Eric Xueyu Chen 3512 phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA Franck Pages 3513 France cohort study (PRODIGE-GERCOR). A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma Aparna Raj Parikh 3514 (mCRC). A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in Yasumasa Takii 3515 patients with colon cancer: Primary analysis of Japan Clinical Oncology Group study JCOG1006. Long-term survival after laparoscopic versus open resection for colorectal liver metastases. Asmund Avdem Fretland LBA3516

Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) Pia J. Osterlund 3517 patients nationwide (prospective RAXO study). A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC). Jeanne Tie 3518

Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France Jean Francois Delattre 3519 phase III trial (PRODIGE-GERCOR). Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer Frank A. Sinicrope 3520 (CC). Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair Heinz-Josef Lenz 3521 deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. Recent changes in overall survival of real-life stage IV colorectal cancer patients. Patricia Hamers 3522 A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability. Hani Goodarzi 3523 The role of maintenance strategy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis. Mohamad Bassam Sonbol 3524

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Julien Taieb 3525 Results of an accent meta-analysis of seven studies. ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer. Tony R. Reid 3526

Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: A multicenter, single-arm, prospective study. Fen Wang 3527

Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood- Yoshiaki Nakamura 3528 based analysis from SCRUM-Japan GI-SCREEN and GOZILA. Screening patients for fluoropyrimidine-related toxicity risk. Olivier Capitain 3529 Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone Dominik Paul Modest 3530 as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109). Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer. Thiru Prasanna 3531 Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer Sakti Chakrabarti 3532 (mCRC) receiving programmed death-1 (PD-1) blockade. RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance. Alexa Betzig Schrock 3533

Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies. Gemma Zucchelli 3534

Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and Shehara Ramyalini 3535 immunogenicity in metastatic colorectal carcinoma. Mendis Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies. Federica Marmorino 3536

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) Carl Christoph Schimanski 3537 after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study Hirokazu Shoji 3538 (NCCH1503). Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled Ofer Margalit 3539 analysis of 3369 patients (pts) in the ARCAD database. Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi- Daniele Rossini 3540 institutional analysis. Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An Volker Heinemann 3541 analysis of FIRE-3 (AIO KRK 0306). cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Alexandre Harle 3542 Results of the real-world multicentric ColoBEAM study. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume Erwin Woff 3543 measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients. ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with ‘watch and wait' approach. Lifeng Yang 3544 Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, Hiroyuki Arai 3545 and MAVERICC trials. Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the Samira Makhloufi 3547 MIROX phase III trial. Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A Eiji Oki 3548 multicenter, phase II clinical trial. Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or Enrique Aranda 3549 cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs). Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients Lisa Salvatore 3550 (pts): A meta-analysis of individual pts data (IPD) from three phase III studies. Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo- Sukeshi Patel Arora 3551 refractory metastatic colorectal cancer (mCRC). Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) James Isaacs 3552 and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers. Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional Brunella Di Stefano 3554 retrospective analysis (REBUS study). Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with Nancy E. Kemeny 3555 resected RAS wild type colorectal cancer hepatic metastases (CRLM). Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer Maria Alessandra Calegari 3556 (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).

A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive Joleen Marie Hubbard 3557 biomarker (OBERTO). Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients. Ina Valeria Zurlo 3558 Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110)- study. Kathrin Heinrich 3559

Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. Toshiki Masuishi 3560

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder. Reese Garcia 3561 Feasibility of a national expert panel to determine resectability in patients with initially unresectable colorectal cancer liver Karen Bolhuis 3562 metastases (CRLM). Aggressiveness of care and overall survival in young metastatic colorectal cancer patients. Madeleine Fish 3563 Association between gene fusions and anti-EGFR resistance signature in colorectal cancer. Thereasa A. Rich 3564 Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic Stein G Larsen 3565 intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer. Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients. Pashtoon Murtaza Kasi 3566 Young-onset colorectal cancer patients disproportionately diagnosed with advanced disease: Patient self-reported journey of Ronit Yarden 3567 symptom duration and misdiagnosis. Tumor and microenvironment evolution during chemotherapy combine with bevacizumab in colorectal cancer liver metastasis. Wangjun Liao 3568

Serial ctDNA analysis as a real-time indicator of neoadjuvant chemoradiotherapy in rectal cancer. Jiaolin Zhou 3569 Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal Thomas Aparicio 3570 canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904). Outcomes of salvage surgery for anal squamous cell carcinoma: A systematic review and meta-analysis. David Patrick Cyr 3571 Factors affecting differential outcomes in the definitive treatment of anal cancer between HIV+ and HIV- patients. Matthew Susko 3572 Chemoradiotherapy for anal cancer: A population-based study of treatment interruption, treatment completion, and associated Michael J. Raphael 3573 outcomes. Combination of tissues analysis and immune infiltrate in localized colon cancer using artificial intelligence in PETACC8 study. Cynthia Reichling 3574

Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French Aline Derosiere 3575 multicenter retrospective cohort. High incidence of advanced stage cancer and prolonged rectal bleeding history before diagnosis in young-onset patients with Gurprataap Singh Sandhu 3576 colorectal cancer. Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable Amir Mehrvarz Sarshekeh 3577 colorectal cancer. Dissection of the lateral lymph nodes with short axis of ≥ 5 mm affects the prognosis in rectal cancer patients: A central review of 738 Koya Hida 3578 lower rectal cancer magnetic resonance images. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. Jenny E. Chu 3579 Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal Alberto F. Sobrero 3580 cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study. Association between pretreatment Fusobacterium nucleatum and cancer pain at six months postsurgery in newly diagnosed Anita Roselyn Peoples 3581 colorectal cancer patients: Results from the ColoCare Study. Germline multigene panel testing in colorectal cancer: Precision therapy and clinical management implications. Edward D. Esplin 3582 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled Aziz Zaanan 3583 analysis of the PETACC8 and NCCTG N0147 (Alliance) trials. Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) Arndt Stahler 3584 patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial). Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal Sebastian Mondaca 3585 cancer. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients. Jia Ke 3586 Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. Christine Megerdichian 3587 Parseghian

Molecular landscape of colorectal cancers harboring R-spondin fusions. Andreas Seeber 3588 Performance comparison of the methylated BCAT1/IKZF1 ctDNA test (COLVERA) with the CEA assay for detection of recurrent Erin L. Symonds 3589 colorectal cancer. Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). Allan Andresson Lima 3590 Pereira Preoperative platelet leukocyte ratio as an independent risk factor for postoperative outcomes in colorectal cancers. Carrie E Ryan 3591 Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing. Jason Willis 3592 Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA- Lisa Miller-Phillips 3593 21's influence on gene expression in the EGFR signaling pathway. Comparison of HER2 overexpression with total Her2 mutation on resistance of EGFR-targeted therapy in Ras wild-type mCRC Wenju Chang 3594 patients. Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Francesca Battaglin 3595 Data from FIRE-3 phase III trial. Differences in pathology and mutational status among colorectal cancer (CRC) patients pre-, post-, and during screening age. Gustavo Dos Santos 3596 Fernandes The 55 STAR study: Prognostic and predictive value of the 55-gene classifier (55GC) in stage III colon cancer. Toshiaki Ishikawa 3597 Urban/rural disparities in stage at presentation of colorectal cancer among young adults in the United States, 2007-2015. Victoria Nguyen 3598

Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC). Hao Xie 3599 Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer. Ryuma Tokunaga 3600 Prognostic stromal and immune response expression patterns in early-stage colorectal cancer to predict genes intrinsically expressed Pratyaksha Wirapati 3601 by tumor epithelial cells. A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer Aparna Raj Parikh 3602 (CRC). Gender differences in prognostic value of immune-related biomarkers in colon cancer patients randomized to surgery or surgery and Lisa Elena Esther 3603 adjuvant chemotherapy treatment. Villabona Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable Maliha Nusrat 3604 (MSS) colorectal cancer (CRC) patients (pts). Differences in clinical outcomes in young-onset colorectal cancer based on ethnicity in an NCI designated comprehensive cancer Benjamin David Fangman 3605 center. Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative Takayuki Yoshino 3606 chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer. The genomic landscape and its prognostic significance for stage III colorectal cancer in Japan: An ancillary study of JCOG0910 Dai Shida 3607 trial—JCOG1506A1. Effect of neoadjuvant treatment on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma: A post-hoc Jianwei Zhang 3608 analysis from 3 prospective studies. Stage-based variation in the impact of colon cancer surveillance. Lucy Gately 3609 Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the Alain Hendlisz 3610 PePiTA study. Long-term outcomes after high-dose chemoradiotherapy for non-surgical management of distal rectal cancer. Edina Dizdarevic 3611 Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. Pablo Emilio Serrano 3612 Aybar Pathway analysis of hypoxia-related factors in early colorectal cancer patients with poor prognosis. Yingxin Tan 3613 Clinical features and survival among patients with standard-onset versus early-onset colorectal cancer by age groups. Ana Acuna Villaorduna 3614 POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease David Lau TPS3615 domain mutant colon cancer—A phase III randomized study. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent Maryam B. Lustberg TPS3616 chemotherapy-induced peripheral neuropathy (CIPN). A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory Stefan Kasper TPS3617 colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316). Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + Ramon Salazar TPS3618 bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion Valerie Boige TPS3619 chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.

Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2. Thomas J. George TPS3620 Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of Yu Sunakawa TPS3621 treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Michael Michael TPS3622 Ave-Rec trial. Efficacy of aspirin for stage III colorectal cancer: A randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). Atsuo Takashima TPS3623

Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add-Aspirin trial. Ruth E Langley TPS3624

Gastrointestinal (Noncolorectal) Cancer Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced Zev A. Wainberg 4009 gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. Manish A. Shah 4010

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric Yelena Yuriy Janjigian 4011 adenocarcinoma. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results Thomas Yau 4012 from CheckMate 040. Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in E. Gabriela Chiorean 4014 metastatic pancreatic cancer (mPC): SWOG S1513. Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic Michael J. Pishvaian 4015 pancreatic cancer (mPDAC). Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the Saroj Vadhan-Raj 4016 CASSINI study. PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial. Sylvie Lorenzen 4018

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A Clarisse Eveno 4019 multicenter, randomized phase II study (PRODIGE 19). Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Hitoshi Katai 4020 cancer (JCOG0912). Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD- Rui-hua Xu 4021 1 antibody. Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis Avani Athauda 4022 of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the Sylvie Lorenzen 4023 stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO. Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations. Bo Wei 4024 Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE). Shukui Qin 4025

A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent Yoshihiko Nakamoto 4026 gastric cancer. A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma Min Hee Hong 4027 (ESCC). Perioperative chemotherapy alone versus preoperative chemoradiotherapy for locally advanced distal esophageal and Shiru Lucy Liu 4028 gastroesophageal junction cancer: A 10-year review of the British Columbia (BC) cancer registry. Clinicopathological features of Epstein–Barr virus associated gastric carcinoma with submucosal invasion. Hiroki Osumi 4029 A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or Yee Chao 4030 advanced adenocarcinoma of the stomach or gastroesophageal junction. Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced Lin Shen 4031 or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study. Ken Kato 4032

Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of Bo Zhang 4033 advanced esophageal squamous cell carcinoma. Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric Woochan Park 4034 cancer patients. POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in Rongbo Lin 4035 advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial. Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune Feng Wang 4036 check point blockade. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer Kohei Shitara 4037 (mGC/mGEJC): Subgroup analysis from TAGS. Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from Wasat Mansoor 4038 TAGS. Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic Eric Van Cutsem 4039 gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). Homologous recombination deficiency as prognostic marker in metastatic gastric cancer. Nuno Sousa 4040 Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and Nataliya Volodymyrivna 4041 gastroesophageal junction (E/GEJ) cancer. Uboha Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC). Nong Xu 4042

Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric MARIA ALSINA 4043 cancer (mGC). Recurrence risk evaluation in stage IB gastric cancer with TP53 codon 72 polymorphism. Satoshi Nishizuka 4044 A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal Tom van den Ende 4045 adenocarcinoma: The PERFECT trial. Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience. Megan Greally 4046

Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer Megan Greally 4047 (EGA) and patterns of subsequent therapy. Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or Antoine Adenis 4048 irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Ken Masuda 4049

Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX' for gastroesophageal adenocarcinoma (GEA). Daniel V.T. Catenacci 4050

Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal Daniel Swinson 4051 cancer (aGOAC): The uncertain randomization of the GO2 phase III trial. The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT). Richard Malthaner 4052 Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer. Matthew K Stein 4053

Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in Xiaoying Zhao 4054 patients with metastatic gastric adenocarcinoma: A randomized phase II trial. Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for Dashan Ai 4055 patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2). Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric Brian D. Badgwell 4056 adenocarcinoma and carcinomatosis or positive cytology. A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results. Jennifer Yon-Li Wo 4057

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results Hirva Mamdani 4058 from big ten cancer research consortium study. Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer Shin Hye Yoo 4059 receiving palliative chemotherapy. Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and Jian-Ming Xu 4060 gastroesophageal junction (GEJ) adenocarcinoma. Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in Sina Vatandoust 4061 patients with advanced gastric cancer and peritoneal metastases. A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunephenotype and the impact on survival in patients Matthew Philip 4062 with esophageal adenocarcinoma. Humphries Landscape of innate and adaptive immunity targets in oesophagogastric adenocarcinoma (OGA). Elizabeth Catherine 4063 Smyth Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with Seung Kim 4064 integrated genomic profiling. Prospective validation of a serum miRNA panel for early detection of gastric cancer. Lihan Zhou 4065 Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric Antonino De Paoli 4066 cancer (LAGC): A phase II multicentric study. The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer. Masanori Tokunaga 4067 Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma. Kirsty Taylor 4068 Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer. Lucy Xiaolu Ma 4069

A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma. Kabir Mody 4070 First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). Masatoshi Kudo 4072

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein Josep M Llovet 4073 (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2). 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for Shukui Qin 4074 advanced hepatocellular carcinoma or biliary tract cancer. Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients Andrea Casadei Gardini 4075 treated with sorafenib: Interim analysis of INNOVATE study. IGF-Child-Pugh score as a predictor of treatment outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Yehia I. Abugabal 4076

Randomized clinical trial of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial Xin Yin 4077 chemoembolization for hepatocellular carcinoma with intermediate stage (BCLC stage B) hepatocellular carcinoma beyond Milan criteria. DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced Heejung Chae 4078 biliary tract cancer (BTC). Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) Yung-Jue Bang 4079 basket studies. Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma. Ian M. Silverman 4080

CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic Tagwa Idris 4081 cholangiocarcinoma. Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study. Junho Kang 4082

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC). Dae Won Kim 4083 Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations. Alice Boileve 4084 Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite Gilbert Spizzo 4085 instability (MSI). Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial. Ali Belkouz 4086

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss Milind M. Javle 4087 of heterozygosity (gLOH). Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular Ghassan K. Abou-Alfa 4088 carcinoma (aHCC) in the phase III CELESTIAL trial. Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study. Yongkun Sun 4089

Cell-free junctional DNA fragment from hepatitis B virus integration in HCC for monitoring postresection recurrence and clonality. Ya-Chun Wang 4090

Novel staging system using carbohydrate antigen (CA) 19-9 in extrahepatic cholangiocarcinoma (ECCC) and its implications on overall Sri Harsha Tella 4091 survival (OS). SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study. Xiaofeng Chen 4092 Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant Shogo Kobayashi 4093 therapy (KHBO1401-1A study). The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer. Jin Won Kim 4094

A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts). Teresa Macarulla 4095 Mercade Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. Anna M. Varghese 4096

A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). Richard D. Kim 4097 Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with Ahmed Omar Kaseb 4098 resectable HCC. Clinical and prognostic significance of serum levels of fatty acid binding proteins in hepatocellular carcinoma (HCC). Yehia I. Abugabal 4099 Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Petra Prins 4100 An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line Ming-Huang Chen 4101 treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14). A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 Timothy Jay Price 4102 results. A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas Christian Fottner 4103 NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC). Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national Paul Girot 4104 retrospective study from the French Group of Endocrine Tumors (GTE). The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in Enrique Grande 4105 patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE). Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 Jaume Capdevila 4106 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). Molecular characterization of the tumour microenvironment in neuroendocrine malignancy. David James Pinato 4107 Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with Richard B. Noto 4108 unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL). 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal Jorge Hernando-Cubero 4109 neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.

Blood-based next-generation sequencing analysis of neuroendocrine tumors. Walid Labib Shaib 4110 Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut Jonathan R. Strosberg 4111 neuroendocrine tumors. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. Nitya Prabhakar Raj 4112 Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors. Andreja Frilling 4113

Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors. Aman Chauhan 4114

Antitumor efficacy of concurrent everolimus with hepatic transarterial bland embolization (evero-embo) in patients with metastatic Lowell Brian Anthony 4115 well differentiated neuroendocrine tumor (NET). Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy. Satya Das 4116

Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma Joon Oh Park 4117 (CCA) patients with FGFR alterations. Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal Lionel Duck 4118 obstruction (IMIO): Results from a phase II multicenter study. Molecular profile of ampulla of vater carcinoma (AVC): A rare tumor type with meaningful molecular alterations. Joao Pinto 4119 Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi- Alwin Kramer 4120 center randomized phase II AIO trial. H3B-6527 clinical biomarker assay development and characterization of HCC patient samples. Pavan Kumar 4121 Variation in the surgical management of locally advanced pancreatic cancer. Bradley Norman Reames 4122

Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer. Adam R Wolfe 4123 A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I Davide Melisi 4124 kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally Paul J. Ross 4125 advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine + nab-paclitaxel (GNP) . The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Sohei Satoi 4126 Prep-02/JSAP-05). Final results of JASPAC05: Phase II trial of neoadjuvant S-1 and concurrent radiotherapy followed by surgery in borderline resectable Shinichiro Takahashi 4127 pancreatic cancer. NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase Waldemar Uhl 4128 II study of the AIO pancreatic cancer group (AIO-PAK-0313)— Safety interim analysis. Metformin use and pancreatic cancer survival in US veterans with diabetes mellitus: Are there racial differences? Adetunji T. Toriola 4129 Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and Pamela N. Munster 4130 ovarian cancer (OvCA). Elevated pretreatment serum IL-8 and PD-L1 and overall survival in a phase III randomized advanced pancreatic cancer clinical trial. Ashok Maddukuri 4131

Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma Wungki Park 4132 (PDAC). Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Andreas Seeber 4133

Hereditary cancer genetic testing among patients with pancreatic cancer. Nassim Taherian 4134 Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic Lawrence G. Lum 4135 pancreatic cancer. Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) Daniel Pietrasz 4136 patients. SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab- Davendra Sohal 4137 paclitaxel for resectable pancreatic adenocarcinoma. Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program Michael J. Pishvaian 4138 whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx).

BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort. Thomas Aparicio 4140 TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin Hideaki Bando TPS4141 in patients with locally advanced esophageal squamous cell carcinoma. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric Salah-Eddin Al-Batran TPS4142 adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab Kynan Feeney TPS4143 with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or Salah-Eddin Al-Batran TPS4144 metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO. Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric Uqba Khan TPS4145 and gastroesophageal junction adenocarcinoma. KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer Yelena Yuriy Janjigian TPS4146 (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study. A single-arm, open phase II clinical trial of anti-programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line Feng Wang TPS4147 treatment of advanced esophageal squamous cell carcinoma. RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of Anica Högner TPS4148 the arbeitsgemeinschaft internistische onkologie (AIO). A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) Rutika Mehta TPS4149 adenocarcinoma. Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma. Haeseong Park TPS4150 Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy In patients (pts) Federica Morano TPS4151 with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma Josep M Llovet TPS4152 (HCC): Phase 3 LEAP-002 study. A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary Vaibhav Sahai TPS4153 tract cancer. A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy Vaibhav Sahai TPS4154 for patients with advanced unresectable biliary tract cancer. Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced Milind M. Javle TPS4155 cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer. Jennifer J. Knox TPS4156 Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with Robin Kate Kelley TPS4157 advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel Mairead Geraldine TPS4158 as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP- McNamara NEC). Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma. Frank Lin TPS4159 A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or Cindy Neuzillet TPS4160 FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM–PRODIGE 63 GERCOR D17-01 study). A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose Kim Anna Reiss TPS4161 cancer has not progressed on platinum-based therapy. Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The genetic education, risk assessment Matthew B. Yurgelun TPS4162 and testing (GENERATE) study. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally Deirdre Jill Cohen TPS4163 advanced unresectable pancreatic cancer (LAUPC). Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer. Jon Holmlund TPS4164

A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected Deirdre Jill Cohen TPS4165 solid tumors. PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine Derek B. Grose TPS4166 (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated William Adrian Hall TPS4167 chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.

Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial. Anup Kasi TPS4168

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial David Andrew Sallman 7009 phase 1b results. Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a B. Douglas Smith 7010 phase 2 randomized trial. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia Courtney Denton Dinardo 7011 (ND AML). Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML). Carlo Gambacorti- 7012 Passerini Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase Francis J. Giles 7013 (CML-CP): 192-week data from the ENESTfreedom study. Pooled safety summary for patients treated with the CD22-directed cytotoxin -tdfk. Robert J. Kreitman 7014 Inferior survival after microbiota injury: A multicenter allo-HCT study. Jonathan U. Peled 7015 Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell Piyanuch Kongtim 7016 transplantation. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation. Richard Jirui Lin 7017 Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients. Gaurav Goyal 7018 Correlation of BRAF V600E mutation with cardiac involvement assessed by heart imaging in a monocentric series of 205 patients with Marine Bravetti 7019 Erdheim-Chester disease. Clinical features, molecular aberrations, treatments, and outcomes in histiocytic sarcoma. Gordon Ruan 7020 Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort Zaid Abdel Rahman 7021 (MCAEC). Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful? Yamil Michelen 7022 Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL. Paul B. Koller 7023 Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia Jeremy Chang 7024 chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib. Time from randomization to first subsequent induction/salvage therapy (ST) in patients with relapsed/refractory (R/R) acute Elias Jabbour 7025 lymphoblastic leukemia (ALL) treated with (InO) in the phase 3 INO-VATE trial. Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study. Gail J. Roboz 7028

Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of Hagop M. Kantarjian 7029 patients treated in salvage one with a long duration of first remission. Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in Olatoyosi Odenike 7030 patients with relapsed/refractory acute myeloid leukemia. Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid Michael Jamie Hochman 7031 leukemia (AML)? Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy. Christine M Karbowski 7032 Clinical validation of long-range PCR assay for MLL partial tandem duplications for acute myeloid leukemia. Sun Hee Rosenthal 7033 Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. Mahran Shoukier 7034 Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression. WayAnne Watson 7035 Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia. Jessica Hochberg 7036

Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in Veronica Guerra 7037 patients with advanced myelodysplastic syndrome (MDS). Identifying Mcl-1 protein dependencies using dimerization-specific antibody biomarker for predicting response to targeted apoptosis Michael H. Cardone 7038 inducing therapies. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Iman Aboudalle 7039

A video decision aid to improve acute myeloid leukemia patients' illness understanding: Results of a pilot trial. Thomas William LeBlanc 7040

IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A Hussein Abbas 7041 subset analysis of a phase 2 study. Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high- Ellen K. Ritchie 7042 risk/secondary acute myeloid leukemia (sAML). First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in Sonja Loges 7043 AML patients unfit for intensive chemotherapy: Phase II open-label study. Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who Ellen K. Ritchie 7044 have not been treated with intensive chemotherapy. The Transplant Optimization Program (TOP): Implementing a geriatric assessment (GA)-guided interdisciplinary clinic (IDC) prior to Benjamin Avi Derman 7045 allogeneic hematopoietic cell transplantation (HCT) in older adults. Late infectious complications in hematopoietic cell transplantation survivors. Eric Jessen Chow 7046 Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. Akash Mukherjee 7047

Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single Ben Kent Tomlinson 7048 agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.

Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched Hind Rafei 7049 unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). Mast cells as mediators of fibrosis and effector cell recruitment in dermal chronic graft-versus-host disease. Ethan Strattan 7050 Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE Jorge E. Cortes 7051 trial. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML- Kiran Naqvi 7052 CP). Discrepancy of blast percentage between the bone marrow aspirate and biopsy and its impact on survival outcomes in patients with Meera Yogarajah 7053 myelodysplastic syndromes excess blast (MDS-EB). Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. Kelly Sharon Chien 7054 Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long Ruben A. Mesa 7055 term benefits. A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients Marina Kremyanskaya 7056 with myelofibrosis (MF). Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. Claire N. Harrison 7057 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory Naveen Pemmaraju 7058 myelofibrosis. Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic Mrinal Mahesh Patnaik 7059 leukemia (CMML). Predictive accuracy of the low erythropoietin level for the diagnosis of polycythemia vera. Oleksandra Lupak 7060 Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly Elias Jabbour TPS7061 diagnosed Philadelphia chromosome–positive (Ph+) ALL. CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia. Farhad Ravandi TPS7062

MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia. Pau Montesinos TPS7063

A phase I/II study of in combination with pembrolizumab for adults with relapsed refractory B-lineage acute Marc Saul Schwartz TPS7064 lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504. A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia Margaret T. Kasner TPS7065 (ALL). A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute Daniel J. DeAngelo TPS7066 myeloid leukemia. A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory Naval Guastad Daver TPS7067 (R/R) FLT3-ITD acute myeloid leukemia (AML). Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML. Richard M. Stone TPS7068

A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) OMER HASSAN JAMY TPS7069 in older patients using fludarabine and total body irradiation (Flu/TBI). A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in Michael J. Mauro TPS7070 chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes. Guillermo Garcia-Manero TPS7071

FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated Srdan Verstovsek TPS7072 with ruxolitinib.

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, Jithma P. Abeykoon 7509 dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).

Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small Paul M. Barr 7510 lymphocytic lymphoma (CLL/SLL) on ibrutinib. Second cancer incidence in CLL patients receiving BTK inhibitors. David Alan Bond 7511 Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). Andrew David Zelenetz 7512

MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin David Jacob Andorsky 7513 lymphoma. Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL John G. Gribben 7514 (AUGMENT). Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) Jeremy S. Abramson 7515 and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001. Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene Michael Wang 7516 maraleucel (Liso-cel) in TRANSCEND NHL 001. Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T Jay Y. Spiegel 7517 consortium. Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in Nancy L. Bartlett 7518 relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Thomas E. Witzig 7519

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. Grzegorz S. Nowakowski 7520

Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma Kami J. Maddocks 7521 (R-R DLBCL): Response rates in patient subgroups with poor prognosis. Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes. William Archibald 7522 Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial. Ian Flinn 7523

Outcomes in chronic lymphocytic leukemia (CLL) patients with NOTCH1 signaling pathway mutations. Daniel R. Helbig 7524 Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia. Camilia M Soof 7525 Outcomes of stem cell transplant in patients with Richter transformation. Yucai Wang 7526 Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts. Michael Y. Choi 7527 Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with (OFA) Fritz Offner 7528 and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene. Matteo Molica 7529

Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia Kerry Anne Rogers 7530 (CLL). Assessing the potential of immunotherapy in treating chronic lymphocytic leukemia through meta-analysis. Jihad Aljabban 7531 with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. David J. Straus 7532

Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT- Hang Su 7533 1 study. Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin Hang Su 7534 lymphoma. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population. Mohamad Barakat 7535

Impact on survival of surveillance imaging after first remission in follicular lymphoma. Jimmy Mao 7536 PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal Tongyu Lin 7537 type: A prospective study. Response to A+CHP by CD30 expression in the ECHELON-2 trial. Ranjana H. Advani 7538 Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or Barbara Pro 7539 vorinostat: A MAVORIC post-hoc analysis. Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based Paolo Strati 7540 therapy. Survival disparities of diffuse large B-cell lymphoma in a community-based cancer center. Vinicius Machado Jorge 7541

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report. Reem Karmali 7542 Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. Deepa Jagadeesh 7543 Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international Amy S. Ruppert 7544 trials (SEAL). Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell Paolo Strati 7545 lymphoma. Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory Alexander F. Lovejoy 7546 DLBCL subjects. Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis. Thomas David Rodgers 7547

Early progression of disease (POD24) as survival predictor in MALT lymphoma. Annarita Conconi 7548 Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell Mohamad Barakat 7549 lymphoma. Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following Akash Mukherjee 7550 targeted small molecules inhibitors (SMIs). A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas. Pierluigi Porcu 7551

Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis. Matthew Joshua Frank 7552

Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib. Sirpa Leppa 7553

Extranodal (EN) and spleen disease by FDG-PET/CT is associated with early clinical failure in untreated follicular lymphoma (FL). Frederique St-Pierre 7554

Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory Sattva Swarup Neelapu 7555 large B cell lymphoma (LBCL). Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials. Yucai Wang 7556

A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma. Hui Liu 7557

Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell Max S. Topp 7558 lymphoma (R/R LBCL). Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study. Saurabh Zanwar 7559 Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy. Reza Sirous 7560

Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. John Lin 7561

Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell Erin Dean 7562 lymphoma. A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B Cell malignancies. Lugui Qiu 7563 Prediagnosis cardiovascular risk and subsequent myocardial infarction (MI) among lymphoma survivors. Talya Salz 7564 Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact Owen A. O'Connor 7565 of mutations in epigenetic operations on response. ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic Ian Flinn TPS7566 leukemia (CLL). 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) Christine Mauz-Körholz TPS7567 with slow early response (SER) to frontline chemotherapy: KEYNOTE-667. Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL). Stephen Opat TPS7568 ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high risk diffuse large B cell Stephen Smith TPS7569 lymphoma patients with novel genomic biomarker DGM1. The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in Jose Caetano Villasboas TPS7570 combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. Herve Tilly TPS7571

ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic Peter Hillmen TPS7572 leukemia/small lymphocytic lymphoma (CLL/SLL). ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients Michael Dickinson TPS7573 with refractory/relapsed follicular lymphoma (r/r FL). ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B Sattva Swarup Neelapu TPS7574 cell lymphoma (LBCL). A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with Marco Montillo TPS7575 atezolizumab and obinutuzumab in richter transformation of CLL.

Hematologic Malignancies—Plasma Cell Dyscrasia Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement. Amandeep Godara 8009 Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or Ping Zhou 8010 smoldering multiple myeloma. Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved. Abdullah Al Saleh 8011

Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. William Bensinger 8012 Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma. Chunrui Li 8013

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma Paul G. Richardson 8014 (TCR-MM). Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study. Brian G. Durie 8015

Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients Aurore Perrot 8016 ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple Herve Avet-Loiseau 8017 myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE. Alessandra Tedeschi 8018

Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. Angela Dispenzieri 8019 Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). Angela Dispenzieri 8020 Phase 1 study of in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple Keren Osman 8021 myeloma. Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. Jeroen Elassaiss-Schaap 8022

Effect of iFISH defined 1q21 amplification/gain in multiple myeloma patients treated on total therapy protocols. Maurizio Zangari 8023 Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). Chutima Kunacheewa 8024 A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory Donna Ellen Reece 8025 multiple myeloma (RRMM) after lenalidomide treatment. Minimal residual disease clinical monitoring and depth of response in multiple myeloma. Joaquin Martinez-Lopez 8026

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. Maria-Victoria Mateos 8027 study. Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR. Thierry Facon 8028

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03). Arthur Bobin 8029 Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients Parameswaran Hari 8030 (PROMMIS). Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal Wilson I. Gonsalves 8031 plasma cells (cPCs) via multiparametric flow cytometry (MFC). Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry. Cristina Gasparetto 8032

Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma. Nathanael Fillmore 8033

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Marcella Tschautscher 8034 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (8:00 AM - 11:00 AM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) Saad Zafar Usmani 8035 with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in Juan Du 8036 multiple myeloma patients. Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose Daniel Heudobler 8037 chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Jonathan L. Kaufman 8038 Updated subgroup analysis of POLLUX based on cytogenetic risk. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. Bharat Nandakumar 8039 Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) Katja Weisel 8040 based on cytogenetic risk: Updated subgroup analysis of CASTOR. Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma. Cecile Gruchet 8041

Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) Cyrille Hulin 8042 receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.

Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple Sara Bringhen 8043 myeloma (RRMM). Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Smith Giri 8044 Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple Christian Leisner 8045 myeloma. Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory Bindu Kanapuru 8047 multiple myeloma (rrMM). A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM). James R. Berenson 8048

Prognosis of young patients with monoclonal gammopathy of undetermined significance. Li Pang 8049 Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). Sheeba K. Thomas 8050 Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study. Sham Mailankody 8051 ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in Michael A. Thompson TPS8052 relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status. Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard- Luciano J. Costa TPS8053 of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6). SGNBCMA-001: A phase 1 study of SEA‑BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory Al-Ola A. Abdallah TPS8054 multiple myeloma. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly Pieter Sonneveld TPS8055 diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple Sonja Zweegman TPS8056 myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

The myeloma-developing regimens using genomics (MyDRUG) master protocol. Daniel Auclair TPS8057 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Cancer Prevention, Hereditary Genetics, and Epidemiology Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. Madison Conces 1507 Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia. Nicholas S. Moore 1508 Effect of germline ATM mutations on clonal hematopoiesis. Thomas Paul Slavin 1509 Antiviral therapy to reduce hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial. Gang Huang 1510

Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel adenocarcinoma (SBA). Alicia Latham 1511 New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. Maria Fernanda Montiel 1512

Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Allison W. Kurian 1513 Initiative. Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer Siddhartha Yadav 1514 patients. Adequacy of self-reported family history in electronic health record for genetic risk assessment for Lynch syndrome. Mala Pande 1515 Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in Yadav Sapkota 1516 adult survivors of childhood cancer: Utility of a two-stage analytic approach. Gliomas in the context of Li-Fraumeni syndrome: An international cohort. Orli Michaeli 1517 Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers. Karen L. Reckamp 1518 Gaining insights into the DICER1 syndrome: An early report from the Italian DICER1 registry. Arcangela De Nicolo 1519 Genetic identification and characterization of Lynch syndrome in a multi-ethnic biobank. Rachel Rosenblum 1520 Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) Mariana Scaranti 1521 patients (pts). Risk of cancer in first-degree relatives of childhood cancer patients: A linked longitudinal population-based registry study. Laura-Maria Madanat- 1522 Harjuoja Rare tumor with matched germline whole exome sequencing to identify somatic and inherited variants of clinical significance. Bryce Daniel Perkins 1523

Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors. Leylah Drusbosky 1524 Preventive surgery after multiplex genetic panel testing (MGPT). Gregory Idos 1525 Preimplantation genetic diagnosis: What do BRCA mutation carriers think? Olivia R Khouri 1526 Prospective Registry of Multiplex Testing (PROMPT): Follow-up. Jamie Brower 1527 Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects. Sarah Abou Alaiwi 1528 Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer Elsa Curtit 1529 patients. Test of InheRET, an online tool to facilitate NCCN Guideline compliant referrals for cancer genetic counseling. Lynn McCain 1530 The PHACT Study: Population Health and Cancer Testing. Mallika Sachdev Dhawan 1531

Characterization of Lynch syndrome (LS) associated cancers in patients with immune dysfunction. Shahla Bari 1532 Safety and efficacy of aspirin for primary prevention of cancer: A meta-analysis of randomized controlled trials. Tarek Haykal 1533 Role of vitamin D supplementation for primary prevention of cancer: Meta-analysis of randomized controlled trials. Varun Samji 1534 Opportunistic off-target cancer screening in organized programs: The EDIFICE 6 survey. Jean F. Morere 1535 Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice Catherine H. Watson 1536 patterns. Implementation of a low-dose computerized tomography (LDCT) lung cancer screening program (LCSP) across a large integrated Marija Bjegovich- 1537 health system. Weidman Analysis of healthy breast tissue from Komen Tissue Bank shows distinct histology, decreased proliferation, and lower periductal Mustafa Basree 1538 collagen deposition in women with prolonged history of breastfeeding. Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women's Health Kathy Pan 1539 Initiative (WHI) Dietary Modification randomized trial. Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco- Jose Luis Perez-Gracia 1540 induced lung adenocarcinoma (LUAD) according to KRAS status. Risk of colon adenoma in patients with breast cancer. Yinghong Wang 1541 The impact of smoking cessation on breast cancer patients' survival. Mazen Jizzini 1542 Effectiveness of low-dose CT scan for lung cancer screening in the community setting. Jason Aboudi Mouabbi 1543 Improving risk assessment of obesity-associated breast cancer. Neil M. Iyengar 1544 Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis. Geoffrey R. Oxnard 1545

A comparison of risk factors for cigarette and e-cigarette use in the United States adult population. Leo Chen 1546 Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes. Zachary Phillip Schwartz 1547

Association between breast cancer mortality-to-incidence ratios and state health disparities in the United States. Yu-Che Lee 1548 Contralateral breast cancer risk according to first breast cancer characteristics among United States women from 1992 to 2015. Cody Ramin 1549

Epidemiology and survival in patients with urethral clear cell carcinoma. Mausam Patel 1550 Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene Pamela Blair Allen 1551 and trichloroethylene. Insulin resistance measured by the triglyceride-glucose index and risk of obesity-related cancers: An epidemiological investigation in Josef Fritz 1552 more than 500,000 individuals. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Insurance disparity in the United States cancer survivors' smoking rates: A trend study from NHIS 2008-2017. Yannan Zhao 1553 Comorbidity and racial differences in risk of mortality of men with breast cancer. Carol Parise 1554 Burden of thrombocytopenia in adult cancer patients receiving chemotherapy. Gerald A. Soff 1555 Cardiometabolic risk factors and survival after cancer in the women's health initiative. Michael S. Simon 1556 Breast cancer screening adherence at multiple timepoints over eight years among women in a familial cohort. Marcy L. Schaeffer 1557 Characteristics of cancer patients with a history of solid organ transplantation: Analysis of a patient cohort reporting to a large cancer Susen Burock 1558 center. Predicting future cancer incidence by age and gender. Wesley B. Garner 1559 Health insurance literacy, financial hardship and financial sacrifices among cancer survivors in the United States. Jingxuan Zhao 1560 Incidental atypical hyperplasia/LCIS in mammoplasty specimens and subsequent risk of breast cancer. Francisco Acevedo 1561 Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? Aline Fusco Fares 1562 A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts). A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation Kimmie McLaurin 1563 status. Risk of anxiety and depression in breast cancer survivors compared to women who have never had cancer: A population-based Helena Carreira 1564 cohort study in the United Kingdom. Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after Paola Ghione 1565 receiving textured breast implants. Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs). Anees B. Chagpar 1566 Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Daniel X. Yang 1567

Adverse effects of early bilateral oophorectomy on body composition: Results from a nationally representative sample of United Pritesh S Karia 1568 States women. “Early impact"• of the lung cancer screening in United States population in the SEER Registries. Isabel M Emmerick 1569 Sex-specific mortality trends in adolescents and young adults with cancer from 2007 to 2016. Allison Close 1570 Racial disparities in cancer survival: A trend analysis based on SEER data (1973-2010). Seyed Navid Alavi 1571 Genomic profiling of pulmonary lymphoepithelioma-like carcinoma (PLELC). Chengzhi Zhou 1572 Relationship of liver cancer with LRP1B or TP53 mutation and tumor mutation burden and survival. Longrong Wang 1573 A pan-cancer analysis of microsatellite instability as a predictor of Lynch syndrome in Chinese population. Pinzhu Huang 1574 Characterization of genomic alterations in Chinese LCNEC and SCLC via comprehensive genomic profiling. Lin Wu 1575 Blood-based genomic profiling of circulating tumor DNA from patients with advanced biliary tract cancer. Junying Wang 1576 Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis. Kelly A. Metcalfe 1577 Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model. Kelly Morgan 1578 Disparities in pretest genetic counseling among a population-based sample of young breast cancer patients. Sonya Reid-Lawrence 1579 Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility. Scott T. Michalski 1580

Implications of incidental germline findings identified in the context of clinical whole exome sequencing (WES) for guiding cancer Bryan P. Schneider 1581 therapy. Unselected germline screening in pancreatic adenocarcinoma yields high rates of pathogenic and likely pathogenic variants (PV) in Carol Cremin 1582 hereditary cancer susceptibility genes. Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and Peter D. Beitsch 1583 PARP inhibitor trial eligibility. Germline mutation profile among Hispanic women with epithelial ovarian cancer (EOC). Yanin Chavarri Guerra 1584 Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from Hinco Jasper Gierman 1585 community oncology practices. Incidence of second primary neoplasms among cancer survivors in the United States, 2000 through 2015. Eric Adjei Boakye 1586 A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial Joanne M. Jeter TPS1587 colectomy. Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery. Katrina Alber TPS1588 Omega-3 fatty acids and ERPR(-) and HER2/neu(+/-) breast cancer prevention. Chidimma Kalu TPS1589

Genitourinary (Nonprostate) Cancer A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. Xinan Sheng 4509 Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic Nazli Dizman 4510 profiling/cell-free DNA results. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic Arlene O. Siefker-Radtke 4511 urothelial carcinoma, preliminary analysis. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and Brian I. Rini 4512 sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously David F. McDermott 4513 untreated advanced renal cell carcinoma with sarcomatoid features. Efficacy of immune checkpoint inhibitors (ICI) & genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell Ziad Bakouny 4514 carcinoma (mRCC). Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in Sumanta K. Pal 4515 first-line metastatic renal cell carcinoma (mRCC). Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Igal Kushnir 4516 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain Hamid Emamekhoo 4517 metastases: Interim analysis of CheckMate 920. Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). Bradley Alexander 4518 McGregor Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally Cora N. Sternberg 4519 advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma Omar Alhalabi 4521 (UBC). Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based Daniel E. Castellano 4522 chemotherapy. Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive Jaleh Fallah 4523 (MI) and metastatic (met) bladder cancer (BC). Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from Arlene O. Siefker-Radtke 4524 CheckMate 275. Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents. Ali Raza Khaki 4525

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint Alicia K. Morgans 4526 inhibitor (CPI) monotherapy in a US clinical practice. Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC). Yohann Loriot 4527

Association of cell-free DNA (cfDNA) levels with myeloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle Jaleh Fallah 4528 invasive (MI) and metastatic (met) bladder cancer (BC). Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with Bernadett Szabados 4529 chemotherapy. Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Ronald De Wit 4530 Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057. Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune- Rafael Morales-Barrera 4531 checkpoint inhibitors. Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of Yaw A. Nyame 4532 care (SOC) regimens. Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Joseph Jacob 4533 Profiling (CGP) Study. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A Jae-Lyun Lee 4534 randomized phase II study (COACH, KCSG GU10-16). Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, Marco Bandini 4535 and therapeutic assessment from multiple datasets. Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer Benjamin Miron 4536 (MIBC). Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations. Brian Winters 4537

Proximity to oil refineries and risk of bladder cancer: A population-based analysis. Tamer Dafashy 4538 Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial Giuseppina Calareso 4540 bladder cancer (MIBC). Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) Xiao X. Wei 4541 with metastatic urothelial cancer (mUC). FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib. Andrea Necchi 4542 Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC). Se Hoon Park 4543 Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated Nicholas Peter Verdini 4544 with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi). Analysis of EGFR mutant urothelial carcinoma (UC) reveals distinct mutational landscape. Russell Madison 4545 KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Peter H. O'Donnell 4546 Updated response and survival results. Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in Begona Mellado 4547 metastatic urothelial carcinoma (mUC). Immune correlates of CD73 expression in patients with urothelial carcinoma (UC). Edwin Lin 4548 An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed Chana Weinstock 4549 death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody. PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non–muscle invasive bladder cancer. Mathieu Roumiguie 4550

A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high- Jianjun Gao 4551 risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 Guru Sonpavde 4552 inhibitors. Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial Danielle Carroll 4553 in metastatic bladder cancer (BISCAY). 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary Xinan Sheng 4554 results of an open-label phase II clinical study. Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of Andrea B. Apolo 4555 cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). Causes of patient ineligibility in clinical trials of metastatic urothelial cancer. Gwynn Ison 4556 Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or Chana Weinstock 4557 programmed death ligand 1 (anti-PD-1/L1) antibody. RNAseq and DNA whole-exome sequence analysis reveal novel response signatures to IO treatment in muscle invasive bladder cancer Gregory Mayhew 4558 (MIBC) patients. A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic Samuel Aaron Funt 4559 urothelial cancer (mUC). Multi-omics profiling of upper-tract urothelial carcinomas. Gabriel G. Malouf 4560 Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder Karim Chamie 4561 cancer (NMIBC) patients. Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, Darren R. Feldman 4563 etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs? Floor Lubberman 4564 Comparative genomic profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111 patients (Pts) with metastatic clear cell Ritesh Kotecha 4565 renal cell carcinoma. Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC). Meredith M. Regan 4566

Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC). Matthew R. Zibelman 4567 Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal Jean-Christophe Pignon 4568 cell carcinoma (mccRCC). KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC- Jae-Lyun Lee 4569 RCC). First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE- Scott S. Tykodi 4570 427 cohort A. Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing Nieves Martinez Chanza 4571 autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal Camillo Porta 4572 cell carcinoma (RCC). Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study. David I. Quinn 4573 Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell Martin Boegemann 4574 carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors Bernard Escudier 4575 in CheckMate 214. Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted Yasser Ged 4576 therapy combinations (IO-VEGF). First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international Shaan Dudani 4577 mRCC database consortium (IMDC). Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with Bimal Bhindi 4578 sunitinib. Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial Daniel Vargas Almeida 4579 growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs). Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma. Durga Udayakumar 4580 Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for Andrea Necchi 4581 therapeutic and biomarker development. Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC). Abhishek Tripathi 4582 Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid Ronan Flippot 4583 differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.

Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study. Gennady Bratslavsky 4584 Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling Joseph Jacob 4585 (CGP) study. A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally Evan Y. Yu TPS4586 advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).

A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in Guru Sonpavde TPS4587 cisplatin-eligible muscle invasive bladder cancer (MIBC). DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive Enrique Grande TPS4588 urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores. ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette- Morgan Roupret TPS4589 Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) Matt D. Galsky TPS4590 chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC). Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer Ashish M. Kamat TPS4591 (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study. A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with Thomas Powles TPS4592 gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer. Christopher J. Hoimes TPS4593

PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer Petros Grivas TPS4594 (BC). A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib Nizar M. Tannir TPS4595 (investigator's choice) in patients with previously untreated advanced renal cell carcinoma. PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in Tian Zhang TPS4596 metastatic untreated renal cell cancer (Alliance A031704). PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell Lauren Christine TPS4597 carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). Harshman

Melanoma/Skin Cancers Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus Gabriella Liszkay 9512 vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel). Allison Betof Warner 9513 Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 Georgina V. Long 9514 cohort 1C. Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF Reinhard Dummer 9515 V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment. Arissa Young 9516 Circulating PD-L1-exosomes to monitor tumor response in melanoma patients. Charlee Nardin 9517 Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous Claus Garbe 9518 melanoma (CM). Three-year survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (31-GEP) test Eddy C. Hsueh 9519 for cutaneous melanoma (CM). One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene Reinhard Dummer 9520 laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with Xieqiao Yan 9521 previously untreated advanced mucosal melanoma (NCT02023710). Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). Meredith Pelster 9522 Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients Mark R. Middleton 9523 with advanced melanoma. Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus Mohammed M. Milhem 9524 granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM. Immunotherapy disparities in metastatic melanoma. Thomas Oliver 9525 Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma Alexander David 9526 (mCSCC; Group 1): 12-month follow-up. Guminski High incidence of brain metastases (BrM) in patients with metastatic cutaneous melanoma (MCM) and mutations in the APC/β- Georgia Sofia Karachaliou 9527 catenin (CTNNB1). Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations. Lili Mao 9528 Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study). Yasuhiro Nakamura 9529

Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma. Mark R. Middleton 9530

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) Georgina V. Long 9531 with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.

Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world. Richard Wayne Joseph 9532 Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients Michael B. Atkins 9533 with advanced melanoma. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma Mohammed M. Milhem 9534 who are naïve to anti-PD-1 therapy. IL-12p40 and MIP3a to predict clinical responses to anti-PD-1 therapy in patients with metastatic melanoma. Jesus Vera Aguilera 9535 Immune profile of metastatic uveal melanoma during treatment with pembrolizumab. Ernesto Rossi 9536 Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal Philippe Saiag 9537 effect. A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination Anna C. Pavlick 9538 compared to Montanide, in melanoma patients in complete clinical remission. 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas. Alexander Noor 9539 Shoushtari Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma Alison Weppler 9540 (mMCC). Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced BRAFV600mut melanoma patients. Elisa Funck-Brentano 9541

Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or Ines Esteves Domingues 9542 combined with ipilimumab (IPI+PD1). Pires Da Silva

Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by Rodabe Navroze Amaria 9543 pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced Xue Bai 9544 melanoma patients. Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and Baptiste Louveau 9545 RB1 expression and treated with vemurafenib. Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) Suthee Rapisuwon 9546 treated with immune checkpoint blockade. Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from Eve Maubec 9547 CARSKIN. ctDNA as a noninvasive monitoring tool in metastatic melanoma. Renata Varaljai 9548 Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma. Sergey Fogt 9549 Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) Charlene Mantia 9550 treated with immune checkpoint inhibitors (ICI). Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without Dirk Schadendorf 9551 ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients. Xue Bai 9552 Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced Zeynep Eroglu 9553 BRAFV600 mutant melanoma. Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. Kaysia Ludford 9554 Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic Asim Amin 9555 melanoma resistant to anti-PD-1/PD-L1 therapy. Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy. Elizabeth Iannotti 9556 Buchbinder Stereotactic radiotherapy combined with immunotherapy is safe and effective: Results from a phase I clinical trial. Gishan Ratnayake 9557 Use of immunotherapy for stage-III and IV melanoma and likelihood of regional and distant lymph node resection and surgical George Molina 9558 resection for distant metastasis. Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma. Sanjiv S. Agarwala 9559 A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic Elizabeth M. Burton 9560 melanoma (MM). Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with Khashayar Esfahani 9561 metastatic melanoma on ipilimumab and chemotherapy. The relationship between obesity and immunotherapy: It's complicated. Douglas MacArthur 9562 Donnelly Mutation landscape of Chinese melanoma patients. Fuxue Huang 9563 Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM). Daniel Ying Wang 9564 Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM). Gino Kim In 9565 Anal melanoma: A comparative comprehensive genomic profiling study. Jeffrey S. Ross 9566 Pretreatment steroid use and completion of immunotherapy: A population-based study. Grace L. Lu-Yao 9567 Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after Fiona Taylor 9568 discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI). Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab. Sara Georges 9569

The clinical utility of neuron-specific enolase serum levels as a biomarker for Merkel cell carcinoma. Linde M. van Veenendaal 9570

Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 Amit Hemadri 9571 inhibitors. Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 Amit Hemadri 9572 inhibitors. Neutrophil to Lymphocyte ratio (NLR): A prognostic marker in melanoma patients receiving immunotherapy. Richard Thomas O'Dwyer 9573

Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune Hanna Eriksson 9574 checkpoint blockade or targeted therapy. Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition. Lucas Basler 9575

Comprehensive genomic profiling reveals distinct patterns of driver mutations and chromosomal alterations in acral and mucosal Zhengyun Zou 9576 melanomas. Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning. Eric Robinson 9577 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th Shirin Bajaj 9578 edition. Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving Amit Hemadri 9579 PD-1 inhibitors. Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors. Alicia Gingrich 9580

Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). Jenny HJ Lee 9581 Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected Dirk Schadendorf 9582 stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. Emilia Nan Tie 9583 An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma Mario Mandala 9584 (CheckMate 238). A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant Julia Katharina Schwarze 9585 therapy following the resection of melanoma macrometastases (MM). A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma. Yana Najjar 9586 Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow Stephanie A. 9587 complete surgical resection: REDUCTOR trial. Blankenstein Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III Annelies H. Boekhout 9588 macroscopic melanoma: A matched cohort study. A population-based model for predicting sentinel lymph node (SLN) status for cutaneous melanoma patients and a clinical decision Phyllis A. Gimotty 9589 rule (CDR) for sparing a SLN biopsy (SLNB). Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) Zeynep Eroglu 9590 without completion lymph node dissection (CLND). Extra-mammary Paget's disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study. Julie Tse 9591 Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC). Jessica Yang 9592 Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: The risk of over and undertreatment stress the need for Viola Franke 9593 expert pathology review. Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 ANA Maria Arance TPS9594 agents: Phase 2 LEAP-004 study. Fernandez A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or Julie E. Stein TPS9595 metastatic basal cell carcinoma (mBCC). Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. Matteo S. Carlino TPS9596

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous Jessica Lyn Geiger TPS9597 squamous cell carcinoma. KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell Jean Jacques Grob TPS9598 carcinoma (cSCC). ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in Marcus O. Butler TPS9599 patients with advanced melanoma following progression on or after anti-PD-1 therapy. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab Maria Gonzalez TPS9600 plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial). CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO Nikhil I. Khushalani TPS9601 monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Glenn J. Hanna TPS9602 Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy. Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable Michael C. Lowe TPS9603 metastatic melanoma. Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular Suthee Rapisuwon TPS9604 melanoma. Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III Irene Reijers TPS9605 melanoma: PRADO trial.

Symptoms and Survivorship Impact of cancer on physical and mental activities of daily living in young adult (YA) survivors. Tyler Garrett Ketterl 11517 Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Jannike Lisa Salchow 11518 Final results of the randomized Motivate AYA–MAYA trial. Predictors of suicide risk in adolescent and young adults (AYA) with cancer. Jeremy Howard Lewin 11519 Candidate SNPs enhance prediction of cognitive impairment after blood or marrow transplantation (BMT) for hematologic Noha Sharafeldin 11520 malignancy (HM). Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A randomized controlled Mélanie Dos Santos 11521 multicenter trial. Acupuncture versus cognitive behavioral therapy for cognitive impairment in cancer survivors with insomnia: Implications for Jun J. Mao 11522 personalized medicine. Improving person-centered communication of goals, proxy, and advance directives in older patients with advanced cancer: Marie Anne Flannery 11523 Secondary analysis from a University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT). Prognostic understanding in hematologic malignancies: A multicenter longitudinal study. Kah Poh Loh 11524 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Comparing nonverbal synchrony in racially concordant and racially discordant oncology interactions. Lauren M. Hamel 11525 Accelerated sarcopenia and outcomes in older adults with cancer: The Health ABC Study. Grant Richard Williams 11526 Age disparities among cancer clinical trial participants: The role of industry sponsorship. Ethan B. Ludmir 11527 Cumulative burden of new-onset chronic health conditions (CHCs) among older cancer survivors. Kelly Kenzik 11528 Early mortality after resection of locally advanced rectal cancer in elderly United States patients. Helmneh M. Sineshaw 11529 Is there a shift in use of subacute rehabilitation (SAR) instead of hospice referral since immunotherapy became available? Jonathan Yeh 11530

End-of-life care and immune checkpoint inhibitors. Hazel O'Sullivan 11531 Goals of care designation associated with improved survival and indicators of quality end-of-life care in pancreatic cancer (PC) Matthew Anaka 11532 patients (pts) undergoing palliative chemotherapy. Immune checkpoint inhibitor use near the end of life. Chad Glisch 11533 Unraveling the high cost of end-of-life care: An oncology care model experience. J. Russell Hoverman 11534 Economics of using telehospice to supplement hospice care in rural areas. Adam Lomenick 11535 Write to recover: The impact of group led creative writing on behavioral health outcomes in cancer patients. Darya Nesterova 11536 Palliative Prognostic Index application at an inpatient palliative care service from a Brazilian tertiary Hospital: A prospective Tiago Pugliese Branco 11537 observational study. Comparing outcomes data from dedicated oncology-subspecialist hospitalists to those from a traditional care model on an inpatient Kristina Fanucci 11538 oncology service. Variation in the intensity of end-of-life care, hospice enrollment, and the cost of care by cancer site. Shitanshu Uppal 11539 Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study. Melisa L. Wong 11540 ELAN-ONCOVAL (Elderly Head and Neck Cancer-Oncology Evaluation) study: Evaluation of the G8 screening tool and the ELAN Cécile Mertens 11541 geriatric evaluation (EGE) for elderly patients (pts) with head and neck squamous cell carcinomas (HNSCC). Fitness scale-4 item (FS4) to predict six-month postoperative mortality of cancer patients aged 75. Armin Shahrokni 11542 Does distress screening lead to mental health care in older adult surgical patients? Kelly Marie Trevino 11543 Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer. Dilip Sankar Babu 11544

Predictive value of an electronic frailty index (FI) in U.S. Veterans with newly diagnosed non-small cell lung cancer (NSCLC). Ayesha Rizwan Sheikh 11545

Older adults' preferred and perceived roles in decision making about palliative chemotherapy: Their decision priorities, and Erin Moth 11546 information preferences. Cancer-specific mortality and competing causes of death in older adults: A prospective, multicenter cohort study (ELCAPA-19). Deborah Assouan 11547

Guided geriatric interventions (GI) in older adults with cancer: What, how, and for whom? The French PACA EST Cohort Experience. Rabia Boulahssass 11548

Pilot randomized trial of a transdisciplinary geriatric intervention for older adults with cancer. Paul Kay 11549 Predicting severe toxicity of targeted therapies in elderly patients with cancer (PreToxE): A multicenter, prospective, and Coriolan Lebreton 11550 retrospective study. Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts. Elena Paillaud 11551 Role of the oncological-multidimensional prognostic index in older patients with metastatic colorectal cancer treated in a real-world Letizia Procaccio 11552 setting. Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D Noam Falbel Ponde 11553 (Alliance). Functional impairment on admission and associated symptom burden and health outcomes among hospitalized patients with Daniel E Lage 11554 advanced cancer. Obesity paradox in older cancer patients for middle and long-term mortality: A prospective multicenter cohort study of 2,071 Claudia Martinez-Tapia 11555 patients. Identifying patient-reported anxiety and depression in older adults with cancer. Reena Jayani 11556 Association of obesity with breast cancer outcome in relation to cancer subtypes. Ana Elisa Lohmann 11557 Physiological and psychosocial effects of a highly structured exercise program on breast cancer survivorship. Judy A. Tjoe 11558 Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. Lawson Eng 11559 Analysis of financial sustainability of survivorship clinics led by advanced practice providers. Maria Alma Rodriguez 11560 Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors. Lawson Eng 11561

Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors. Antonio Di Meglio 11562

Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Caroline Hesko 11563 Return to work after breast cancer: Comprehensive longitudinal analyses of its determinants. Agnes Dumas 11564 Polypharmacy risk among five-year cancer survivors. Christine D. Hsu 11565 High temporal variability of clinical side effects with and without adjuvant chemotherapy in 4,684 early breast cancer patients in the Paul H. Cottu 11566 CANTO trial. Female fertility preservation (FP) at pediatric cancer centers: A report from the Children's Oncology Group (COG). Jennifer Levine 11567 Effect of race/ethnicity on long-term cytopenias and major infections in adolescent young adult breast cancer survivors. Candice Sauder 11568

The CAROLE (CArdiac Related Oncologic Late Effects) Study: A Phase II, single-arm feasibility trial. Lindsay Puckett 11569 Temporal trends among survivors of rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). Pooja Hingorani 11570 Cardiovascular disease risk in survivors of 20 adult cancers. Helen Strongman 11571 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Total body irradiation (TBI) and risk of breast subsequent malignant neoplasm (SMN) after blood or marrow transplantation (BMT): A Andrew Michael 11572 report from the BMT survivor study (BMTSS). McDonald Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after Mohammad Issam Abu 11573 chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG). Zaid Body weight changes in young breast cancer survivors and associated predictors. Tal Sella 11574 Prospective trial in early-stage breast cancer (EBC) patients (pts) submitted to nutrition evidence-based educational intervention: Luisa Carbognin 11575 Early results of adherence to dietary guidelines (ADG) and body weight change (BWC). Cardiorespiratory fitness and cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer. Jingyi Gong 11576

Combination of olanzapine and aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer Mukesh Shanthilal 11577 patients. Single-fraction stereotactic versus standard conventional multifraction radiation for predominantly non-spine bone metastases: A Quynh Nguyen 11578 randomized phase II trial. “If you don't ask, you won't know"•: Do patient-reported outcome (PRO) instruments capture the symptom experience of patients Brooke Peterson Gabster 11579 treated with immune checkpoint inhibitors (ICIs)? Patient level factors associated with chronic opioid use in cancer patients. Colleen Ann Cuthbert 11580 Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate Ramila Shilpakar 11581 cancer pain. Naldemedine for opioid-induced constipation in patients receiving palliative care: A real-world registry study (Phase-R OIC Study). Masaki Shimizu 11582

Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care service among gynecologic Ashley Graul 11583 oncology patients. Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation. AnnaLynn Williams 11584

A community oncology palliative program: Early results for cost and quality measures within OCM program claims data. Adil Jamal Akhtar 11585

Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: Results from the ReDOS trial. Aminah Jatoi 11586

Correlates of distress for cancer patients: Results from multi-institution use of holistic patient-reported screening tool. Christine B. Weldon 11587

Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical Joseph M. Unger 11588 trials. Risk factors for opioid abuse/dependence in hospitalized cancer patients in the United States. Veli Bakalov 11589 The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for Ian Kleckner 11590 interoceptive brain circuitry. Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of Daniele Rossini 11591 TRIBE and TRIBE2 studies. Supportive care medications (SCMs) and pharmacogenomics (PGx) relevance in 6,985 cancer patients (pts) undergoing distress Jai Narendra Patel 11592 screening. Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving Lee S. Schwartzberg 11594 anthracycline/cyclophosphamide (AC) chemotherapy (CT). Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4. Rudolph M. Navari 11595 Survival and safety of monosialotetrahexosylganglioside in GI cancer patients with oxaliplatin-induced peripheral neurotoxicity-result Zhou Likun 11596 from TJMUCH-GI-001 trial. Validation of a new prognostic body composition parameter in cancer patients. Paolo Pedrazzoli 11597 Effect of whey protein isolate supplementation on body composition, muscle strength, and treatment tolerance in malnourished Paolo Pedrazzoli 11598 advanced cancer patients undergoing chemotherapy. Interim analyses of the efficacy of a collaborative care intervention for patients diagnosed with comorbid cancer and depression. Jennifer Lynne Steel 11599

Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial. David Hui 11600 Growth of palliative care (PC) in United States cancer centers: A national survey. David Hui 11601 The development of a nomogram to determine the risk for inappropriate opioid use in cancer patients. Sriram J. Yennu 11602 Predictors and trajectories of fatigue in ovarian and uterine cancer. Hanneke Poort 11603 Phase 2 trial of Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer. Camilla Zimmermann 11604 Effect on pain outcomes in patients treated for painful bone metastases with biopolar RFA: The OPuS One study. Sandeep Bagla 11605 Progress and trends in the utilization and adoption of palliative care in patients with terminal gynecologic cancer in the United Anthony Milki 11606 States: A study of 4,264 women. A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing Laura Luque 11607 autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).

Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients Mario E. Lacouture 11608 receiving taxane-based regimen: Final results. Lower costs of care, improved discharge disposition, and improved survival of advanced cancer patients (ACP) receiving early Christopher Daugherty 11609 inpatient palliative care (PC) compared to standard oncologic care (SOC). Learning from best scalp cooling practices in a registry: Differences in results from n>7000 patients with solid tumors. Corina van den Hurk 11610 Therapy discontinuation processes in a gynecologic oncology population. Catherine H. Watson 11611 Communicating Oncologic Prognosis with Empathy (COPE) Pilot Study. Boone W. Goodgame 11613 2019 ASCO Annual Meeting Planner Monday, June 3 - Poster Presentations (1:15 PM - 4:15 PM) (Purple Abstract IDs are are for posters that will be discussed at a Poster Discussion Session) Presentation Title Presenter Abstract # Engaging care partners in breast cancer care and communication. Jennifer Aufill 11614 Current practice for screening and management of financial distress at NCCN member institutions. Nandita Khera 11615 How far do laypersons believe in the cure of cancer? Results of the EDIFICE6 survey. Thibault De La Motte 11616 Rouge Advanced cancer patients' changes in terminal illness understanding (TIU) and their psychological well-being. Login S. George 11617 After cancer, what's more important? The survivorship care plan or the survivorship care visit? Harish Saiganesh 11618 Lung cancer stigma: A ten-year look at patient and oncologist attitudes about lung cancer. Jennifer C. King 11619 Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, Lidia Schapira 11620 symptoms, and illness mindsets (N=220). Relationship between perceptions of treatment goals and psychological distress in patients with advanced cancer. Amanda L. Jankowski 11621 The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer. Jeffrey M. Peppercorn 11622 Depression and anxiety symptoms in bereaved caregivers of patients with advanced cancer. Olivia Vanbenschoten 11623 Effectiveness of psychological distress reduction with cognitive behavioral therapy for oncological patients: A one-year follow-up Alessandro Rossi 11624 study. Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet Richard Francis Dunne 11625 need. The importance of altruism to biomarker development for pancreatic cancer. Danny HJ Heo 11626 The psychosocial and financial burden on caregivers of young-onset colorectal cancer patients. Kim Lynn Newcomer 11627 Till death do us part: Existential loneliness (EL), psychosocial distress, and survival of advanced cancer patients (ACPs), and their Fay J. Hlubocky 11628 spousal caregivers (SCs). Improve: A community-based physical activity intervention to improve functional and health outcomes in older breast cancer Cynthia Owusu TPS11629 survivors: Rationale, design, and methods. Implementation of complex perioperative intervention in older patients with cancer (IMPROVED program). Elena Paillaud TPS11630 eMouvoir: Randomized study estimating the impact of a personalized and remote support centered on physical activity (PA) for Laurence Vanlemmens TPS11631 patients (pts) after breast cancer (BC). Physical activity platform to improve bone health in cancer survivors. Cathy Skinner TPS11632 A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in Tara B. Sanft TPS11633 women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.

Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective Kerryn Reding TPS11634 cardio-oncology study. Patient controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain: A randomized, Rongbo Lin TPS11635 controlled, multicenter, phase III trial, HMORCT09-1. Impact of a regular exercise program on amount of exercise and QOL metrics in patients on immune therapy. Nicole Brenna Quenelle TPS11636